



Audited annual report  
**Candriam Equities L**

31 December 2023



# Candriam Equities L

SICAV under Luxembourg Law

Audited annual report for the year  
from January 1, 2023 to December 31, 2023



## Table of contents

|   |    |
|---|----|
| Administration of the SICAV   | 4  |
| Details about the SICAV   | 5  |
| Report of the Board of Directors  | 6  |
| Audit report  | 12 |
| Statement of net assets as at December 31, 2023                         | 15 |
| Statement of changes in net assets for the year ended December 31, 2023 | 20 |
| Statistics  | 25 |
| Investment portfolio as at December 31, 2023                            | 29 |
| Candriam Equities L Australia   | 29 |
| Candriam Equities L Biotechnology                                       | 31 |
| Candriam Equities L Emerging Markets                                    | 35 |
| Candriam Equities L EMU Innovation                                      | 39 |
| Candriam Equities L Europe Innovation                                   | 42 |
| Candriam Equities L Europe Optimum Quality                              | 45 |
| Candriam Equities L Global Demography                                   | 48 |
| Candriam Equities L Life Care   | 51 |
| Candriam Equities L Meta Globe  | 54 |
| Candriam Equities L Oncology Impact                                     | 57 |
| Candriam Equities L Risk Arbitrage Opportunities                        | 60 |
| Candriam Equities L Robotics & Innovative Technology                    | 62 |
| Notes to the financial statements - Schedule of derivative instruments  | 65 |
| Other notes to the financial statements                                 | 69 |
| Additional unaudited information  | 83 |
| Sustainable Finance Disclosure Regulation (SFDR)                        | 90 |



## Administration of the SICAV

### Board of Directors

#### Chairman

Tanguy DE VILLENFAGNE  
Advisor to the Group Strategic Committee  
Candriam

#### Directors

Thierry BLONDEAU  
Independent Director

Isabelle CABIE  
Global Head of Corporate Sustainability  
Candriam

Catherine DELANGHE  
Independent Director

Pascal DEQUENNE  
Global Head of Operations  
Candriam

Vincent HAMELINK (until 19 april 2023)  
Member of the Group Strategic Committee  
Candriam

Aurore PELLE (since 20 april 2023)  
Senior Internal Auditor  
Candriam

Jean-Yves MALDAGUE  
Managing Director  
Candriam

### Registered Office

5, Allée Scheffer  
L-2520 Luxembourg

### Depositary and Principal Paying Agent

CACEIS Bank, Luxembourg Branch  
5, Allée Scheffer  
L-2520 Luxembourg

### Management Company

Candriam  
SERENITY - Bloc B  
19-21, Route d'Arlon  
L-8009 Strassen

The functions of **Administrative Agent, Domiciliary Agent** and **Transfer Agent** (including **the Register Holding** business) have been delegated to:

CACEIS Bank, Luxembourg Branch  
5, Allée Scheffer  
L-2520 Luxembourg

Implementation of the **Portfolio Management** activities (except for the sub-fund Candriam Equities L Australia) is performed directly by Candriam and/or by one or more of its branches:

Candriam – Belgian Branch  
58, Avenue des Arts  
B-1000 Bruxelles

Candriam – Succursale française  
40, Rue Washington  
F-75408 Paris Cedex 08

Candriam – UK Establishment  
Aldersgate Street 200,  
London EC1A 4 HD

For Candriam Equities L Australia, the implementation of **Portfolio Management** is delegated to:

Ausbil Investment Management Limited  
Grosvenor Place, Level 27, 225 George Street  
Sydney NSW 2000 Australia

Implementation of the **securities lending and borrowing transactions** is performed by Candriam and/or by one or more of its branches and is partly delegated to:

CACEIS Bank, Luxembourg Branch  
5, Allée Scheffer  
L-2520 Luxembourg

### “Réviseur d’entreprises agréé”

PricewaterhouseCoopers, Société coopérative  
2, Rue Gerhard Mercator  
L-2182 Luxembourg

### Financial Services

in Belgium :  
Belfius Banque S.A.  
11, Place Rogier  
B-1210 Brussels



## Details about the SICAV

Candriam Equities L (the "SICAV") publishes a detailed annual report on its activities, the assets under management. The report includes a combined statement of net assets and a combined statement of changes in net assets expressed in EUR, investment portfolio of each sub-fund and the audit report. This report is available at the registered office of the SICAV and at the registered office of the banks designated to provide financial services in the countries in which the SICAV is sold.

Furthermore, every six months a report is issued containing notably the composition of the portfolio, the number of shares in circulation and the number of shares issued or repurchased since the date of the previous report.

The shares are only available in registered form.

The Annual General Meeting of Shareholders of the SICAV is held each year at the registered office of the SICAV or at any other place in Luxembourg as specified in the convening notice. It shall take place within 6 months after the financial year-end.

Notice for all general meetings is sent to all registered shareholders by registered mail at their address specified in the share registrar, at least 8 days before the General Meeting. These notices indicate the time and place of the General Meeting as well as the conditions of admission, the agenda and the quorum and majority required under Luxembourg law.

In addition, notice shall be published in the "Recueil électronique des sociétés et associations" ("RESA") of the Grand Duchy of Luxembourg and in a Luxembourg newspaper the "Luxemburger Wort" as well as in the press of the countries where the SICAV is marketed if the legislation so requires.

The financial year of the SICAV ends on December 31, of each year.

The net asset value per share of each share class of each sub-fund, the subscription, redemption or conversion's price of each share class of each subfund may be obtained from the registered office of the SICAV and from the banks designated to provide financial services in the countries where the shares of the SICAV are distributed.

A detailed statement of the movements in the portfolio is available free of charge upon request at the registered office of the SICAV.

The prospectus, Key Information Documents for packaged retail and insurance-based investment products (PRIIPs KIID), the SICAV's Articles of Incorporation and financial reports are available to the public free of charge, at the SICAV's registered office.



## Report of the Board of Directors

### Economic and financial background

At **United States**, in January and February 2023, with the exception of residential real estate, the vast majority of economic indicators remain fairly positive, despite past rate hikes by the Federal Reserve (Fed). On February 1, the latter raised its key rate by 25 basis points to 4.75%. Over these two months, more than 700,000 new jobs were created. The ISM service sector index stood at 55.1 in February. This briefly pushed the ten-year rate above 4% in early March. However, the closure by the authorities of the 16th largest US bank (Silicon Valley Bank) on March 10, following excessive deposit outflows, and, a few days later, of Signature Bank, have raised fears of contagion to other medium-sized banks. The FDIC, in consultation with the Federal Reserve and the US Treasury, can invoke a "Systemic Risk Exception", which enables it to insure all the deposits of these two banks (insured deposits (< \$250,000) and uninsured deposits). To avoid a liquidity and contagion problem, the Fed is opening a new borrowing facility (BTFFP - Bank Term Funding Program), the special feature of which is that the government bonds used as collateral are valued at par and not at market price. With the authorities in charge, the risk of contagion diminishes and stress on financial markets is reduced. In addition, thanks to reduced tensions in supply chains and lower energy and industrial metal prices, total inflation in the first few months of 2023 is falling steadily (5% in March 2023). Core inflation, on the other hand, is stagnating, hovering around 5.5. Indeed, while goods inflation is slowing, the "real estate" component of inflation (over 30% of CPI) and that of non-real estate services are not. On the other hand, wage growth is still significant, and is an important input in the price of services. These are the reasons why, despite the developments in March, the Federal Reserve raised its key rate by a further 25 basis points to 5% on March 22. At the end of March, the ten-year rate was 35 basis points lower at 3.48% than at the end of 2022. The stock market grew by 7%. In the second quarter, as in the rest of the world, the manufacturing sector experienced sluggish growth, while the service sector grew steadily. Over 600,000 new jobs were created during the quarter, while wage growth and underlying inflation slowed only slowly. In June, the unemployment rate was 3.6%. GDP growth in the 2th quarter was 0.5% quarter-on-quarter, after 0.6% in the first quarter. This led the Fed, on May 3, to raise its key rate by 25 basis points to 5.25%. However, at the FOMC meeting on June 14, the Federal Reserve announced a pause in its tightening cycle. This underpins the performance of the stock market, which rose - particularly in June - by 8.3% over the quarter, driven by the excitement surrounding companies linked to artificial intelligence. The ten-year rate rose by 33 basis points to 3.81%. In the third quarter, despite a tightening of 525 basis points - the final 25 basis point increase was decided on July 26 - and the downgrading of the US debt rating by Fitch in early August, the US economy continued to create over 650,000 jobs over the quarter. In September, the unemployment rate stood at 3.8%, the ISM service sector index remained above 50 and, in general, other economic indicators remained positive. Despite these good indicators, at its meeting on September 20, the Federal Reserve maintained its key rate unchanged at 5.5%, believing it to be sufficiently restrictive. These developments are leading the market to anticipate that the US will not fall into recession, but that the Fed will keep rates high for longer, despite core inflation falling to 4.1% (in September). During the quarter, caught between the absence of any prospect of recession in the United States and OPEC+ production cuts, the price of oil continued to climb. Both Brent and WTI exceeded \$90 a barrel at the end of September (compared with around \$70 at the beginning of July). All this pushed the ten-year rate up to 4.57% at the end of September, 77 basis points higher than at the end of June. Over the same period, in response to the sharp rise in interest rates, the stock market fell by 3.6%. At the beginning of October, both the labor market and activity in the services sector remained buoyant. At the end of October, third-quarter GDP growth was announced at 1.2% quarter-on-quarter (the fifth consecutive quarter with growth in excess of 2% quarter-on-quarter on an annualized basis). Against this backdrop, and with the bond risk premium rising sharply, the ten-year yield is almost 5%. However, at the beginning of November, job creation of barely 100,000, mortgage rates above 8% and slightly weaker ISM figures led the markets to think that activity might be slowing more sharply than expected, and that the Federal Reserve might cut its key rate faster than anticipated. This pushes the ten-year rate down. This movement was amplified in mid-December at the Federal Reserve's latest meeting, when its governor gave a more "dovish" message and federal funds rate projections for 2024 were lower than in September. All in all, after this bond rally, the ten-year yield closes the year at 3.87%, three basis points higher than at the end of 2022. The S&P500 ended 2023 up 24.2% on the year at 4770, helped by an 11.2% rise in the fourth quarter.



## Report of the Board of Directors

### Economic and financial background (Continued)

In the euro zone, in the first quarter 2023, while total inflation (6.9% in March) has been falling steadily since its peak in October 2022, core inflation has been rising steadily (5.7% in March) in a context where the labor market remains tight. The unemployment rate is 6.5% and wage growth is strong. In addition, as gas prices continue to fall, the outlook for growth has been revised upwards, as have expectations of terminal rates from the European Central Bank (ECB). On February 2, the latter raised its key rate by 50 basis points to 3%. Despite developments in the US banking system, the ECB raised its key rate by a further 50 basis points to 3.5% at its meeting on March 16. Indeed, as Christine Lagarde points out, the European banking sector is resilient, well capitalized and has no liquidity problems. The other reason is the ECB's latest macroeconomic forecasts, which show that inflation is likely to remain too high for too long. Over the weekend of March 18 and 19, the Swiss National Bank and the Swiss Financial Market Supervisory Authority are organizing the takeover of Credit Suisse by UBS. All in all, at the end of March, compared with the end of 2022, the German ten-year rate fell by 27 basis points to 2.3%. The stock market grew by 11.9%. In the second quarter, although both the manufacturing and services PMIs deteriorated, the services PMI remained above 50. Compared with the start of the year, consumer confidence is improving, but is becoming more heterogeneous between eurozone countries. As for the job market, it remains buoyant. With salaries growing by around five percent, the growth in the wage bill means that purchasing power is likely to improve as inflation falls. While total inflation continues to slow (5.5% in June), core inflation is showing more downward rigidity (5.5% in June). For this reason, the ECB raised its key rate twice, on May 4 and June 15 respectively, each time by 25 basis points. At the end of June, the ECB's key rate was 4%, the German ten-year yield was 2.39% and the stock market was up 1.0% over the quarter. In the third quarter, despite differing domestic dynamics between the Eurozone and the United States, European rates moved in tandem with US rates throughout the quarter, but with less amplitude. Although inflation is falling, it remains high (4.3% in September) and core inflation is decelerating even more slowly (4.5%). This is why the ECB raised rates twice more during the quarter (first on July 27 to 4.25%, then on September 14 to 4.5%). In this environment of higher interest rates, business is slowing down. While the PMI index for the eurozone manufacturing sector has been below 50 for the past fourteen months, in August the PMI for the services sector also fell below this threshold. It's becoming clear that growth in the eurozone will be sluggish at best, especially as production cuts by OPEC+ countries weigh on the price of Brent crude. Indeed, third-quarter GDP growth showed a quarter-on-quarter contraction of 0.1%. Overall, between the third quarter of 2023 and the third quarter of 2022, GDP in the eurozone rose by just 0.1%. Although partially offset by government aid, the main reason for this lack of growth is the energy shock, which has weighed heavily on household purchasing power and business activity. The only really positive element in the eurozone economy is the labor market, which remains buoyant. Unemployment remains low at 6.5% (in September) and wage growth is still fairly high. This helps household consumption to hold up and provides support for growth. Overall, the German ten-year yield rose by 42 basis points over the quarter to 2.81%. The stock market lost 4.6% over the same period. The fourth quarter was marked by PMI surveys for both the manufacturing and services sectors, which deteriorated further (the composite index averaged 47 over the quarter). However, with inflation falling and wages continuing to rise, this should enable households to regain purchasing power. At the end of October, German ten-year yields followed the trend in US yields, reaching almost 3%. As in the United States, weak growth is prompting expectations of a faster cut in ECB key rates, especially as November's inflation and core inflation figures are down to 2.4% and 3.5% respectively. At the last ECB meeting, however, the President of the ECB indicated that this was not the time to cut key rates. In fact, the labor market remains buoyant and wage growth is still relatively high, which is having an impact on service prices in particular. All in all, after the bond rally, the ten-year yield closes the year at 2%, 56 basis points lower than at the end of 2022. The stock market ended 2023 up 16% for the year, helped by a 7.5% rise in the fourth quarter

**Candriam Equities L Biotechnology - Candriam Equities L Global Demography - Candriam Equities L Life Care - Candriam Equities L Meta Globe - Candriam Equities L Oncology Impact - Candriam Equities L Robotics & Innovative Technology - Candriam Equities L EMU Innovation - Candriam Equities L Europe Innovation - Candriam Equities L Europe Optimum Quality - Candriam Equities L Emerging Markets**

### Global

Global equity markets started the year on a positive note. After an incredibly difficult 2022, investors started to price a more benign inflation environment in January, supporting interest-rate sensitive sectors, such as consumer discretionary and information technology. The market uptrend was temporarily interrupted by the collapse of Silicon Valley Bank and the struggle of Crédit Suisse, but investors basically embraced better-than-expected economic growth figures, easing inflation pressures and the first prospect of less monetary tightening. Information technology jumped over the quarter, together with communication services and consumer discretionary, whereas the defensive consumer staples and health care sectors underperformed.

The strong uptrend of the first quarter continued into the second one. Growth sectors strongly outperformed value on the back of weakening, but reasonable economic growth data, more visibility on central banks' monetary tightening and plateauing long-term rates. Information technology was the best performing sector over the quarter, mostly driven by positive sentiment around the development of artificial intelligence solutions. Also consumer discretionary continued to outperform the broader market quite significantly. Financials in the meantime started to recover from the regional banking crisis in the US and Crédit Suisse uncertainty, though still underperforming the broader equity market. The most remarkable performance over the quarter nevertheless came from the so-called Magnificent 7 that jumped another 30% bringing their half year close to close to 85%.

After two consecutive quarters of strong gains, global equity markets had to give away some ground in the third quarter of the year. This time growth stocks underperformed, whereas value was quite resilient. The main reason behind the equity market correction was the strong bond market sell-off due to rising interest rates. In addition, investors were spooked by the strong jump in energy prices on the back of Russia's and Saudi-Arabia's oil output cut extension. Without surprise, energy strongly outperformed over the quarter, even gaining more than 10%. Interest-rate sensitive sectors, such as information technology and utilities, were the main underperformers, whereas the defensive health care sector outperformed. Smaller companies continued to underperform large caps.



## Report of the Board of Directors

**Candriam Equities L Biotechnology - Candriam Equities L Global Demography - Candriam Equities L Life Care - Candriam Equities L Meta Globe - Candriam Equities L Oncology Impact - Candriam Equities L Robotics & Innovative Technology - Candriam Equities L EMU Innovation - Candriam Equities L Europe Innovation - Candriam Equities L Europe Optimum Quality - Candriam Equities L Emerging Markets (Continued)**

The last quarter of the year started on a false note. After reaching a high for the year in the third quarter, investors became worried about rising oil prices, a weak Chinese economy and especially a surprisingly strong US labour market. Investors feared the strong labour market might have put an end to cooling down inflation pressures, while the Federal Reserve stated to raise interest rates as long as needed to bring inflation down towards the targeted level. A strong US dollar and a spike in long-term interest rates penalized equity markets strongly in October. Fortunately, there was light at the end of the tunnel. A series of softer inflation prints in the US (and Europe) was enough to remove the fears and make investors shift to expect pre-emptive cuts from the central banks. That view was then confirmed the December Federal Open Market Committee meeting where the latest projections suggested at least three rate cuts over 2024. Investors finally got their year-end present after all with equity markets delivering a more than 10% gain in the final quarter.

To sum up 2023, it was an impressive year for equity markets. The MSCI World All Countries Net Return USD Index ended the year with a 22% gain. Developed markets outperformed emerging markets by more than 10%, as the latter were mainly penalized by the significant Chinese equity market drop. Information technology was the strongest outperformer over the year, driven by the artificial intelligence revolution and Magnificent 7, followed by communication services and consumer discretionary. The defensive utilities, consumer staples and health care sectors underperformed.

### Europe

European equities ended the first quarter of 2023 significantly higher, despite continued inflation pressures, a rapid increase in long-term interest rates and the turmoil in the banking sector. Investors welcomed better-than-expected economic figures on the back of weak energy prices and a strong resilience of services activity. The European Central Bank meanwhile updated its macroeconomic expectations with higher growth and lower inflation. In this context, European stocks delivered a more than 10% gain over the quarter. Information technology, consumer discretionary and communication services outperformed the broader European market over the quarter. Energy and real estate were the sole sectors posting a negative quarterly performance.

The European equity market continued their uptrend in the second quarter. Investors' focus remained on inflation and economic figures. The latter appeared resilient at first sight, but the outlook for the manufacturing sector became quite bleak. Core inflation remained above 5%, urging the central bank for another rate hike. The European market gained around 2.3%, driven by the continuing strength of information technology and the rebound of the financial sector. Communication services and real estate were particularly weak over the quarter.

The third quarter was kind of reality check for investors, with European equities losing around 2%. Following the strong rally in the first half of the year, the deterioration of the region's growth data with continued inflationary pressures, scared investors off. PMI's dropped below 50 and the CPI remained well above the ECB's target on the back of rising oil and gas prices. It didn't come as a surprise in that context that energy was the best performing sector, even gaining almost 14% over the quarter. Also real estate performed well, while consumer discretionary and information technology were subject to profit taking after their impressive gain in the first six months of the year. The defensive health care sector also outperformed over the period.

After the reality check in the third quarter and a weak October-month on the back of surging yields and increased geopolitical uncertainty, investors received their year-end present. European equities gained more than 6.5% in the last three months of the year, recouping all the losses made during the summer correction. Markets welcomed slowing inflation figures, combined with a slowing, but resilient global economy that increased the likelihood of more accommodative central banks in the developing world. The German 10-year yield dropped almost 90 bps in that context, supporting interest-rate sensitive sectors such as real estate, information technology, utilities and consumer discretionary. Energy lagged significantly, dropping around 4%, while health care's performance was flat over the last quarter.

### US

US equities started the year on a positive note: activity indicators (PMI's) surprised positively, labour market data remained resilient and the consumer price index report showed easing inflation pressures. The sole risk that temporarily appeared was related to the US' regional banking sector. The collapse of Silicon Valley Bank was the second largest banking failure in US history and led to a sell-off in the banking sector. Despite that, the Federal Reserve raised its key interest rate by 25 bps in March. In that context, US equities gained over 7% over the quarter, driven by the strong performance of among others information technology, communication services and consumer discretionary. Together with financials and energy, the defensive health care sector was one of the main underperforming sectors.

The second quarter was even stronger than the first quarter, almost entirely driven by the largest growth stocks, and especially technology-related stocks that received a boost by the artificial intelligence revolution. The so-called Magnificent 7 added another 30% to their performance bringing their half year close to close to 85%. Besides that, US inflation fell sharply to around 4% thanks to base effects from oil prices that came down significantly. US markets ended the second quarter with an 8.6% gain and three sectors outperforming the broader market, namely information technology, consumer discretionary and communication services. Energy and utilities were the sole sectors with a negative quarterly performance.

After two consecutive positive quarters, markets experienced a reality check. Investors were worried about weaker-than-expected economic data, fears for "higher for longer" rates to tame sticky inflation and the large US fiscal deficit. That resulted in a sell-off of bond markets and triggered profit taking on more expensive growth stocks. In that context, utilities, real estate, consumer staples and information technology were severely penalized. Energy strongly outperformed over the quarter on the back of rising energy prices following Russia's and Saudi-Arabia's oil output cut extension.

The final quarter of the year, although starting on a false note, was the strongest quarter of the year with an almost 12% gain for the S&P 500. Fears for "higher for longer" rates eased following a series of softer inflation prints. Market started pricing interest rate cuts in 2024, which was confirmed by the central bank. The last meeting of the year suggested three rate cuts for 2024 and strongly supported growth stocks. Besides the strong real estate rebound, anticipating 2024's interest rate cuts, information technology was the best performing sector once again, followed by finance, industrials, consumer discretionary and communication services. The sole sector ending the year with a negative quarterly return was energy.





## Report of the Board of Directors

**Candriam Equities L Biotechnology - Candriam Equities L Global Demography - Candriam Equities L Life Care - Candriam Equities L Meta Globe - Candriam Equities L Oncology Impact - Candriam Equities L Robotics & Innovative Technology - Candriam Equities L EMU Innovation - Candriam Equities L Europe Innovation - Candriam Equities L Europe Optimum Quality - Candriam Equities L Emerging Markets (Continued)**

To conclude, it was a great year for US equities, but with a lot of performance dispersion.

### Emerging Markets

In 2023, Emerging Markets saw continued challenges and volatilities. Against the backdrop of global liquidity conditions, the Fed maintained a steadfast tightening policy throughout the year, marked by multiple rate hikes. Facing consequences from deposit withdrawals, US regional banks were the first casualties of higher rates and tighter liquidity conditions. With such events, broader weakness in the financial sector had a spill-over on EM financials as well, the majority of which eventually recovered as fundamentals stayed intact.

China concluded the year with historically low valuations, defying investors' anticipations of a robust post-Covid recovery. Instead, the country confronted multiple endogenous risks, notably a widespread real estate crisis putting pressure on the refinancing capacity of major property companies such as Evergrande and Country Garden. Additionally, the under-regulated shadow banking sector formed another hurdle to China's economic growth. The government began rolling out a series of stimulus in the second half of the year, but the accumulating policies were not meaningful enough to rekindle investors' enthusiasm. Geopolitical conflicts were another challenge, yet China delivered a more conciliatory tone to the US mitigating the stress. On the other hand, India gained favour as an outstanding global player. The country managed to achieve resilient economic growth, positioning as a competitive production centre in the global supply chain. India's positive development trajectory was affirmed by both its central bank and international organizations such as the World Bank, upgrading the country's GDP growth forecast.

On the thematic front, Artificial Intelligence (AI) emerged as the latest and most influential technology trend. This proved particularly advantageous for export-oriented Taiwan and South Korea, enabling them to regain momentum in the face of global demand weakness. Effectively, the Asia-Pacific region possesses a good coverage of the semi-conductor supply chain, gathering several global chip leaders. Moreover, the year-end saw recovery signs against the downturn cycle, as the industrial production was picking up in the region.

Elsewhere among EM countries, central banks demonstrated effectiveness to curb inflation. Many EM countries, such as some in LatAm, entered rate cutting and further easing cycles earlier than their DM peers. Brazil's economy showcased resilience regardless of some initial concerns over the elections, and Mexico continued to reap the benefits from the US near-shoring effect. In Emerging Europe, recovery was also observed in Poland and Greece.

As the final chapter of the year unfolded in December, the narrative took on new dimensions. After a period of rises and stagnation, the Fed eventually adopted a more dovish posture for rate policy, signalling an expected peak of the hiking cycle and potential rate cuts in 2024. The welcomed shift boosted market performance across regions. However, questions lingered, including the US' enduring debt deficit. The unfortunate conflicts around the Red Sea added to volatilities. As a result, commodity pockets witnessed some significant movements, and the global supply chain, already under strain, became more delicate.

Overall 2023, continued to remain a year of large deviation in market performance of EM regions. On one hand broader EM markets outside China displayed strong resilience tracking gains in global markets, at the same time the slowdown concerns in China weighed on China equity returns.

## Candriam Equities L Australia

### 2023 Market Review

The Candriam Equities L - Australia portfolio generated performance for the year ending December 2023 of +9.98% (net of fees) versus the benchmark return of +8.42%, as measured by the S&P/ASX All Ordinaries Index.

At a sector level this year, the Portfolio benefited from the overweight positions in the Materials and Information Technology sectors. The underweight positions in the Industrials, Communication Services and Utilities sectors also added value. Conversely, the overweight positions in the Energy, Consumer Staples, Health Care and Financials sectors detracted value. The underweight positions in the Consumer Discretionary and Real Estate sectors also detracted value.

At a stock level, the overweight positions in James Hardie, Xero, Block, Goodman Group, BlueScope Steel, Aristocrat Leisure, Evolution Mining, NextDC, Sandfire Resources and QBE Insurance contributed to relative performance. Conversely, the overweight positions in Treasury Wine Estates, IGO, IDP Education, Lynas Rare Earths, 29Metals, ResMed and Allkem detracted from relative performance. The nil positions in Fortescue Metals, Wesfarmers and REA Group also detracted value.

The economy is slowing, as intended, and we see economic growth below trend in 2024, but with some support from resources demand especially, that will see Australia avoid recession. In this environment, we believe earnings growth will be harder to find, but we still expect there to be pockets of growth. On aggregate, we see earnings growth for FY24<sup>1</sup> at a similar level to FY23. There is room for some upward surprise in certain sectors as Australia's economy remains relatively resilient and is operating near full employment.

On EPS growth, FY23 earnings growth was slightly down, which compared to FY21 (+30%) and FY22 (+21%) where earnings were driven by massive fiscal and monetary stimulus, represented a huge stall in earnings growth as the market adjusted to the normalisation of rates. If FY23 could be described as a 'growth pause' in earnings, we would suggest FY24 will be another flat year of earnings growth that can best be described as a 'consolidation' as balance sheets and P&Ls normalise for a future where interest rates are more normal, and only genuine growth in earnings matters.

<sup>1</sup> It is important to note that Australia reports financial years that end in 30 June each year, which is different to Europe where financials are reported on a calendar year basis ending on 31 December. For ease of reference, references to the full year 12-months of results that are reported as at 30 June each year. Market consensus numbers also follow this pattern.



## Report of the Board of Directors

### Candriam Equities L Australia (Continued)

#### Outlook

Our reading of the economy is that with economic growth harder to come by in 2024, so will be the case for system earnings growth. However, the average outcome for EPS growth in FY24 and into FY25 masks several areas in the economy where we expect to see growth.

From the perspective of cyclicalities, the market is currently balanced on edge, between a negative view based on household spending that is being impacted by high inflation, higher rates, utilities and food costs; and a positive outlook that sees households adjusting because of a relatively resilient economy and a cushion of excess savings. In cyclical sectors there are some names that still stand out, but overall, we remain cautious. In this market, with a subtrend economic growth outlook, Ausbil favours earnings growth from GDP agnostic sectors and stocks, and quality leaders with demonstrated operational and pricing leverage. Quality telecommunications are expected to perform in this environment.

From the viewpoint of opportunity to generate growth, we expect earnings growth to come from fundamental demand generated by a number of themes, including: demand for resources from China; the shift to decarbonisation and the electrification of things; global changes in energy markets; and specific opportunities in technology companies that are cashflow positive and can generate positive earnings growth. Because growth opportunities are notionally longer in duration, the increase in real rates means that good opportunities for earnings growth in this space are cheaper than before the rate rises.

In aggregate terms, the market is expecting little earnings growth to June 30 financial year 2024. On balance, we see potential upside relative to consensus driven by better than forecast commodity prices, particularly for the bulks and energy. In the non-resource sectors, better earnings growth outcomes are likely in the health care, technology, telecommunications, commercial services, and to a lesser extent the banking sector.

While rising rates had punished technology names across 2022, the plateauing and normalisation of rates as well as cost-out programs saw them re-rating in 2023. Ausbil sees technology as a potential earnings rerate in FY24, however, as most are long duration growth assets, the impact will be variable.

Value is also emerging in quality REITs, particularly those with exposure to data centres and housing given population growth. Certain names within the infrastructure space are also offering value following the recent downward adjustment in prices.

The overall valuation of the Australian equity market is currently sitting close to long-term average multiples on a suppressed earnings outlook. Despite this, our conclusion on earnings growth opportunities heading into calendar 2024 is that the average never really tells the story on its own. Consensus currently expects earnings contraction in FY24 of -4.3% for the S&P/ASX 200, then a return to earnings growth of +4.3% in FY25, however we believe that earnings growth well above system can be achieved in some sectors in FY24, and through key quality opportunities looking ahead.

#### SFDR

The Candriam Equities L - Australia Fund is classified as article 6 under SFDR. It does not integrate ESG characteristics in the management framework.

#### Taxonomy alignment

Not relevant.

#### Candriam Equities L Risk Arbitrage Opportunities

2023 was a mixed year for M&A arbitrage funds in general. The first half of the year was marked by a fairly low level of M&A activity and two successive deal failures in the United States: First Horizon Corp and Tegna Inc. These failures caused a deterioration in returns on the strategy, mainly in the first quarter. The second half of the year saw an upturn in performance due to the rebound in M&A activity, stabilising interest rates and the easing of pressure from regulators.

This recovery was mainly driven by North America, which saw total deal volume exceed \$1,000 billion over the last 6 months of the year, placing this half-year among the five best of the last two decades in terms of volume. Deals in excess of \$20 billion played a key role, with the sector themes of technology, energy and healthcare as the main drivers of this recovery.

The improvement in the regulatory environment, less hostile following the US regulator's defeat in the two lawsuits relating to the Activision/Microsoft and Horizon Therapeutics/Amgen deals, contributed greatly to the wave of announcements at the end of the year. The stabilisation of interest rates also played a positive role.

In Europe, however, the recovery was not as marked, with the number of announced mergers and acquisitions not following the same trend as in North America.

At Candriam, there was also a change in the management team at the end of the first quarter following the departure of the two senior managers who had been in place since 2018. The significant recovery in the fund's performance following the arrival of the new head of management is therefore explained by these elements inherent in the strategy, but also by the marked improvement in the investment process. Following this management change, a new investment strategy was also introduced to the Candriam Risk Arbitrage Opportunities fund. This concerns special situations in which a maximum of 15% of AuM may be invested in companies that are the subject of pre-announced takeovers, either by the company itself, which means that it is being put up for sale, or by the recognised press specialising in the field, which indicates that the company is going to be taken over. The aim of this investment pocket is to introduce a new outperformance driver into the fund.

The performance indicators for our strategy are currently in the green and we expect 2024 to follow on from the second half of 2023, which bodes well for our fund. We are positioned to benefit from this environment, and the expected rates of return should enable us to achieve our management objectives.

The fund ended the year in negative territory, despite a second half that was more in line with performance targets.

None of the issuers in the portfolio has suffered a credit event.



## Report of the Board of Directors

### Candriam Equities L Risk Arbitrage Opportunities (Continued)

#### Credit Derivatives

The portfolio did not use credit derivatives during the period.

The performance of the units is as follows:

| <i>Entity Name</i>  | <i>Entity Currency</i> | <i>Return Begin date</i> | <i>Return End Date</i> | <i>NAV per share return</i> | <i>Ref. NAV per share return</i> | <i>Net Excess Return</i> |
|---|------------------------|--------------------------|------------------------|-----------------------------|----------------------------------|--------------------------|
| <i>Candriam Equities L Risk Arbitrage Opportunities - C Cap</i> | <i>EUR</i>             | <i>30/12/2022</i>        | <i>29/12/2023</i>      | <i>- 1.98%</i>              | <i>3.29%</i>                     | <i>-5.27%</i>            |
| <i>Candriam Equities L Risk Arbitrage Opportunities - Z Cap</i> | <i>EUR</i>             | <i>30/12/2022</i>        | <i>29/12/2023</i>      | <i>-0.36%</i>               | <i>3.29%</i>                     | <i>-3.65%</i>            |
| <i>Candriam Equities L Risk Arbitrage Opportunities - I Cap</i> | <i>EUR</i>             | <i>30/12/2022</i>        | <i>29/12/2023</i>      | <i>- 1.39%</i>              | <i>3.29%</i>                     | <i>-4.68%</i>            |

*Past performance is not indicative of future performance.*

#### SFDR

Candriam Equities L Risk Arbitrage Opportunities is classified as an SFDR article 6.

It does not systematically integrate ESG characteristics into its management framework. Nevertheless, sustainability risks are taken into account in investment decisions through Candriam's exclusion policy which excludes certain controversial activities.

#### Taxonomy

The investments underlying this financial product do not take into account the European Union's criteria for environmentally sustainable economic activities.

The Board of Directors

Luxembourg, March 28, 2024.



## Audit report

To the Shareholders of  
**CANDRIAM EQUITIES L**

---

### Our opinion

In our opinion, the accompanying financial statements give a true and fair view of the financial position of CANDRIAM EQUITIES L (the “Fund”) and of each of its sub-funds as at 31 December 2023, and of the results of their operations and changes in their net assets for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements.

#### *What we have audited*

The Fund’s financial statements comprise:

- the statement of net assets as at 31 December 2023;
- the statement of changes in net assets for the year then ended;
- the investment portfolio as at 31 December 2023; and
- the notes to the financial statements - Schedule of derivative instruments and the other notes to the financial statements, which include a summary of significant accounting policies.

---

### Basis for opinion

We conducted our audit in accordance with the Law of 23 July 2016 on the audit profession (Law of 23 July 2016) and with International Standards on Auditing (ISAs) as adopted for Luxembourg by the “Commission de Surveillance du Secteur Financier” (CSSF). Our responsibilities under the Law of 23 July 2016 and ISAs as adopted for Luxembourg by the CSSF are further described in the “Responsibilities of the “Réviseur d’entreprises agréé” for the audit of the financial statements” section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

We are independent of the Fund in accordance with the International Code of Ethics for Professional Accountants, including International Independence Standards, issued by the International Ethics Standards Board for Accountants (IESBA Code) as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the financial statements. We have fulfilled our other ethical responsibilities under those ethical requirements.

---

### Other information

The Board of Directors of the Fund is responsible for the other information. The other information comprises the information stated in the annual report but does not include the financial statements and our audit report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

---

*PricewaterhouseCoopers, Société coopérative, 2 rue Gerhard Mercator, B.P. 1443, L-1014 Luxembourg  
T : +352 494848 1, F : +352 494848 2900, [www.pwc.lu](http://www.pwc.lu)*

*Cabinet de révision agréé. Expert-comptable (autorisation gouvernementale n°10028256)  
R.C.S. Luxembourg B 65 477 - TVA LU25482518*



In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

---

#### **Responsibilities of the Board of Directors of the Fund for the financial statements**

The Board of Directors of the Fund is responsible for the preparation and fair presentation of the financial statements in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements, and for such internal control as the Board of Directors of the Fund determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors of the Fund is responsible for assessing the Fund's and each of its sub-funds' ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors of the Fund either intends to liquidate the Fund or close any of its sub-funds or to cease operations, or has no realistic alternative but to do so.

---

#### **Responsibilities of the “Réviseur d’entreprises agréé” for the audit of the financial statements**

The objectives of our audit are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an audit report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control;
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors of the Fund;



- conclude on the appropriateness of the Board of Directors of the Fund's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's or any of its sub-funds' ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our audit report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or conditions may cause the Fund or any of its sub-funds to cease to continue as a going concern;
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

PricewaterhouseCoopers, Société coopérative  
Represented by

Luxembourg, 4 April 2024

Sébastien Sadzot



## Statement of net assets as at December 31, 2023

|   |      | Candriam Equities  |                      |                    |
|---|------|--------------------|----------------------|--------------------|
|   |      | L Australia        | L Biotechnology      | L Emerging Markets |
|   |      | AUD                | USD                  | EUR                |
| <b>Assets</b>   |      |                    |                      |                    |
| Investment portfolio at market value                              | 2a   | 228,462,253        | 1,510,110,505        | 952,332,995        |
| Cash at bank and broker   | 13   | 758,966            | 59,427,725           | 23,082,959         |
| Receivable for investments sold                                   |      | 0                  | 3,970,438            | 2,404,605          |
| Receivable on subscriptions                                       |      | 167,379            | 53,765,425           | 212,231            |
| Receivable on CFD   |      | 0                  | 0                    | 0                  |
| Dividends receivable on CFD                                       | 2f   | 0                  | 0                    | 0                  |
| Receivable on reverse repurchase agreements                       | 9    | 0                  | 0                    | 0                  |
| Interest and dividends receivable, net                            |      | 87,743             | 116,350              | 1,111,076          |
| Net unrealised appreciation on forward foreign exchange contracts | 2g,h | 0                  | 2,574,794            | 0                  |
| Net unrealised appreciation on futures                            | 2e   | 0                  | 0                    | 0                  |
| Other assets  |      | 0                  | 23,625               | 0                  |
| <b>Total assets</b>   |      | <b>229,476,341</b> | <b>1,629,988,862</b> | <b>979,143,866</b> |
| <b>Liabilities</b>  |      |                    |                      |                    |
| Bank overdraft  |      | 0                  | 230,496              | 2                  |
| Payable on investments purchased                                  |      | 0                  | 36,475,398           | 0                  |
| Payable on redemptions  |      | 164,483            | 3,082,178            | 4,023,978          |
| Payable on CFD  |      | 0                  | 0                    | 0                  |
| Dividends payable on CFD  | 7    | 0                  | 0                    | 0                  |
| Net unrealised depreciation on forward foreign exchange contracts | 2g,h | 0                  | 0                    | 2,135              |
| Net unrealised depreciation on futures                            | 2e   | 0                  | 0                    | 0                  |
| Net unrealised depreciation on CFD                                | 2f   | 0                  | 0                    | 0                  |
| Management fees payable   | 3    | 224,970            | 1,424,247            | 504,592            |
| Operating and Administrative Expenses payable                     | 5    | 49,431             | 324,704              | 251,149            |
| Performance fees payable  | 6    | 0                  | 1,307,841            | 0                  |
| Subscription tax payable  | 7    | 93,631             | 494,461              | 332,320            |
| Other liabilities   | 8    | 4                  | 36,764               | 4,324,238          |
| <b>Total liabilities</b>  |      | <b>532,519</b>     | <b>43,376,089</b>    | <b>9,438,414</b>   |
| <b>Total net assets</b>   |      | <b>228,943,822</b> | <b>1,586,612,773</b> | <b>969,705,452</b> |



## Statement of net assets as at December 31, 2023

|   |      | Candriam Equities<br>L EMU Innovation | Candriam Equities<br>L Europe<br>Innovation | Candriam Equities<br>L Europe<br>Optimum<br>Quality |
|---|------|---------------------------------------|---|---|
|   |      | EUR                                   | EUR   | EUR   |
| <b>Assets</b>   |      |                                       |   |   |
| Investment portfolio at market value                              | 2a   | 44,607,984                            | 865,126,164                                 | 544,683,476   |
| Cash at bank and broker   | 13   | 3,346,721                             | 35,970,568                                  | 18,459,292  |
| Receivable for investments sold                                   |      | 0                                     | 0   | 0   |
| Receivable on subscriptions                                       |      | 0                                     | 388,836                                     | 165,988   |
| Receivable on CFD   |      | 0                                     | 0   | 0   |
| Dividends receivable on CFD                                       | 2f   | 0                                     | 0   | 0   |
| Receivable on reverse repurchase agreements                       | 9    | 0                                     | 0   | 0   |
| Interest and dividends receivable, net                            |      | 562                                   | 385,858                                     | 268,679   |
| Net unrealised appreciation on forward foreign exchange contracts | 2g,h | 0                                     | 0   | 0   |
| Net unrealised appreciation on futures                            | 2e   | 0                                     | 0   | 2,636,250   |
| Other assets  |      | 65,956                                | 166,995                                     | 542,441   |
| <b>Total assets</b>   |      | <b>48,021,223</b>                     | <b>902,038,421</b>                          | <b>566,756,126</b>                                  |
| <b>Liabilities</b>  |      |                                       |   |   |
| Bank overdraft  |      | 0                                     | 90,282                                      | 0   |
| Payable on investments purchased                                  |      | 0                                     | 0   | 0   |
| Payable on redemptions  |      | 0                                     | 1,479,966                                   | 629,817   |
| Payable on CFD  |      | 0                                     | 0   | 0   |
| Dividends payable on CFD  | 7    | 0                                     | 0   | 0   |
| Net unrealised depreciation on forward foreign exchange contracts | 2g,h | 0                                     | 42,960                                      | 0   |
| Net unrealised depreciation on futures                            | 2e   | 0                                     | 0   | 0   |
| Net unrealised depreciation on CFD                                | 2f   | 0                                     | 0   | 0   |
| Management fees payable   | 3    | 5,965                                 | 1,018,445                                   | 757,616   |
| Operating and Administrative Expenses payable                     | 5    | 7,900                                 | 206,688                                     | 139,013   |
| Performance fees payable  | 6    | 0                                     | 0   | 0   |
| Subscription tax payable  | 7    | 1,240                                 | 559,365                                     | 526,653   |
| Other liabilities   | 8    | 0                                     | 0   | 0   |
| <b>Total liabilities</b>  |      | <b>15,105</b>                         | <b>3,397,706</b>                            | <b>2,053,099</b>                                    |
| <b>Total net assets</b>   |      | <b>48,006,118</b>                     | <b>898,640,715</b>                          | <b>564,703,027</b>                                  |





## Statement of net assets as at December 31, 2023

|   |      | Candriam Equities<br>L Global<br>Demography | Candriam Equities<br>L Life Care | Candriam Equities<br>L Meta Globe |
|---|------|---|----------------------------------|-----------------------------------|
|   |      | EUR   | USD                              | USD                               |
| <b>Assets</b>   |      |   |                                  |                                   |
| Investment portfolio at market value                              | 2a   | 1,482,102,718                               | 713,440,334                      | 142,257,036                       |
| Cash at bank and broker   | 13   | 87,110,274                                  | 16,238,616                       | 7,088,065                         |
| Receivable for investments sold                                   |      | 0   | 0                                | 0                                 |
| Receivable on subscriptions                                       |      | 2,187,757                                   | 0                                | 0                                 |
| Receivable on CFD   |      | 0   | 0                                | 0                                 |
| Dividends receivable on CFD                                       | 2f   | 0   | 0                                | 0                                 |
| Receivable on reverse repurchase agreements                       | 9    | 0   | 0                                | 0                                 |
| Interest and dividends receivable, net                            |      | 849,973                                     | 475,367                          | 30,809                            |
| Net unrealised appreciation on forward foreign exchange contracts | 2g,h | 0   | 0                                | 0                                 |
| Net unrealised appreciation on futures                            | 2e   | 0   | 0                                | 0                                 |
| Other assets  |      | 39,936                                      | 0                                | 0                                 |
| <b>Total assets</b>   |      | <b>1,572,290,658</b>                        | <b>730,154,317</b>               | <b>149,375,910</b>                |
| <b>Liabilities</b>  |      |   |                                  |                                   |
| Bank overdraft  |      | 0   | 0                                | 0                                 |
| Payable on investments purchased                                  |      | 0   | 0                                | 0                                 |
| Payable on redemptions  |      | 1,190,449                                   | 19,547                           | 0                                 |
| Payable on CFD  |      | 0   | 0                                | 0                                 |
| Dividends payable on CFD  | 7    | 0   | 0                                | 0                                 |
| Net unrealised depreciation on forward foreign exchange contracts | 2g,h | 0   | 0                                | 0                                 |
| Net unrealised depreciation on futures                            | 2e   | 0   | 0                                | 0                                 |
| Net unrealised depreciation on CFD                                | 2f   | 0   | 0                                | 0                                 |
| Management fees payable   | 3    | 1,867,777                                   | 2,228                            | 27                                |
| Operating and Administrative Expenses payable                     | 5    | 368,746                                     | 50,008                           | 18,235                            |
| Performance fees payable  | 6    | 0   | 0                                | 0                                 |
| Subscription tax payable  | 7    | 1,367,048                                   | 18,277                           | 3,736                             |
| Other liabilities   | 8    | 0   | 0                                | 0                                 |
| <b>Total liabilities</b>  |      | <b>4,794,020</b>                            | <b>90,060</b>                    | <b>21,998</b>                     |
| <b>Total net assets</b>   |      | <b>1,567,496,638</b>                        | <b>730,064,257</b>               | <b>149,353,912</b>                |



## Statement of net assets as at December 31, 2023

|   |      | Candriam Equities<br>L Oncology Impact | Candriam Equities<br>L Risk Arbitrage<br>Opportunities | Candriam Equities<br>L Robotics &<br>Innovative<br>Technology |
|---|------|--|--|---|
|   |      | USD                                    | EUR  | USD   |
| <b>Assets</b>   |      |  |  |   |
| Investment portfolio at market value                              | 2a   | 1,833,721,726                          | 19,483,544   | 1,779,881,479   |
| Cash at bank and broker   | 13   | 43,394,307                             | 11,933,033   | 54,182,365  |
| Receivable for investments sold                                   |      | 0                                      | 378,520  | 0   |
| Receivable on subscriptions                                       |      | 4,143,786                              | 0  | 646,677   |
| Receivable on CFD   |      | 0                                      | 233,291  | 0   |
| Dividends receivable on CFD                                       | 2f   | 0                                      | 121,874  | 0   |
| Receivable on reverse repurchase agreements                       | 9    | 0                                      | 21,100,086   | 0   |
| Interest and dividends receivable, net                            |      | 967,377                                | 138,126  | 284,002   |
| Net unrealised appreciation on forward foreign exchange contracts | 2g,h | 5,239,533                              | 32,599   | 413,106   |
| Net unrealised appreciation on futures                            | 2e   | 0                                      | 0  | 0   |
| Other assets  |      | 0                                      | 0  | 1,000   |
| <b>Total assets</b>   |      | <b>1,887,466,729</b>                   | <b>53,421,073</b>                                      | <b>1,835,408,629</b>  |
| <b>Liabilities</b>  |      |  |  |   |
| Bank overdraft  |      | 23,168,103                             | 0  | 0   |
| Payable on investments purchased                                  |      | 0                                      | 3,208,364  | 0   |
| Payable on redemptions  |      | 1,756,736                              | 80,523   | 676,105   |
| Payable on CFD  |      | 0                                      | 288,428  | 0   |
| Dividends payable on CFD  | 7    | 0                                      | 32,951   | 0   |
| Net unrealised depreciation on forward foreign exchange contracts | 2g,h | 0                                      | 0  | 0   |
| Net unrealised depreciation on futures                            | 2e   | 0                                      | 47,950   | 0   |
| Net unrealised depreciation on CFD                                | 2f   | 0                                      | 113,741  | 0   |
| Management fees payable   | 3    | 835,531                                | 2,102  | 349,530   |
| Operating and Administrative Expenses payable                     | 5    | 307,131                                | 8,173  | 169,525   |
| Performance fees payable  | 6    | 0                                      | 0  | 0   |
| Subscription tax payable  | 7    | 89,668                                 | 1,241  | 62,626  |
| Other liabilities   | 8    | 0                                      | 0  | 0   |
| <b>Total liabilities</b>  |      | <b>26,157,169</b>                      | <b>3,783,473</b>                                       | <b>1,257,786</b>  |
| <b>Total net assets</b>   |      | <b>1,861,309,560</b>                   | <b>49,637,600</b>                                      | <b>1,834,150,843</b>  |



Statement of net assets as at December 31, 2023

|   |      | Combined             |
|---|------|----------------------|
|   |      | EUR                  |
| <b>Assets</b>   |      |                      |
| Investment portfolio at market value                              | 2a   | 9,462,363,211        |
| Cash at bank and broker   | 13   | 343,618,777          |
| Receivable for investments sold                                   |      | 6,377,420            |
| Receivable on subscriptions                                       |      | 56,066,716           |
| Receivable on CFD   |      | 233,291              |
| Dividends receivable on CFD                                       | 2f   | 121,874              |
| Receivable on reverse repurchase agreements                       | 9    | 21,100,086           |
| Interest and dividends receivable, net                            |      | 4,504,836            |
| Net unrealised appreciation on forward foreign exchange contracts | 2g,h | 7,480,599            |
| Net unrealised appreciation on futures                            | 2e   | 2,636,250            |
| Other assets  |      | 837,620              |
| <b>Total assets</b>   |      | <b>9,905,340,680</b> |
| <b>Liabilities</b>  |      |                      |
| Bank overdraft  |      | 21,272,196           |
| Payable on investments purchased                                  |      | 36,228,233           |
| Payable on redemptions  |      | 12,516,549           |
| Payable on CFD  |      | 288,428              |
| Dividends payable on CFD  | 7    | 32,951               |
| Net unrealised depreciation on forward foreign exchange contracts | 2g,h | 45,095               |
| Net unrealised depreciation on futures                            | 2e   | 47,950               |
| Net unrealised depreciation on CFD                                | 2f   | 113,741              |
| Management fees payable   | 3    | 6,659,575            |
| Operating and Administrative Expenses payable                     | 5    | 1,799,414            |
| Performance fees payable  | 6    | 1,183,942            |
| Subscription tax payable  | 7    | 3,451,098            |
| Other liabilities   | 8    | 4,357,522            |
| <b>Total liabilities</b>  |      | <b>87,996,694</b>    |
| <b>Total net assets</b>   |      | <b>9,817,343,986</b> |



## Statement of changes in net assets for the year ended December 31, 2023

|  |    | Candriam Equities<br>L Australia | Candriam Equities<br>L Biotechnology | Candriam Equities<br>L Emerging<br>Markets |
|--|----|----------------------------------|--------------------------------------|--|
|  |    | AUD                              | USD                                  | EUR  |
| <b>Net assets at the beginning of the year</b>   |    | <b>227,441,918</b>               | <b>1,767,239,462</b>                 | <b>1,204,443,591</b>                       |
| <b>Income</b>  |    |                                  |                                      |  |
| Dividends, net   | 2k | 7,590,575                        | 7,195,847                            | 18,402,762                                 |
| Interest received on CFD   |    | 0                                | 0                                    | 0  |
| Interest on securities lending   | 10 | 0                                | 87,455                               | 13,588                                     |
| Bank interest  |    | 36,149                           | 1,273,539                            | 743,580                                    |
| Dividends received on CFD  |    | 0                                | 0                                    | 0  |
| Interest on reverse repurchase agreements  |    | 0                                | 0                                    | 0  |
| Other income   |    | 68,630                           | 2                                    | 3,620                                      |
| <b>Total income</b>  |    | <b>7,695,354</b>                 | <b>8,556,843</b>                     | <b>19,163,550</b>                          |
| <b>Expenses</b>  |    |                                  |                                      |  |
| Management fees  | 3  | 2,777,098                        | 16,712,199                           | 6,365,768                                  |
| Performance fees   | 6  | 0                                | 2,128,950                            | 0  |
| Operating and Administrative Expenses  | 5  | 594,614                          | 3,936,166                            | 3,605,526                                  |
| Depository fees  | 5  | 10,114                           | 69,539                               | 54,679                                     |
| Subscription tax   | 7  | 156,145                          | 929,848                              | 556,704                                    |
| Transaction costs  | 2j | 88,382                           | 698,781                              | 2,250,552                                  |
| Interest paid on CFD   |    | 0                                | 0                                    | 0  |
| Bank interest  |    | 0                                | 20,543                               | 900  |
| Other expenses   |    | 0                                | 0                                    | 932  |
| <b>Total expenses</b>  |    | <b>3,626,353</b>                 | <b>24,496,026</b>                    | <b>12,835,061</b>                          |
| <b>Net income / (loss) from investments</b>  |    | <b>4,069,001</b>                 | <b>(15,939,183)</b>                  | <b>6,328,489</b>                           |
| Net realised gain / (loss) on sales of investments   | 2b | 11,272,130                       | 74,400,802                           | (30,818,779)                               |
| Net realised gain / (loss) on options  | 2e | 0                                | 0                                    | 0  |
| Net realised gain / (loss) on forward foreign exchange contracts                           | 2g | 0                                | (541,792)                            | (179,431)                                  |
| Net realised gain / (loss) on futures  | 2e | 0                                | 0                                    | 0  |
| Net realised gain / (loss) on CFD  | 2f | 0                                | 0                                    | 0  |
| Net realised gain / (loss) on foreign exchange   |    | (16,231)                         | (4,493,236)                          | (27,419,205)                               |
| <b>Net realised gain / (loss)</b>  |    | <b>15,324,900</b>                | <b>53,426,591</b>                    | <b>(52,088,926)</b>                        |
| Change in net unrealised appreciation / depreciation on investments                        | 2a | 6,808,355                        | 47,223,575                           | 82,734,584                                 |
| Change in net unrealised appreciation / depreciation on forward foreign exchange contracts | 2g | 0                                | 2,478,295                            | (1,601)                                    |
| Change in net unrealised appreciation / depreciation on futures                            | 2e | 0                                | 0                                    | 0  |
| Change in net unrealised appreciation / depreciation on CFD                                | 2f | 0                                | 0                                    | 0  |
| <b>Net increase / (decrease) in net assets as a result of operations</b>                   |    | <b>22,133,255</b>                | <b>103,128,461</b>                   | <b>30,644,057</b>                          |
| <b>Evolution of the capital</b>  |    |                                  |                                      |  |
| Subscriptions of shares  |    | 38,136,218                       | 312,199,202                          | 210,492,585                                |
| Redemptions of shares  |    | (58,032,800)                     | (595,050,951)                        | (466,896,487)                              |
| Dividends distributed  | 11 | (734,769)                        | (903,401)                            | (8,978,294)                                |
| Currency translation   |    | 0                                | 0                                    | 0  |
| <b>Net assets at the end of the year</b>   |    | <b>228,943,822</b>               | <b>1,586,612,773</b>                 | <b>969,705,452</b>                         |



## Statement of changes in net assets for the year ended December 31, 2023

|  |    | Candriam Equities<br>L EMU Innovation | Candriam Equities<br>L Europe<br>Innovation | Candriam Equities<br>L Europe<br>Optimum<br>Quality |
|--|----|---------------------------------------|---|---|
|  |    | EUR                                   | EUR   | EUR   |
| <b>Net assets at the beginning of the year</b>   |    | <b>58,916,622</b>                     | <b>1,241,599,848</b>                        | <b>791,623,230</b>                                  |
| <b>Income</b>  |    |                                       |   |   |
| Dividends, net   | 2k | 739,990                               | 19,024,254                                  | 13,159,086  |
| Interest received on CFD   |    | 0                                     | 0   | 0   |
| Interest on securities lending   | 10 | 1,212                                 | 102,055                                     | 41,666  |
| Bank interest  |    | 69,796                                | 1,282,792                                   | 538,268   |
| Dividends received on CFD  |    | 0                                     | 0   | 0   |
| Interest on reverse repurchase agreements  |    | 0                                     | 1,188                                       | 0   |
| Other income   |    | 50                                    | 1,771                                       | 1,616   |
| <b>Total income</b>  |    | <b>811,048</b>                        | <b>20,412,060</b>                           | <b>13,740,636</b>                                   |
| <b>Expenses</b>  |    |                                       |   |   |
| Management fees  | 3  | 76,119                                | 13,615,805                                  | 9,541,654   |
| Performance fees   | 6  | 0                                     | 0   | 0   |
| Operating and Administrative Expenses  | 5  | 94,115                                | 3,009,584                                   | 1,787,749   |
| Depository fees  | 5  | 2,173                                 | 51,144                                      | 27,875  |
| Subscription tax   | 7  | 5,015                                 | 911,275                                     | 756,039   |
| Transaction costs  | 2j | 36,651                                | 931,436                                     | 678,509   |
| Interest paid on CFD   |    | 0                                     | 0   | 0   |
| Bank interest  |    | 557                                   | 35  | 67,515  |
| Other expenses   |    | 99                                    | 1   | 213   |
| <b>Total expenses</b>  |    | <b>214,729</b>                        | <b>18,519,280</b>                           | <b>12,859,554</b>                                   |
| <b>Net income / (loss) from investments</b>  |    | <b>596,319</b>                        | <b>1,892,780</b>                            | <b>881,082</b>                                      |
| Net realised gain / (loss) on sales of investments   | 2b | 2,485,854                             | 32,861,068                                  | (656,340)   |
| Net realised gain / (loss) on options  | 2e | 0                                     | 0   | (61,000)  |
| Net realised gain / (loss) on forward foreign exchange contracts                           | 2g | 0                                     | 20,535                                      | 0   |
| Net realised gain / (loss) on futures  | 2e | 0                                     | 1   | (43,631,649)  |
| Net realised gain / (loss) on CFD  | 2f | 0                                     | 0   | 0   |
| Net realised gain / (loss) on foreign exchange   |    | (100,205)                             | 1,277,263                                   | 6,634,410   |
| <b>Net realised gain / (loss)</b>  |    | <b>2,981,968</b>                      | <b>36,051,647</b>                           | <b>(36,833,497)</b>                                 |
| Change in net unrealised appreciation / depreciation on investments                        | 2a | 4,468,367                             | 24,665,323                                  | 45,726,617  |
| Change in net unrealised appreciation / depreciation on forward foreign exchange contracts | 2g | 0                                     | (40,807)                                    | 0   |
| Change in net unrealised appreciation / depreciation on futures                            | 2e | 0                                     | 0   | (1,583,910)   |
| Change in net unrealised appreciation / depreciation on CFD                                | 2f | 0                                     | 0   | 0   |
| <b>Net increase / (decrease) in net assets as a result of operations</b>                   |    | <b>7,450,335</b>                      | <b>60,676,163</b>                           | <b>7,309,210</b>                                    |
| <b>Evolution of the capital</b>  |    |                                       |   |   |
| Subscriptions of shares  |    | 2,044,042                             | 286,957,356                                 | 20,386,048  |
| Redemptions of shares  |    | (20,404,881)                          | (684,940,692)                               | (250,218,432)                                       |
| Dividends distributed  | 11 | 0                                     | (5,651,960)                                 | (4,397,029)   |
| Currency translation   |    | 0                                     | 0   | 0   |
| <b>Net assets at the end of the year</b>   |    | <b>48,006,118</b>                     | <b>898,640,715</b>                          | <b>564,703,027</b>                                  |



## Statement of changes in net assets for the year ended December 31, 2023

|  |    | Candriam Equities<br>L Global<br>Demography | Candriam Equities<br>L Life Care | Candriam Equities<br>L Meta Globe |
|--|----|---|----------------------------------|-----------------------------------|
|  |    | EUR   | USD                              | USD                               |
| <b>Net assets at the beginning of the year</b>   |    | <b>1,323,111,408</b>                        | <b>611,819,118</b>               | <b>4,168,458</b>                  |
| <b>Income</b>  |    |   |                                  |                                   |
| Dividends, net   | 2k | 18,886,605                                  | 7,451,626                        | 221,940                           |
| Interest received on CFD   |    | 0   | 0                                | 0                                 |
| Interest on securities lending   | 10 | 311   | 2,558                            | 0                                 |
| Bank interest  |    | 1,602,178                                   | 378,571                          | 78,076                            |
| Dividends received on CFD  |    | 0   | 0                                | 0                                 |
| Interest on reverse repurchase agreements  |    | 0   | 0                                | 0                                 |
| Other income   |    | 940   | 803                              | 8                                 |
| <b>Total income</b>  |    | <b>20,490,034</b>                           | <b>7,833,558</b>                 | <b>300,024</b>                    |
| <b>Expenses</b>  |    |   |                                  |                                   |
| Management fees  | 3  | 20,008,034                                  | 12,219                           | 167                               |
| Performance fees   | 6  | 0   | 0                                | 0                                 |
| Operating and Administrative Expenses  | 5  | 3,977,892                                   | 418,608                          | 66,077                            |
| Depository fees  | 5  | 63,893                                      | 28,067                           | 1,958                             |
| Subscription tax   | 7  | 1,847,620                                   | 65,535                           | 6,909                             |
| Transaction costs  | 2j | 1,542,905                                   | 473,845                          | 27,904                            |
| Interest paid on CFD   |    | 0   | 0                                | 0                                 |
| Bank interest  |    | 69,908                                      | 14,442                           | 431                               |
| Other expenses   |    | 0   | 123,771                          | 0                                 |
| <b>Total expenses</b>  |    | <b>27,510,252</b>                           | <b>1,136,487</b>                 | <b>103,446</b>                    |
| <b>Net income / (loss) from investments</b>  |    | <b>(7,020,218)</b>                          | <b>6,697,071</b>                 | <b>196,578</b>                    |
| Net realised gain / (loss) on sales of investments   | 2b | 40,526,829                                  | (16,151,363)                     | 1,835,977                         |
| Net realised gain / (loss) on options  | 2e | 0   | 0                                | 0                                 |
| Net realised gain / (loss) on forward foreign exchange contracts                           | 2g | 0   | 10,396                           | 1,159,665                         |
| Net realised gain / (loss) on futures  | 2e | 0   | 0                                | 0                                 |
| Net realised gain / (loss) on CFD  | 2f | 0   | 0                                | 0                                 |
| Net realised gain / (loss) on foreign exchange   |    | (14,675,572)                                | (2,977,093)                      | (769,187)                         |
| <b>Net realised gain / (loss)</b>  |    | <b>18,831,039</b>                           | <b>(12,420,989)</b>              | <b>2,423,033</b>                  |
| Change in net unrealised appreciation / depreciation on investments                        | 2a | 175,279,395                                 | 41,362,674                       | 18,140,238                        |
| Change in net unrealised appreciation / depreciation on forward foreign exchange contracts | 2g | 0   | 0                                | 0                                 |
| Change in net unrealised appreciation / depreciation on futures                            | 2e | 0   | 0                                | 0                                 |
| Change in net unrealised appreciation / depreciation on CFD                                | 2f | 0   | 0                                | 0                                 |
| <b>Net increase / (decrease) in net assets as a result of operations</b>                   |    | <b>194,110,434</b>                          | <b>28,941,685</b>                | <b>20,563,271</b>                 |
| <b>Evolution of the capital</b>  |    |   |                                  |                                   |
| Subscriptions of shares  |    | 278,473,604                                 | 101,842,147                      | 130,148,425                       |
| Redemptions of shares  |    | (222,520,924)                               | (10,364,986)                     | (5,526,242)                       |
| Dividends distributed  | 11 | (5,677,884)                                 | (2,173,707)                      | 0                                 |
| Currency translation   |    | 0   | 0                                | 0                                 |
| <b>Net assets at the end of the year</b>   |    | <b>1,567,496,638</b>                        | <b>730,064,257</b>               | <b>149,353,912</b>                |



## Statement of changes in net assets for the year ended December 31, 2023

|  |    | Candriam Equities<br>L Oncology Impact | Candriam Equities<br>L Risk Arbitrage<br>Opportunities | Candriam Equities<br>L Robotics &<br>Innovative<br>Technology |
|--|----|--|--|---|
|  |    | USD                                    | EUR  | USD   |
| <b>Net assets at the beginning of the year</b>   |    | <b>1,931,126,606</b>                   | <b>55,130,876</b>                                      | <b>1,256,539,992</b>  |
| <b>Income</b>  |    |  |  |   |
| Dividends, net   | 2k | 16,273,865                             | 250,397  | 8,318,933   |
| Interest received on CFD   |    | 0                                      | 300,846  | 0   |
| Interest on securities lending   | 10 | 0                                      | 0  | 31  |
| Bank interest  |    | 3,193,454                              | 321,504  | 1,753,369   |
| Dividends received on CFD  |    | 0                                      | 199,775  | 0   |
| Interest on reverse repurchase agreements  |    | 0                                      | 683,415  | 0   |
| Other income   |    | 0                                      | 410  | 15  |
| <b>Total income</b>  |    | <b>19,467,319</b>                      | <b>1,756,347</b>                                       | <b>10,072,348</b>   |
| <b>Expenses</b>  |    |  |  |   |
| Management fees  | 3  | 11,030,389                             | 26,895   | 3,469,489   |
| Performance fees   | 6  | 0                                      | 0  | 0   |
| Operating and Administrative Expenses  | 5  | 3,770,453                              | 99,278   | 1,659,788   |
| Depository fees  | 5  | 85,248                                 | 2,304  | 68,535  |
| Subscription tax   | 7  | 385,891                                | 5,176  | 229,596   |
| Transaction costs  | 2j | 545,730                                | 67,707   | 246,457   |
| Interest paid on CFD   |    | 0                                      | 1,116,737  | 0   |
| Bank interest  |    | 168,536                                | 9,134  | 85,171  |
| Other expenses   |    | 0                                      | 4,437  | 2,950   |
| <b>Total expenses</b>  |    | <b>15,986,247</b>                      | <b>1,331,668</b>                                       | <b>5,761,986</b>  |
| <b>Net income / (loss) from investments</b>  |    | <b>3,481,072</b>                       | <b>424,679</b>   | <b>4,310,362</b>  |
| Net realised gain / (loss) on sales of investments   | 2b | (33,898,080)                           | (1,532,528)  | (29,654,913)  |
| Net realised gain / (loss) on options  | 2e | 0                                      | 0  | 0   |
| Net realised gain / (loss) on forward foreign exchange contracts                           | 2g | (7,673,431)                            | 660,389  | (196,162)   |
| Net realised gain / (loss) on futures  | 2e | 0                                      | (97,587)   | 0   |
| Net realised gain / (loss) on CFD  | 2f | 0                                      | 644,309  | 0   |
| Net realised gain / (loss) on foreign exchange   |    | (5,293,284)                            | (1,757,777)  | (14,183,719)  |
| <b>Net realised gain / (loss)</b>  |    | <b>(43,383,723)</b>                    | <b>(1,658,515)</b>                                     | <b>(39,724,432)</b>   |
| Change in net unrealised appreciation / depreciation on investments                        | 2a | 52,218,941                             | 1,967,807  | 569,340,306   |
| Change in net unrealised appreciation / depreciation on forward foreign exchange contracts | 2g | 4,717,592                              | (426,590)  | 408,216   |
| Change in net unrealised appreciation / depreciation on futures                            | 2e | 0                                      | (47,950)   | 0   |
| Change in net unrealised appreciation / depreciation on CFD                                | 2f | 0                                      | (165,446)  | 0   |
| <b>Net increase / (decrease) in net assets as a result of operations</b>                   |    | <b>13,552,810</b>                      | <b>(330,694)</b>                                       | <b>530,024,090</b>  |
| <b>Evolution of the capital</b>  |    |  |  |   |
| Subscriptions of shares  |    | 307,945,764                            | 9,344,676  | 190,078,301   |
| Redemptions of shares  |    | (385,908,780)                          | (14,507,258)   | (139,082,538)   |
| Dividends distributed  | 11 | (5,406,840)                            | 0  | (3,409,002)   |
| Currency translation   |    | 0                                      | 0  | 0   |
| <b>Net assets at the end of the year</b>   |    | <b>1,861,309,560</b>                   | <b>49,637,600</b>                                      | <b>1,834,150,843</b>  |



## Statement of changes in net assets for the year ended December 31, 2023

|  |    | Combined              |
|--|----|-----------------------|
|  |    | EUR                   |
| <b>Net assets at the beginning of the year</b>   |    | <b>10,039,206,017</b> |
| <b>Income</b>  |    |                       |
| Dividends, net   | 2k | 110,874,151           |
| Interest received on CFD   |    | 300,846               |
| Interest on securities lending   | 10 | 240,346               |
| Bank interest  |    | 10,624,897            |
| Dividends received on CFD  |    | 199,775               |
| Interest on reverse repurchase agreements  |    | 684,603               |
| Other income   |    | 51,537                |
| <b>Total income</b>  |    | <b>122,976,155</b>    |
| <b>Expenses</b>  |    |                       |
| Management fees  | 3  | 79,615,575            |
| Performance fees   | 6  | 1,927,262             |
| Operating and Administrative Expenses  | 5  | 21,859,170            |
| Depository fees  | 5  | 437,660               |
| Subscription tax   | 7  | 5,642,769             |
| Transaction costs  | 2j | 7,366,273             |
| Interest paid on CFD   |    | 1,116,737             |
| Bank interest  |    | 409,782               |
| Other expenses   |    | 120,398               |
| <b>Total expenses</b>  |    | <b>118,495,626</b>    |
| <b>Net income / (loss) from investments</b>  |    | <b>4,480,529</b>      |
| Net realised gain / (loss) on sales of investments   | 2b | 46,687,800            |
| Net realised gain / (loss) on options  | 2e | (61,000)              |
| Net realised gain / (loss) on forward foreign exchange contracts                           | 2g | (6,053,818)           |
| Net realised gain / (loss) on futures  | 2e | (43,729,235)          |
| Net realised gain / (loss) on CFD  | 2f | 644,309               |
| Net realised gain / (loss) on foreign exchange   |    | (61,141,879)          |
| <b>Net realised gain / (loss)</b>  |    | <b>(59,173,294)</b>   |
| Change in net unrealised appreciation / depreciation on investments                        | 2a | 998,337,328           |
| Change in net unrealised appreciation / depreciation on forward foreign exchange contracts | 2g | 6,414,724             |
| Change in net unrealised appreciation / depreciation on futures                            | 2e | (1,631,860)           |
| Change in net unrealised appreciation / depreciation on CFD                                | 2f | (165,446)             |
| <b>Net increase / (decrease) in net assets as a result of operations</b>                   |    | <b>943,781,452</b>    |
| <b>Evolution of the capital</b>  |    |                       |
| Subscriptions of shares  |    | 1,774,726,983         |
| Redemptions of shares  |    | (2,723,644,932)       |
| Dividends distributed  | 11 | (35,925,163)          |
| Currency translation   |    | (180,800,371)         |
| <b>Net assets at the end of the year</b>   |    | <b>9,817,343,986</b>  |





## Statistics

### Candriam Equities L Australia

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>AUD</b> |                              | <b>228,943,822</b>                         | <b>227,441,918</b>                         | <b>186,504,713</b>                         |
| C                       | LU0078775011 | Capitalisation | AUD        | 45,822.42                    | 2,018.65                                   | 1,835.48                                   | 1,867.64                                   |
| C                       | LU0078775284 | Distribution   | AUD        | 32,225.76                    | 921.20                                     | 858.41                                     | 905.55                                     |
| C - EUR - Unhedged      | LU0256780106 | Capitalisation | EUR        | 53,834.57                    | 310.92                                     | 291.47                                     | 299.13                                     |
| I                       | LU0133348622 | Capitalisation | AUD        | 16,056.51                    | 2,495.38                                   | 2,243.37                                   | 2,256.78                                   |
| I - EUR - Unhedged      | LU0256781096 | Capitalisation | EUR        | 63,760.23                    | 317.91                                     | 294.72                                     | 298.95                                     |
| N                       | LU0133347731 | Capitalisation | AUD        | 656.34                       | 1,789.58                                   | 1,634.62                                   | 1,670.95                                   |
| N - EUR - Unhedged      | LU0256780874 | Capitalisation | EUR        | 3,374.27                     | 290.07                                     | 273.22                                     | 281.60                                     |
| R                       | LU0942225839 | Capitalisation | AUD        | 16,034.20                    | 229.79                                     | 207.10                                     | 208.87                                     |
| V                       | LU0317020385 | Capitalisation | AUD        | 1.00                         | 1,920.69                                   | 1,723.88                                   | 1,731.85                                   |
| Z                       | LU0240973742 | Capitalisation | AUD        | 114.85                       | 2,740.88                                   | 2,450.56                                   | 2,451.59                                   |

### Candriam Equities L Biotechnology

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>USD</b> |                              | <b>1,586,612,773</b>                       | <b>1,767,239,462</b>                       | <b>1,866,851,208</b>                       |
| C                       | LU0108459040 | Capitalisation | USD        | 420,087.15                   | 827.12                                     | 771.93                                     | 783.64                                     |
| C                       | LU0108459552 | Distribution   | USD        | 159,433.82                   | 759.86                                     | 713.31                                     | 728.29                                     |
| C - EUR - Hedged        | LU1120766206 | Capitalisation | EUR        | 451,021.15                   | 195.25                                     | 185.53                                     | 195.73                                     |
| C - EUR - Unhedged      | LU1120766388 | Capitalisation | EUR        | 858,486.48                   | 212.07                                     | 204.95                                     | 195.36                                     |
| I                       | LU0133360163 | Capitalisation | USD        | 5,814.35                     | 5,519.62                                   | 5,132.42                                   | 5,263.87                                   |
| I - CHF - Hedged        | LU2478813442 | Capitalisation | CHF        | 187.90                       | 1,555.20                                   | 1,512.61                                   | -  |
| I - EUR - Hedged        | LU1006082199 | Capitalisation | EUR        | 11,828.50                    | 2,033.90                                   | 1,938.19                                   | 2,051.00                                   |
| I - EUR - Unhedged      | LU1120766032 | Capitalisation | EUR        | 20,015.14                    | 2,130.25                                   | 2,049.28                                   | 1,972.79                                   |
| I - GBP - Unhedged      | LU1269737059 | Capitalisation | GBP        | 243.55                       | 3,320.75                                   | 3,271.81                                   | 2,983.63                                   |
| L                       | LU0574798848 | Capitalisation | USD        | 13,552.84                    | 808.74                                     | 756.03                                     | 768.69                                     |
| N                       | LU0133359157 | Capitalisation | USD        | 72,033.86                    | 590.07                                     | 552.73                                     | 563.70                                     |
| R                       | LU0942225912 | Capitalisation | USD        | 664,641.44                   | 261.79                                     | 242.19                                     | 243.95                                     |
| R - CHF - Hedged        | LU1269736754 | Capitalisation | CHF        | 3,318.87                     | 200.26                                     | 193.68                                     | 202.42                                     |
| R - EUR - Hedged        | LU1708110975 | Capitalisation | EUR        | 14,743.62                    | 202.94                                     | 192.25                                     | 200.07                                     |
| R - EUR - Unhedged      | LU1269736838 | Capitalisation | EUR        | 60,035.14                    | 311.77                                     | 298.55                                     | 282.20                                     |
| R - GBP - Unhedged      | LU1269736911 | Capitalisation | GBP        | 1,429.21                     | 348.61                                     | 341.80                                     | 305.75                                     |
| R2                      | LU1397644557 | Capitalisation | USD        | 137,218.65                   | 222.78                                     | 205.32                                     | 206.03                                     |
| R2                      | LU1397644631 | Distribution   | USD        | 189,164.28                   | 239.63                                     | 222.05                                     | 223.99                                     |
| R2 - EUR - Unhedged     | LU1397644805 | Capitalisation | EUR        | 467.00                       | 244.40                                     | 233.12                                     | 219.55                                     |
| S - JPY - Unhedged      | LU1820816558 | Capitalisation | JPY        | 102,023.04                   | 296,212.00                                 | 255,437.00                                 | 223,650.00                                 |
| V                       | LU0317020203 | Capitalisation | USD        | 63,629.61                    | 2,016.72                                   | 1,872.73                                   | 1,916.83                                   |
| V2                      | LU2026682919 | Capitalisation | USD        | 18,189.48                    | 1,804.37                                   | 1,665.09                                   | 1,673.04                                   |
| Z                       | LU0240982651 | Capitalisation | USD        | 3,554.00                     | 2,271.30                                   | 2,082.37                                   | 2,078.74                                   |

### Candriam Equities L Emerging Markets

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>EUR</b> |                              | <b>969,705,452</b>                         | <b>1,204,443,591</b>                       | <b>1,913,356,155</b>                       |
| BF                      | LU1904319164 | Capitalisation | EUR        | -                            | -  | 1,746.28                                   | 2,293.30                                   |
| BF                      | LU1397645364 | Distribution   | EUR        | 152,302.38                   | 1,363.27                                   | 1,346.90                                   | 1,811.40                                   |
| C                       | LU0056052961 | Capitalisation | EUR        | 247,284.16                   | 854.49                                     | 837.99                                     | 1,120.67                                   |
| C                       | LU0056053001 | Distribution   | EUR        | 163,168.13                   | 555.61                                     | 559.18                                     | 766.35                                     |
| C - USD - Hedged        | LU1293437023 | Capitalisation | USD        | 533.30                       | 179.11                                     | 172.29                                     | 225.74                                     |
| I                       | LU0133355080 | Capitalisation | EUR        | 10,180.86                    | 1,013.93                                   | 982.70                                     | 1,299.12                                   |
| I                       | LU1269737562 | Distribution   | EUR        | 1.00                         | 1,608.37                                   | 1,599.54                                   | 2,166.05                                   |
| I - GBP - Unhedged      | LU1269737489 | Capitalisation | GBP        | 1.00                         | 2,515.78                                   | 2,479.49                                   | 3,107.94                                   |
| I2 - USD - Unhedged     | LU1774694167 | Capitalisation | USD        | 8,758.00                     | 1,582.20                                   | -  | -  |
| L                       | LU0574798921 | Capitalisation | EUR        | 7,015.51                     | 839.87                                     | 824.53                                     | 1,103.43                                   |
| N                       | LU0133352731 | Capitalisation | EUR        | 2,201.19                     | 766.35                                     | 753.96                                     | 1,011.59                                   |
| P                       | LU0596238260 | Capitalisation | EUR        | 180,965.40                   | 1,074.94                                   | 1,037.57                                   | 1,365.78                                   |
| R                       | LU0942226134 | Capitalisation | EUR        | 200.47                       | 144.79                                     | 140.74                                     | 186.54                                     |
| R - GBP - Unhedged      | LU1269737307 | Capitalisation | GBP        | 4.00                         | 255.29                                     | 252.46                                     | 317.30                                     |
| R2                      | LU1397645018 | Capitalisation | EUR        | 448,173.22                   | 163.42                                     | 158.23                                     | 208.93                                     |
| R2                      | LU1397645109 | Distribution   | EUR        | 3,713.42                     | 157.08                                     | 156.00                                     | 210.99                                     |



## Statistics

### Candriam Equities L Emerging Markets (Continued)

| Name | ISIN         | Share type     | Currency | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|------|--------------|----------------|----------|------------------------------|--|--|--|
| V    | LU0317020112 | Capitalisation | EUR      | 2.00                         | 1,036.93                                   | 1,001.61                                   | 1,320.11                                   |
| V2   | LU1397645281 | Capitalisation | EUR      | 651.93                       | 1,585.84                                   | 1,533.78                                   | 2,022.74                                   |
| Z    | LU0240980523 | Capitalisation | EUR      | 132,661.36                   | 1,207.45                                   | 1,162.68                                   | 1,526.78                                   |

### Candriam Equities L EMU Innovation

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>EUR</b> |                              | <b>48,006,118</b>                          | <b>58,916,622</b>                          | <b>87,250,657</b>                          |
| C                       | LU0317020898 | Capitalisation | EUR        | 3,088.92                     | 129.50                                     | 114.59                                     | 147.53                                     |
| I                       | LU0317021433 | Capitalisation | EUR        | 8,223.12                     | 1,452.07                                   | 1,270.96                                   | 1,618.68                                   |
| R                       | LU1293437379 | Capitalisation | EUR        | 7.00                         | 190.48                                     | 167.13                                     | 213.38                                     |
| S                       | LU0317021276 | Capitalisation | EUR        | -                            | -  | 1,695.29                                   | 2,152.60                                   |
| Z                       | LU0317021359 | Capitalisation | EUR        | 20,486.00                    | 1,740.91                                   | 1,515.42                                   | 1,919.43                                   |

### Candriam Equities L Europe Innovation

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>EUR</b> |                              | <b>898,640,715</b>                         | <b>1,241,599,848</b>                       | <b>1,986,442,269</b>                       |
| C                       | LU0344046155 | Capitalisation | EUR        | 146,885.92                   | 2,939.02                                   | 2,754.40                                   | 3,610.88                                   |
| C                       | LU0344046239 | Distribution   | EUR        | 703,601.63                   | 263.98                                     | 253.33                                     | 341.07                                     |
| C - USD - Hedged        | LU1293437882 | Capitalisation | USD        | 7,393.91                     | 174.73                                     | 160.22                                     | 203.13                                     |
| I                       | LU0344046668 | Capitalisation | EUR        | 29,533.77                    | 2,605.07                                   | 2,412.31                                   | 3,127.85                                   |
| I - USD - Hedged        | LU1293437965 | Capitalisation | USD        | 701.82                       | 1,356.37                                   | 1,229.84                                   | 1,543.02                                   |
| L                       | LU0654531002 | Capitalisation | EUR        | 13,299.16                    | 2,893.80                                   | 2,715.38                                   | 3,563.70                                   |
| N                       | LU0344046312 | Capitalisation | EUR        | 298,142.22                   | 88.35                                      | 83.08                                      | 109.39                                     |
| R                       | LU1293438005 | Capitalisation | EUR        | 52,574.41                    | 270.77                                     | 251.48                                     | 327.03                                     |
| R2                      | LU1397646503 | Capitalisation | EUR        | 6,121.70                     | 223.41                                     | 206.64                                     | 267.71                                     |
| R2                      | LU1397646685 | Distribution   | EUR        | 29,184.63                    | 216.46                                     | 205.00                                     | 272.56                                     |
| S                       | LU2026683057 | Capitalisation | EUR        | 7,235.43                     | 1,650.15                                   | 1,525.81                                   | 1,975.42                                   |
| V                       | LU0344046403 | Capitalisation | EUR        | 7,705.52                     | 1,802.64                                   | 1,665.11                                   | 2,153.57                                   |
| V2                      | LU2026683131 | Capitalisation | EUR        | 24,538.13                    | 2,143.27                                   | 1,981.72                                   | 2,565.69                                   |
| Z                       | LU0344046585 | Capitalisation | EUR        | 13,569.40                    | 2,731.48                                   | 2,514.23                                   | 3,240.54                                   |

### Candriam Equities L Europe Optimum Quality

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>EUR</b> |                              | <b>564,703,027</b>                         | <b>791,623,230</b>                         | <b>1,041,629,101</b>                       |
| C                       | LU0304859712 | Capitalisation | EUR        | 2,707,514.53                 | 144.08                                     | 142.46                                     | 161.04                                     |
| C                       | LU0304860058 | Distribution   | EUR        | 1,536,611.19                 | 90.94                                      | 92.35                                      | 107.17                                     |
| I                       | LU0304860645 | Capitalisation | EUR        | 44,048.31                    | 219.98                                     | 214.77                                     | 239.99                                     |
| I                       | LU1269737729 | Distribution   | EUR        | 67.31                        | 1,624.61                                   | 1,628.06                                   | 1,866.62                                   |
| L                       | LU0574799226 | Capitalisation | EUR        | 159,715.50                   | 141.72                                     | 140.28                                     | 158.75                                     |
| N                       | LU0304860561 | Capitalisation | EUR        | 8,811.55                     | 165.45                                     | 164.12                                     | 186.29                                     |
| R                       | LU1293438187 | Capitalisation | EUR        | 1,683.70                     | 200.11                                     | 195.86                                     | 219.36                                     |
| R2                      | LU1397646842 | Capitalisation | EUR        | 1,724.14                     | 195.27                                     | 190.58                                     | 212.84                                     |
| R2                      | LU1397646925 | Distribution   | EUR        | 1,443.84                     | 180.49                                     | 180.81                                     | 207.19                                     |
| V                       | LU0317019536 | Capitalisation | EUR        | 1.50                         | 1,985.82                                   | 1,935.67                                   | 2,159.41                                   |
| Z                       | LU0317112661 | Capitalisation | EUR        | 90.08                        | 237.48                                     | 230.56                                     | 256.17                                     |

### Candriam Equities L Global Demography

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>EUR</b> |                              | <b>1,567,496,638</b>                       | <b>1,323,111,408</b>                       | <b>1,416,644,708</b>                       |
| C                       | LU0654531184 | Capitalisation | EUR        | 2,744,920.73                 | 288.22                                     | 252.87                                     | 299.30                                     |
| C                       | LU0654531267 | Distribution   | EUR        | 1,717,708.23                 | 243.00                                     | 216.68                                     | 260.52                                     |
| I                       | LU0654531341 | Capitalisation | EUR        | 28,974.14                    | 3,203.60                                   | 2,776.08                                   | 3,248.80                                   |
| I - USD - Unhedged      | LU2328285445 | Capitalisation | USD        | 1.00                         | 1,450.83                                   | 1,215.25                                   | 1,516.52                                   |
| L                       | LU0654531697 | Capitalisation | EUR        | 322,243.86                   | 285.04                                     | 250.32                                     | 296.56                                     |
| N                       | LU0654531424 | Capitalisation | EUR        | 6,610.13                     | 280.55                                     | 246.89                                     | 293.40                                     |
| R                       | LU1598288089 | Capitalisation | EUR        | 3,437.22                     | 277.14                                     | 240.85                                     | 282.69                                     |
| R2                      | LU1397647733 | Capitalisation | EUR        | 160,424.76                   | 261.66                                     | 226.56                                     | 264.92                                     |



## Statistics

### Candriam Equities L Global Demography (Continued)

| Name                | ISIN         | Share type     | Currency | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|---------------------|--------------|----------------|----------|------------------------------|--|--|--|
| R2                  | LU1397647816 | Distribution   | EUR      | 4,895.15                     | 253.75                                     | 223.22                                     | 265.05                                     |
| V2 - USD - Unhedged | LU2439121216 | Capitalisation | USD      | 70,166.48                    | 1,708.21                                   | 1,426.55                                   | -  |
| Z                   | LU1397647907 | Capitalisation | EUR      | 5,806.04                     | 3,401.40                                   | 2,929.80                                   | 3,408.05                                   |

### Candriam Equities L Life Care

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>USD</b> |                              | <b>730,064,257</b>                         | <b>611,819,118</b>                         | <b>19,087,939</b>                          |
| BF                      | LU2223682787 | Capitalisation | USD        | 302,084.00                   | 1,527.78                                   | 1,470.42                                   | -  |
| BF                      | LU2223682860 | Distribution   | USD        | 109,561.83                   | 1,507.82                                   | 1,470.42                                   | -  |
| C                       | LU2223680658 | Capitalisation | USD        | 1,513.54                     | 161.66                                     | 158.38                                     | 170.25                                     |
| I                       | LU2223680815 | Capitalisation | USD        | 1,745.37                     | 1,657.59                                   | 1,610.82                                   | 1,717.21                                   |
| I - EUR - Unhedged      | LU2346867125 | Capitalisation | EUR        | 93.00                        | 1,569.58                                   | -  | -  |
| R                       | LU2223681201 | Capitalisation | USD        | 58.63                        | 157.11                                     | 152.76                                     | 162.99                                     |
| R2                      | LU2223681896 | Capitalisation | USD        | -                            | -  | 152.42                                     | -  |
| V                       | LU2223682274 | Capitalisation | USD        | 1.00                         | 1,674.45                                   | 1,621.57                                   | 1,723.13                                   |
| Z                       | LU2223682357 | Capitalisation | USD        | 57,992.00                    | 1,725.02                                   | 1,662.43                                   | 1,757.91                                   |

### Candriam Equities L Meta Globe

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>USD</b> |                              | <b>149,353,912</b>                         | <b>4,168,458</b>                           | <b>-</b>                                   |
| BF - EUR - Unhedged     | LU2476791202 | Capitalisation | EUR        | 33,369.77                    | 1,693.24                                   | -  | -  |
| BF - EUR - Unhedged     | LU2476793323 | Distribution   | EUR        | 46,465.58                    | 1,693.24                                   | -  | -  |
| C                       | LU2476793240 | Capitalisation | USD        | 78.34                        | 207.11                                     | 141.76                                     | -  |
| I                       | LU2476792861 | Capitalisation | USD        | 1.00                         | 2,092.57                                   | 1,419.07                                   | -  |
| R                       | LU2476792432 | Capitalisation | USD        | 10.00                        | 209.08                                     | 141.89                                     | -  |
| V                       | LU2476791467 | Capitalisation | USD        | 1.00                         | 2,100.21                                   | 1,419.41                                   | -  |
| Z                       | LU2476791384 | Capitalisation | USD        | 2.00                         | 2,321.34                                   | 1,561.43                                   | -  |

### Candriam Equities L Oncology Impact

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>USD</b> |                              | <b>1,861,309,560</b>                       | <b>1,931,126,606</b>                       | <b>2,425,748,609</b>                       |
| BF - EUR - Unhedged     | LU1940963215 | Capitalisation | EUR        | 123,149.64                   | 2,550.94                                   | 2,589.38                                   | 2,667.77                                   |
| BF - EUR - Unhedged     | LU1940963306 | Distribution   | EUR        | 114,638.72                   | 2,417.06                                   | 2,488.13                                   | 2,605.47                                   |
| C                       | LU1864481467 | Capitalisation | USD        | 493,184.19                   | 253.45                                     | 253.04                                     | 282.79                                     |
| C                       | LU1864481541 | Distribution   | USD        | 10,766.38                    | 222.53                                     | 225.49                                     | 256.89                                     |
| C - EUR - Hedged        | LU1864481624 | Capitalisation | EUR        | 442,499.13                   | 193.31                                     | 197.73                                     | 228.44                                     |
| C - EUR - Unhedged      | LU1864484214 | Capitalisation | EUR        | 209,040.39                   | 222.98                                     | 230.42                                     | 241.68                                     |
| I                       | LU1864482358 | Capitalisation | USD        | 91,518.45                    | 2,653.28                                   | 2,624.19                                   | 2,905.31                                   |
| I                       | LU1864482432 | Distribution   | USD        | 34,037.42                    | 1,490.20                                   | 1,473.86                                   | 1,801.74                                   |
| I - EUR - Hedged        | LU2015349330 | Capitalisation | EUR        | 53,553.34                    | 1,958.31                                   | 1,984.36                                   | 2,271.08                                   |
| I - GBP - Unhedged      | LU1864482515 | Capitalisation | GBP        | 6,095.08                     | 2,059.28                                   | 2,158.43                                   | 2,121.89                                   |
| N                       | LU2346866234 | Capitalisation | USD        | 1,055.99                     | 145.48                                     | -  | -  |
| N - EUR - Hedged        | LU1864482606 | Capitalisation | EUR        | 139,264.77                   | 193.12                                     | 198.33                                     | 230.04                                     |
| N - EUR - Unhedged      | LU2346866317 | Capitalisation | EUR        | 528.35                       | 143.59                                     | -  | -  |
| PI                      | LU1864483836 | Capitalisation | USD        | 6,297.85                     | 2,356.14                                   | 2,319.95                                   | 2,557.07                                   |
| R                       | LU1864482788 | Capitalisation | USD        | 19,122.19                    | 264.02                                     | 261.40                                     | 289.69                                     |
| R                       | LU1864482861 | Distribution   | USD        | 6,730.00                     | 179.57                                     | 180.40                                     | 203.79                                     |
| R - EUR - Hedged        | LU1864483083 | Capitalisation | EUR        | 15,417.90                    | 179.94                                     | 182.53                                     | 209.04                                     |
| R - EUR - Unhedged      | LU1864483166 | Capitalisation | EUR        | 187,281.82                   | 235.50                                     | 241.32                                     | 250.99                                     |
| R - GBP - Unhedged      | LU1864482945 | Capitalisation | GBP        | 21,141.72                    | 145.75                                     | 152.94                                     | 150.53                                     |
| R2                      | LU1864483240 | Capitalisation | USD        | 1,755.00                     | 141.24                                     | 139.33                                     | 153.86                                     |
| R2                      | LU1864483323 | Distribution   | USD        | 280,225.72                   | 234.36                                     | 234.60                                     | 264.05                                     |
| R2 - EUR - Hedged       | LU1864483596 | Distribution   | EUR        | 464.00                       | 164.34                                     | 168.65                                     | 196.26                                     |
| S - JPY - Asset Hedged  | LU2015349090 | Distribution   | JPY        | 21,043.68                    | 19,542.00                                  | 20,794.00                                  | 23,085.00                                  |
| S - JPY - Unhedged      | LU2015348522 | Distribution   | JPY        | 96,934.03                    | 27,336.00                                  | 25,545.00                                  | 24,980.00                                  |
| SF2 - EUR - Unhedged    | LU2295688928 | Capitalisation | EUR        | 119,045.68                   | 1,017.94                                   | 1,035.15                                   | 1,068.42                                   |
| V                       | LU1864483752 | Capitalisation | USD        | 25,315.62                    | 2,206.09                                   | 2,174.91                                   | 2,400.14                                   |
| V - GBP - Unhedged      | LU2425425506 | Capitalisation | GBP        | 12,971.95                    | 1,696.49                                   | 1,772.47                                   | -  |
| Z                       | LU1864483919 | Capitalisation | USD        | 39,203.94                    | 2,479.14                                   | 2,432.36                                   | 2,671.42                                   |



## Statistics

### Candriam Equities L Risk Arbitrage Opportunities

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>EUR</b> |                              | <b>49,637,600</b>                          | <b>55,130,876</b>                          | <b>79,103,061</b>                          |
| C                       | LU2223682944 | Capitalisation | EUR        | 7.00                         | 142.90                                     | 145.77                                     | 151.65                                     |
| I                       | LU2223683082 | Capitalisation | EUR        | 1.00                         | 1,452.66                                   | 1,472.90                                   | 1,522.70                                   |
| PI                      | LU2223683678 | Capitalisation | EUR        | -                            | -  | 147.88                                     | 152.11                                     |
| R                       | LU2223683322 | Capitalisation | EUR        | 7.00                         | 144.60                                     | 146.85                                     | 152.08                                     |
| S                       | LU2223683751 | Capitalisation | EUR        | 6,666.67                     | 1,488.59                                   | 1,497.47                                   | 1,536.52                                   |
| V                       | LU2223683835 | Capitalisation | EUR        | 1.00                         | 1,461.34                                   | 1,478.11                                   | 1,524.75                                   |
| Z                       | LU2223683918 | Capitalisation | EUR        | 26,625.31                    | 1,491.39                                   | 1,496.54                                   | 1,531.65                                   |

### Candriam Equities L Robotics & Innovative Technology

| Name                    | ISIN         | Share type     | Currency   | Number of shares outstanding | Net asset value per share as at 31.12.2023 | Net asset value per share as at 31.12.2022 | Net asset value per share as at 31.12.2021 |
|-------------------------|--------------|----------------|------------|------------------------------|--|--|--|
| <b>Total net assets</b> |              |                | <b>USD</b> |                              | <b>1,834,150,843</b>                       | <b>1,256,539,992</b>                       | <b>659,073,624</b>                         |
| BF                      | LU2226954738 | Capitalisation | USD        | 584,580.91                   | 1,697.50                                   | 1,196.13                                   | -  |
| BF                      | LU2226954902 | Distribution   | USD        | 162,674.82                   | 1,672.71                                   | 1,196.13                                   | -  |
| C                       | LU1502282558 | Capitalisation | USD        | 50,150.70                    | 384.59                                     | 276.14                                     | 408.44                                     |
| C                       | LU1502282715 | Distribution   | USD        | 26,148.95                    | 354.20                                     | 258.89                                     | 390.30                                     |
| C - EUR - Hedged        | LU1806526718 | Capitalisation | EUR        | 21,600.52                    | 238.51                                     | 175.73                                     | 271.45                                     |
| C - EUR - Unhedged      | LU1502282632 | Capitalisation | EUR        | 206,936.39                   | 348.14                                     | 258.72                                     | 359.14                                     |
| I                       | LU1502282806 | Capitalisation | USD        | 13,870.02                    | 4,092.93                                   | 2,911.08                                   | 4,265.59                                   |
| I - EUR - Unhedged      | LU1613213971 | Capitalisation | EUR        | 43,940.25                    | 3,388.26                                   | 2,494.29                                   | 3,430.07                                   |
| N - EUR - Hedged        | LU1806526809 | Capitalisation | EUR        | 19,690.30                    | 247.89                                     | 183.38                                     | 284.12                                     |
| R                       | LU1502282988 | Capitalisation | USD        | 8,630.91                     | 406.30                                     | 289.28                                     | 424.30                                     |
| R                       | LU1708110629 | Distribution   | USD        | 2,111.54                     | 270.96                                     | 196.35                                     | 293.45                                     |
| R - EUR - Hedged        | LU1613220596 | Capitalisation | EUR        | 32,041.48                    | 243.09                                     | 177.62                                     | 271.91                                     |
| R - EUR - Unhedged      | LU1598284849 | Capitalisation | EUR        | 83,177.99                    | 385.91                                     | 284.38                                     | 391.46                                     |
| R - GBP - Hedged        | LU1613217964 | Capitalisation | GBP        | 890.87                       | 298.22                                     | 214.55                                     | 324.78                                     |
| V - EUR - Unhedged      | LU2402073626 | Capitalisation | EUR        | 19,640.20                    | 1,663.90                                   | -  | -  |
| Z                       | LU1502283010 | Capitalisation | USD        | 33,487.77                    | 4,320.86                                   | 3,048.62                                   | 4,431.45                                   |



## Candriam Equities L Australia

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in AUD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b>       |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Australia</b>   |           |          |                          |              |
| 29METALS --- REGISTERED SHS  | 1,346,380 | AUD      | 868,415                  | 0.38         |
| ALLKEM LIMITED   | 273,126   | AUD      | 2,684,829                | 1.17         |
| ALTIUM   | 38,759    | AUD      | 1,815,859                | 0.79         |
| ANZ BANKING GROUP LTD  | 286,473   | AUD      | 7,425,380                | 3.24         |
| ARISTOCRAT LEISURE   | 158,660   | AUD      | 6,476,501                | 2.83         |
| BHP GROUP LTD  | 448,850   | AUD      | 22,626,528               | 9.88         |
| BLUESCOPE STEEL  | 227,159   | AUD      | 5,315,521                | 2.32         |
| BOSS RESOURCES LTD   | 143,000   | AUD      | 576,290                  | 0.25         |
| COMMONWEALTH BANK OF AUSTRALIA   | 153,283   | AUD      | 17,137,039               | 7.49         |
| CSL LTD  | 68,900    | AUD      | 19,750,185               | 8.63         |
| EVOLUTION MINING   | 1,136,347 | AUD      | 4,499,934                | 1.97         |
| GOODMAN GROUP - STAPLED SECURITY   | 393,839   | AUD      | 9,964,127                | 4.35         |
| IDP EDUCATION  | 134,107   | AUD      | 2,686,163                | 1.17         |
| IGO NL   | 438,936   | AUD      | 3,972,371                | 1.74         |
| LYNAS RARE EARTHS LTD  | 806,935   | AUD      | 5,777,655                | 2.52         |
| MACQUARIE GROUP  | 54,035    | AUD      | 9,922,447                | 4.33         |
| NAT. AUSTRALIA BANK  | 465,501   | AUD      | 14,290,881               | 6.24         |
| NEXTDC LTD   | 265,280   | AUD      | 3,642,294                | 1.59         |
| PALADIN ENERGY   | 1,200,000 | AUD      | 1,182,000                | 0.52         |
| QBE INSURANCE GROUP  | 308,386   | AUD      | 4,567,197                | 1.99         |
| RESMED - CDI RATIO OF 10 CDIS PER ORD SH   | 250,377   | AUD      | 6,369,591                | 2.78         |
| RIO TINTO  | 77,124    | AUD      | 10,462,642               | 4.57         |
| SANDFIRE RESSOURCE LTD   | 432,230   | AUD      | 3,172,568                | 1.39         |
| SANTOS LTD   | 969,356   | AUD      | 7,367,106                | 3.22         |
| SUNCORP GROUP  | 322,392   | AUD      | 4,465,129                | 1.95         |
| TELSTRA CORP   | 1,726,054 | AUD      | 6,835,174                | 2.99         |
| TRANSURBAN GROUP   | 207,552   | AUD      | 2,845,538                | 1.24         |
| TREASURY WINE ESTATES LTD  | 526,269   | AUD      | 5,673,180                | 2.48         |
| WEBJET LTD   | 421,697   | AUD      | 3,095,256                | 1.35         |
| WOODSIDE ENERGY SHARES   | 123,583   | AUD      | 3,838,488                | 1.68         |
| WOOLWORTHS GRP - REGISTERED  | 154,376   | AUD      | 5,742,787                | 2.51         |
| WORLEY LTD   | 318,283   | AUD      | 5,557,221                | 2.43         |
|  |           |          | <b>210,606,296</b>       | <b>91.99</b> |
| <b>Ireland</b>   |           |          |                          |              |
| JAMES HARDIES IND/CHESS UNITS OF FOR SEC   | 108,955   | AUD      | 6,154,868                | 2.69         |
|  |           |          | <b>6,154,868</b>         | <b>2.69</b>  |
| <b>New Zealand</b>   |           |          |                          |              |
| XERO   | 52,690    | AUD      | 5,917,087                | 2.58         |
|  |           |          | <b>5,917,087</b>         | <b>2.58</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| BLOCK --- SHS CHESS DEPOSITORY INTERESTS   | 49,563    | AUD      | 5,784,002                | 2.53         |
|  |           |          | <b>5,784,002</b>         | <b>2.53</b>  |
| <b>Total Shares</b>  |           |          | <b>228,462,253</b>       | <b>99.79</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          | <b>228,462,253</b>       | <b>99.79</b> |
| <b>Total investment portfolio</b>  |           |          | <b>228,462,253</b>       | <b>99.79</b> |
| Acquisition cost   |           |          | 186,582,976              |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Australia

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                          |              |
|--------------------------|--------------|
| Australia                | 91.99        |
| Ireland                  | 2.69         |
| New Zealand              | 2.58         |
| United States of America | 2.53         |
|                          | <b>99.79</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Banks and other financial institutions     | 23.25        |
| Coal mining and steel industry & Chemicals | 13.38        |
| Biotechnology                              | 8.63         |
| Precious metals and stones                 | 7.99         |
| Petroleum                                  | 7.32         |
| Internet and internet services             | 4.97         |
| Non ferrous metals                         | 4.57         |
| Real estate                                | 4.35         |
| Retail trade and department stores         | 3.86         |
| Miscellaneous services                     | 3.77         |
| Communication                              | 2.99         |
| Hotels and restaurants                     | 2.83         |
| Pharmaceuticals                            | 2.78         |
| Building materials                         | 2.69         |
| Tobacco and alcoholic drinks               | 2.48         |
| Insurance                                  | 1.99         |
| Healthcare                                 | 1.17         |
| Utilities                                  | 0.77         |
|  | <b>99.79</b> |



## Candriam Equities L Biotechnology

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Belgium</b>   |           |          |                          |              |
| UCB  | 61,186    | EUR      | 5,332,781                | 0.34         |
|  |           |          | <b>5,332,781</b>         | <b>0.34</b>  |
| <b>Canada</b>  |           |          |                          |              |
| XENON PHARMA --- REGISTERED SHS  | 530,884   | USD      | 24,452,517               | 1.54         |
|  |           |          | <b>24,452,517</b>        | <b>1.54</b>  |
| <b>Cayman Islands</b>  |           |          |                          |              |
| BEIGENE - REG SHS  | 1,113,572 | HKD      | 15,701,222               | 0.99         |
| LEGEND BIOTECH CORP  | 111,026   | USD      | 6,680,434                | 0.42         |
| MOONLAKE IMMUNOTHERAPEUTICS  | 185,000   | USD      | 11,172,150               | 0.70         |
|  |           |          | <b>33,553,806</b>        | <b>2.11</b>  |
| <b>Denmark</b>   |           |          |                          |              |
| GENMAB AS  | 52,380    | DKK      | 16,726,922               | 1.05         |
| ZEALAND PHARMA   | 70,000    | DKK      | 3,871,176                | 0.24         |
|  |           |          | <b>20,598,098</b>        | <b>1.30</b>  |
| <b>France</b>  |           |          |                          |              |
| SANOFI   | 446,550   | EUR      | 44,276,944               | 2.79         |
|  |           |          | <b>44,276,944</b>        | <b>2.79</b>  |
| <b>Germany</b>   |           |          |                          |              |
| BIONTECH - ADR 1 SHS   | 40,303    | USD      | 4,253,578                | 0.27         |
| MORPHOSYS  | 50,931    | EUR      | 1,912,872                | 0.12         |
|  |           |          | <b>6,166,450</b>         | <b>0.39</b>  |
| <b>Ireland</b>   |           |          |                          |              |
| ALKERMES   | 837,779   | USD      | 23,239,989               | 1.46         |
| JAZZ PHARMACEUTICALS PLC   | 139,633   | USD      | 17,174,859               | 1.08         |
| PROTHENA CORP  | 82,000    | USD      | 2,979,880                | 0.19         |
|  |           |          | <b>43,394,728</b>        | <b>2.74</b>  |
| <b>Japan</b>   |           |          |                          |              |
| EISAI  | 90,500    | JPY      | 4,526,926                | 0.29         |
|  |           |          | <b>4,526,926</b>         | <b>0.29</b>  |
| <b>Luxembourg</b>  |           |          |                          |              |
| AKERO THERAPEUTICS INC   | 184,000   | USD      | 4,296,400                | 0.27         |
| KARUNA THERAPEUTICS INC  | 57,201    | USD      | 18,104,689               | 1.14         |
| REVOLUTION MEDICINES INC   | 253,556   | USD      | 7,271,986                | 0.46         |
| SPRINGWORKS THERAPEUTICS INC   | 75,000    | USD      | 2,737,500                | 0.17         |
| SYNDAX PHARMACEUTICALS INC   | 365,000   | USD      | 7,887,650                | 0.50         |
|  |           |          | <b>40,298,225</b>        | <b>2.54</b>  |
| <b>Netherlands</b>   |           |          |                          |              |
| ARGENX SE  | 52,094    | EUR      | 19,766,927               | 1.25         |
| MERUS - REG SHS  | 212,151   | USD      | 5,834,153                | 0.37         |
| PHARVARIS NV   | 50,000    | USD      | 1,402,500                | 0.09         |
|  |           |          | <b>27,003,580</b>        | <b>1.70</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| CRISPR THERAP --- NAMEN-AKT  | 59,675    | USD      | 3,735,655                | 0.24         |
|  |           |          | <b>3,735,655</b>         | <b>0.24</b>  |
| <b>United Kingdom</b>  |           |          |                          |              |
| ASTRAZENECA PLC  | 324,025   | GBP      | 43,784,002               | 2.76         |
| BICYCLE THERAPEUTICS PLC   | 288,295   | USD      | 5,212,374                | 0.33         |
| IMMUNOCORE HOLDINGS PLC-ADR  | 55,000    | USD      | 3,757,600                | 0.24         |
|  |           |          | <b>52,753,976</b>        | <b>3.32</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| 4D MOLECULAR THERAPEUTICS INC  | 198,000   | USD      | 4,011,480                | 0.25         |
| 89BIO --- REGISTERED SHS   | 280,000   | USD      | 3,127,601                | 0.20         |
| ALNYLAM PHARMACEUTICALS INC  | 230,326   | USD      | 44,086,700               | 2.78         |
| ALPINE IMMUNE SCIENCES   | 470,000   | USD      | 8,958,200                | 0.56         |
| AMGEN INC  | 372,648   | USD      | 107,330,078              | 6.76         |
| AMICUS THERAPEUTICS  | 553,879   | USD      | 7,859,543                | 0.50         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.





Candriam Equities L Biotechnology

Investment portfolio as at December 31, 2023

| Description                        | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|------------------------------------|-----------|----------|--------------------------|--------------|
| APELLIS PHARMA                     | 337,507   | USD      | 20,203,170               | 1.27         |
| ARCELLX INC                        | 40,000    | USD      | 2,220,001                | 0.14         |
| ARROWHEAD PHARMACEUTICALS INC      | 185,054   | USD      | 5,662,652                | 0.36         |
| ARVINAS - REG SHS                  | 139,282   | USD      | 5,732,847                | 0.36         |
| ASCENDIS PHARMA ADR REP 1SHS       | 99,375    | USD      | 12,516,281               | 0.79         |
| AVIDITY BIOSCI --- REGISTERED SHS  | 290,067   | USD      | 2,625,106                | 0.17         |
| AXSOME THERAPEUTICS INC            | 85,084    | USD      | 6,771,835                | 0.43         |
| BEAM THERAPEUTICS INC              | 212,665   | USD      | 5,788,741                | 0.36         |
| BIOGEN IDEC INC                    | 162,114   | USD      | 41,950,240               | 2.64         |
| BIOMARIN PHARMACEUTICAL INC        | 279,796   | USD      | 26,977,930               | 1.70         |
| BLUEPRINT MEDICINES CORP           | 20,156    | USD      | 1,859,189                | 0.12         |
| BRIDGEBIO PHARM - REG SHS          | 299,000   | USD      | 12,070,630               | 0.76         |
| BRUKER BIOSCIENCES                 | 100,628   | USD      | 7,394,145                | 0.47         |
| CELLEX THERAPEUTICS INC            | 317,509   | USD      | 12,592,407               | 0.79         |
| CEREVEL THERAPEUTICS HOLDINGS INC  | 167,221   | USD      | 7,090,170                | 0.45         |
| CHINOOK THERAPEUTICS               | 386,155   | USD      | 382,293                  | 0.02         |
| CRINETIC PHARMA - REG SHS          | 80,000    | USD      | 2,846,400                | 0.18         |
| CYTOKINETICS INC                   | 267,240   | USD      | 22,311,867               | 1.41         |
| DANAHER CORP                       | 95,467    | USD      | 22,085,336               | 1.39         |
| DENALI THRPTCS - REG SHS           | 357,878   | USD      | 7,680,062                | 0.48         |
| DESIGN THERAPEUTICS INC            | 225,000   | USD      | 596,250                  | 0.04         |
| DISC MEDICINE INC                  | 80,000    | USD      | 4,620,800                | 0.29         |
| DYNE THERAPEUTICS INC              | 763,624   | USD      | 10,156,199               | 0.64         |
| EDGEWISE THERAPE                   | 308,000   | USD      | 3,369,520                | 0.21         |
| ELI LILLY & CO                     | 50,000    | USD      | 29,146,000               | 1.84         |
| EXACT SCIENCES CORP                | 70,000    | USD      | 5,178,600                | 0.33         |
| EXELIXIS                           | 384,968   | USD      | 9,235,382                | 0.58         |
| EYEPOINT PHARMACEUTICALS INC       | 140,000   | USD      | 3,235,400                | 0.20         |
| GILEAD SCIENCES INC                | 1,176,375 | USD      | 95,298,140               | 6.01         |
| GUARDANT HEALTH --- REGISTERED SHS | 175,000   | USD      | 4,733,750                | 0.30         |
| HALOZYME THERAPEUT -SHS-           | 180,997   | USD      | 6,689,649                | 0.42         |
| IDEAYA BIOSCIENCES INC             | 80,000    | USD      | 2,846,399                | 0.18         |
| ILLUMINA INC                       | 110,760   | USD      | 15,422,222               | 0.97         |
| IMMUNOGEN INC                      | 339,681   | USD      | 10,071,542               | 0.63         |
| INCYTE CORP                        | 421,823   | USD      | 26,486,266               | 1.67         |
| INHIBRX - REG SHS                  | 135,069   | USD      | 5,132,622                | 0.32         |
| INSMED                             | 310,200   | USD      | 9,613,099                | 0.61         |
| INTELLIA THERAPEUTICS INC          | 91,275    | USD      | 2,782,974                | 0.18         |
| IONIS PHARMACEUTICALS NEW          | 629,067   | USD      | 31,824,499               | 2.01         |
| IOVANCE BIOTHERAPEUTICS INC        | 766,367   | USD      | 6,230,563                | 0.39         |
| KEROS THERAPEUTICS INC             | 462,065   | USD      | 18,371,704               | 1.16         |
| KRYSTAL BIOTECH - REG SHS          | 55,000    | USD      | 6,823,300                | 0.43         |
| KURA ONCOLOGY - REGISTERED         | 174,402   | USD      | 2,507,901                | 0.16         |
| KYMERA THERAPEUTICS INC            | 185,476   | USD      | 4,722,219                | 0.30         |
| MADRIGAL PHARMACEUTICALS INC       | 27,000    | USD      | 6,247,260                | 0.39         |
| MERCK & CO INC                     | 165,000   | USD      | 17,988,300               | 1.13         |
| MODERNA INC                        | 347,625   | USD      | 34,571,306               | 2.18         |
| MORPHIC HLDG                       | 249,933   | USD      | 7,218,065                | 0.45         |
| NATERA                             | 60,000    | USD      | 3,758,400                | 0.24         |
| NEUROCRINE BIOSCIENCES             | 275,616   | USD      | 36,315,164               | 2.29         |
| NURIX THERAPETC - REG SHS          | 354,992   | USD      | 3,663,517                | 0.23         |
| NUVALENT INC-A SHARES              | 118,000   | USD      | 8,683,620                | 0.55         |
| PACIRA PHARMACEUTICALS INC         | 191,901   | USD      | 6,474,740                | 0.41         |
| PLIANT THERAPEUTICS INC            | 453,000   | USD      | 8,203,830                | 0.52         |
| PROTAGONIST THERAPEUTICS INC       | 537,000   | USD      | 12,313,410               | 0.78         |
| PTC THERAPEUTICS                   | 291,652   | USD      | 8,037,929                | 0.51         |
| RAPT THERAPEUTICS INC              | 313,262   | USD      | 7,784,561                | 0.49         |
| REGENERON PHARMACEUTICALS INC      | 120,260   | USD      | 105,623,156              | 6.66         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.





## Candriam Equities L Biotechnology

Investment portfolio as at December 31, 2023

| Description  | Quantity | Currency | Market value<br>(in USD) | % net assets |
|--|----------|----------|--------------------------|--------------|
| RELAY THERAPTCS - REGISTERED SHS   | 352,641  | USD      | 3,882,577                | 0.24         |
| ROCKET PHARMCTC  | 110,000  | USD      | 3,296,700                | 0.21         |
| SAGE THERAPEUTICS INC  | 227,000  | USD      | 4,919,090                | 0.31         |
| SAREPTA THERAPEUTICS   | 139,000  | USD      | 13,403,770               | 0.84         |
| SCHRODINGER INC  | 142,000  | USD      | 5,083,600                | 0.32         |
| SEAGEN INC   | 110,047  | USD      | 25,200,763               | 1.59         |
| STRUCTURE THERAPEUTICS INCORPORATION   | 210,000  | USD      | 8,559,600                | 0.54         |
| SUTRO BIOPHARMA INC  | 347,812  | USD      | 1,492,113                | 0.09         |
| THERMO FISHER SCIENT SHS   | 43,755   | USD      | 23,224,716               | 1.46         |
| TWIST BIOSCIENCE CORPORATION   | 71,360   | USD      | 2,630,330                | 0.17         |
| ULTRAGENYX PHARMACEUTICAL INC  | 148,480  | USD      | 7,100,314                | 0.45         |
| VERTEX PHARMACEUTICALS INC   | 269,220  | USD      | 109,542,927              | 6.90         |
| VERVE THERAPEUTICS INC   | 310,000  | USD      | 4,321,400                | 0.27         |
| XENCOR INC   | 341,298  | USD      | 7,245,757                | 0.46         |
| <b>Total Shares</b>  |          |          | <b>1,204,016,819</b>     | <b>75.89</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |          |          | <b>1,510,110,505</b>     | <b>95.18</b> |
| <b>Total investment portfolio</b>  |          |          | <b>1,510,110,505</b>     | <b>95.18</b> |
| Acquisition cost   |          |          | 1,370,021,258            |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Biotechnology

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                          |              |
|--------------------------|--------------|
| United States of America | 75.89        |
| United Kingdom           | 3.32         |
| France                   | 2.79         |
| Ireland                  | 2.74         |
| Luxembourg               | 2.54         |
| Cayman Islands           | 2.11         |
| Netherlands              | 1.70         |
| Canada                   | 1.54         |
| Denmark                  | 1.30         |
| Germany                  | 0.39         |
| Belgium                  | 0.34         |
| Japan                    | 0.29         |
| Switzerland              | 0.24         |
|                          | <b>95.18</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Biotechnology                          | 46.42        |
| Pharmaceuticals                        | 41.21        |
| Banks and other financial institutions | 3.90         |
| Electronics and semiconductors         | 1.46         |
| Machine and apparatus construction     | 1.39         |
| Healthcare                             | 0.46         |
| Miscellaneous services                 | 0.33         |
|  | <b>95.18</b> |



## Candriam Equities L Emerging Markets

Investment portfolio as at December 31, 2023

| Description  | Quantity   | Currency | Market value<br>(in EUR) | % net assets |
|--|------------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |            |          |                          |              |
| <b>Shares</b>  |            |          |                          |              |
| <b>Brazil</b>  |            |          |                          |              |
| BANCO DO BRASIL SA   | 1,100,000  | BRL      | 11,337,315               | 1.17         |
| ITAUUNIBANCO PREFERENTIAL SHARE  | 2,240,000  | BRL      | 14,158,907               | 1.46         |
| LOCALIZA RENT A CAR SA   | 720,000    | BRL      | 8,520,710                | 0.88         |
| PRIO SA  | 1,200,000  | BRL      | 10,282,461               | 1.06         |
| RAIA DROGASIL SA   | 1,460,000  | BRL      | 7,987,049                | 0.82         |
| WEG SA   | 740,000    | BRL      | 5,082,319                | 0.52         |
|  |            |          | <b>57,368,761</b>        | <b>5.92</b>  |
| <b>Cayman Islands</b>  |            |          |                          |              |
| AIRTAC INTL  | 128,000    | TWD      | 3,820,523                | 0.39         |
| ALCHIP TECHNOLOGIES LIMITED  | 108,000    | TWD      | 10,452,653               | 1.08         |
| ALIBABA GROUP  | 2,840,000  | HKD      | 24,834,479               | 2.56         |
| ANTA SPORTS PRODUCTS   | 260,000    | HKD      | 2,278,090                | 0.23         |
| BAIDU - PREFERENTIAL SHARE -A  | 430,000    | HKD      | 5,774,516                | 0.60         |
| CHINA RESOURCES LAND LTD -RC-  | 2,320,000  | HKD      | 7,513,822                | 0.77         |
| JD.COM INC - CL A  | 280,000    | HKD      | 3,643,556                | 0.38         |
| KANZHUN LTD SHS A SPONSORED US DEPOSITAR   | 200,000    | USD      | 2,949,842                | 0.30         |
| KUAISHOU TECHNOLOGY  | 920,000    | HKD      | 5,634,673                | 0.58         |
| LI AUTO INC  | 380,000    | HKD      | 6,465,635                | 0.67         |
| MEITUAN - SHS 114A/REG S   | 970,000    | HKD      | 9,189,049                | 0.95         |
| NETEASE INC  | 460,000    | HKD      | 7,480,973                | 0.77         |
| NU HLDG - REG SHS -A-  | 860,000    | USD      | 6,505,377                | 0.67         |
| PINDUODUO  | 160,000    | USD      | 21,017,623               | 2.17         |
| TENCENT HOLDINGS LTD   | 830,000    | HKD      | 28,187,014               | 2.91         |
|  |            |          | <b>145,747,825</b>       | <b>15.03</b> |
| <b>Hong Kong</b>   |            |          |                          |              |
| BYD ELECTRONIC -RC-  | 1,880,000  | HKD      | 7,958,915                | 0.82         |
|  |            |          | <b>7,958,915</b>         | <b>0.82</b>  |
| <b>India</b>   |            |          |                          |              |
| ABB SHS  | 186,000    | INR      | 9,432,638                | 0.97         |
| APL APOLLO TUBES LTD   | 440,000    | INR      | 7,346,175                | 0.76         |
| APOLLO HOSPITALS   | 120,000    | INR      | 7,445,306                | 0.77         |
| AXIS BANK  | 1,360,000  | INR      | 16,295,064               | 1.68         |
| BAJAJ FINANCE LTD  | 124,000    | INR      | 9,876,651                | 1.02         |
| BHARTI AIRTEL LTD(DEMATERIALIZED)  | 1,520,000  | INR      | 17,053,943               | 1.76         |
| HDFC BANK - REGISTERED SHS   | 450,000    | INR      | 8,360,562                | 0.86         |
| ICICI BANK   | 880,000    | INR      | 9,532,810                | 0.98         |
| INDRAPRASTHA GAS LTD   | 1,360,000  | INR      | 6,179,204                | 0.64         |
| KPIT TECHNOLOGIES LTD  | 420,000    | INR      | 6,940,811                | 0.72         |
| MAHINDRA&MAHINDRA  | 360,000    | INR      | 6,767,298                | 0.70         |
| RELIANCE INDUSTRIES DEMATERIALIZED   | 770,000    | INR      | 21,635,167               | 2.23         |
| SBI CARDS & PAYMENT SERVICES LTD   | 720,000    | INR      | 5,955,723                | 0.61         |
| TATA MOTORS  | 1,120,000  | INR      | 9,495,157                | 0.98         |
| TORRENT PHARMACEUTICALS DEMATERIALIZED   | 360,000    | INR      | 9,021,825                | 0.93         |
| VARUN BEVERAGES LTD  | 1,050,000  | INR      | 14,118,104               | 1.46         |
|  |            |          | <b>165,456,438</b>       | <b>17.06</b> |
| <b>Indonesia</b>   |            |          |                          |              |
| ANEKA TAMBANG SHS  | 19,000,000 | IDR      | 1,901,142                | 0.20         |
| BANK CENTRAL ASIA DEP  | 19,800,000 | IDR      | 10,922,689               | 1.13         |
| BANK MANDIRI   | 22,000,000 | IDR      | 7,811,143                | 0.81         |
| SUMBER ALFARIA TRIJAYA TBK   | 34,000,000 | IDR      | 5,846,326                | 0.60         |
|  |            |          | <b>26,481,300</b>        | <b>2.73</b>  |
| <b>Luxembourg</b>  |            |          |                          |              |
| PROYA COSMETICS CO   | 360,577    | CNY      | 4,565,080                | 0.47         |
| PT MERDEKA COPPER GOLD TBK   | 24,000,000 | IDR      | 3,802,870                | 0.39         |
| SHANGHAI BAOSIGHT SOFTWARE CO LTD  | 699,098    | CNY      | 4,345,321                | 0.45         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Emerging Markets

Investment portfolio as at December 31, 2023

| Description                              | Quantity   | Currency | Market value<br>(in EUR) | % net assets |
|--|------------|----------|--------------------------|--------------|
| TATA ELXSI LTD                           | 54,000     | INR      | 5,121,257                | 0.53         |
| VOLTRONIC POWER TECHNOLOGY CORP          | 90,000     | TWD      | 4,548,101                | 0.47         |
| YADEA GROUP HOLDINGS LTD                 | 2,279,700  | HKD      | 3,617,818                | 0.37         |
|  |            |          | <b>26,000,447</b>        | <b>2.68</b>  |
| <b>Malaysia</b>                          |            |          |                          |              |
| PRESS MTL ALUMI - REGISTERED             | 8,000,000  | MYR      | 7,576,145                | 0.78         |
|  |            |          | <b>7,576,145</b>         | <b>0.78</b>  |
| <b>Mexico</b>                            |            |          |                          |              |
| AMERICA MOVIL SAB DE CV                  | 14,400,000 | MXN      | 11,983,495               | 1.24         |
| CEMEX-CPO REPR 2 SHS -A-.1 SHS -B-       | 7,000,000  | MXN      | 5,008,050                | 0.52         |
| GRUMA SHS-B-                             | 520,000    | MXN      | 8,663,340                | 0.89         |
| GRUPO AEROPORTUARIO DEL PACIFICO SAB-B-  | 200,000    | MXN      | 3,165,830                | 0.33         |
| GRUPO FINANCIERO BANORTE -O-             | 1,580,000  | MXN      | 14,455,832               | 1.49         |
|  |            |          | <b>43,276,547</b>        | <b>4.46</b>  |
| <b>People's Republic of China</b>        |            |          |                          |              |
| AIER EYE HOSPITAL GRP CO LTD -A-         | 1,419,396  | CNY      | 2,860,053                | 0.29         |
| ANHUI HUAHENG BIOTECHNOLOG-A             | 359,956    | CNY      | 5,772,170                | 0.60         |
| BANK OF JIANGSU CO LTD                   | 12,799,881 | CNY      | 10,906,766               | 1.12         |
| BEIJING COMPASS TECHNOLOGY DEVELOPMENT C | 579,949    | CNY      | 4,451,259                | 0.46         |
| BYD COMPANY LTD -H-                      | 302,000    | HKD      | 7,489,393                | 0.77         |
| CHINA MERCHANTS BANK CO LTD -H-          | 2,000,000  | HKD      | 6,292,364                | 0.65         |
| CMOC GROUP LIMITED                       | 14,000,884 | HKD      | 6,915,096                | 0.71         |
| CONTEMPORARY AMPEREX TECHN-A             | 116,300    | CNY      | 2,418,374                | 0.25         |
| FLAT GLASS GROUP -H- REGS                | 1,120,000  | HKD      | 1,707,451                | 0.18         |
| LONGSHINE TECHNOLOGY GROUP CO LTD        | 939,887    | CNY      | 1,962,088                | 0.20         |
| LUZHOU OLD CELLAR -A-                    | 158,000    | CNY      | 3,610,704                | 0.37         |
| NARI TECHNOLOGY -A-                      | 1,459,792  | CNY      | 4,150,010                | 0.43         |
| NINGBO DEYE TECHNOLOGY CO -A             | 220,559    | CNY      | 2,356,952                | 0.24         |
| NONGFU SPRING - REG SHS -H- UNI          | 1,620,000  | HKD      | 8,460,337                | 0.87         |
| PING AN INS (GRP) CO -H-                 | 2,820,000  | HKD      | 11,530,641               | 1.19         |
| SHANDONG GOLD - REG SHS -H-              | 4,240,000  | HKD      | 7,268,235                | 0.75         |
| SHENZHEN TRANSSION HOLDING CO LTD        | 280,000    | CNY      | 4,935,806                | 0.51         |
| SZ INNOVANCE TECHNOLOGY -A-              | 439,768    | CNY      | 3,536,651                | 0.36         |
| YANTAI JEREH OILFIELD SERVICES GROUP     | 1,599,961  | CNY      | 5,728,411                | 0.59         |
|  |            |          | <b>102,352,761</b>       | <b>10.56</b> |
| <b>Poland</b>                            |            |          |                          |              |
| DINA POLSKA S.A.                         | 84,000     | PLN      | 8,934,357                | 0.92         |
|  |            |          | <b>8,934,357</b>         | <b>0.92</b>  |
| <b>South Africa</b>                      |            |          |                          |              |
| CAPITEC BANK HOLDINGS LTD                | 92,000     | ZAR      | 9,004,906                | 0.93         |
| FIRSTRAND LTD                            | 3,160,000  | ZAR      | 11,239,381               | 1.16         |
| GOLD FIELDS                              | 880,000    | ZAR      | 12,573,945               | 1.30         |
| NASPERS LTD                              | 81,000     | ZAR      | 11,978,410               | 1.24         |
|  |            |          | <b>44,796,642</b>        | <b>4.62</b>  |
| <b>South Korea</b>                       |            |          |                          |              |
| DAEJOO ELEC MATERIALS                    | 50,000     | KRW      | 3,023,855                | 0.31         |
| DB INSURANCE RG REGISTERED SHS           | 208,000    | KRW      | 12,186,135               | 1.26         |
| HPSP CO LTD                              | 120,000    | KRW      | 3,683,223                | 0.38         |
| JYP ENTERTAINMENT CORP REGISTERED SHS    | 78,000     | KRW      | 5,530,715                | 0.57         |
| KB FINANCIAL GROUP INC                   | 428,000    | KRW      | 16,207,582               | 1.67         |
| LG CHEM                                  | 22,000     | KRW      | 7,684,231                | 0.79         |
| SAMSUNG BIOLOGICS CO LTD                 | 12,400     | KRW      | 6,596,483                | 0.68         |
| SAMSUNG ELECTRONICS CO LTD               | 686,000    | KRW      | 37,693,892               | 3.89         |
| SAMSUNG ENGINEERING                      | 520,000    | KRW      | 10,555,493               | 1.09         |
| SK HYNIX INC                             | 268,000    | KRW      | 26,544,127               | 2.74         |
|  |            |          | <b>129,705,736</b>       | <b>13.38</b> |
| <b>Taiwan</b>                            |            |          |                          |              |
| ACCTON TECHNOLOGY CORPORATION            | 800,000    | TWD      | 12,364,687               | 1.28         |
| CHAILEASE HOLDING COMPANY LTD            | 1,620,000  | TWD      | 9,239,826                | 0.95         |
| CHINATRUST FINANCIAL HLDGS               | 15,200,000 | TWD      | 12,734,682               | 1.31         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Emerging Markets

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in EUR) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| DELTA ELECTRONIC INCS  | 880,000   | TWD      | 8,152,892                | 0.84         |
| PRIME VIEW INTERNATIONAL CO LTD  | 600,000   | TWD      | 3,493,083                | 0.36         |
| QUANTA COMPUTER INC  | 780,000   | TWD      | 5,174,905                | 0.53         |
| REALTEK SEMICONDUCTOR CORP   | 360,000   | TWD      | 5,016,209                | 0.52         |
| TAIWAN SEMICONDUCTOR CO  | 4,720,000 | TWD      | 82,715,740               | 8.53         |
|  |           |          | <b>138,892,024</b>       | <b>14.32</b> |
| <b>Thailand</b>  |           |          |                          |              |
| AIRPORTS THAILAND-UNITS NON-VOT DEP REC  | 4,000,000 | THB      | 6,307,816                | 0.65         |
| BANGKOK DUSIT MEDICAL SERVICES PUBLIC  | 3,800,000 | THB      | 2,783,093                | 0.29         |
| KASIKORN BANK UNITS NVDR   | 1,120,000 | THB      | 3,990,551                | 0.41         |
| PTT PUBLIC COMPANY LTD LIMITED   | 6,800,000 | THB      | 6,416,026                | 0.66         |
|  |           |          | <b>19,497,486</b>        | <b>2.01</b>  |
| <b>Turkey</b>  |           |          |                          |              |
| BIM BIRLESIK MAGAZALAR   | 1,120,000 | TRY      | 10,527,442               | 1.09         |
| TURKIYE GARANTI BANKASI AS (NAMEN-AKT)   | 3,600,000 | TRY      | 6,195,418                | 0.64         |
|  |           |          | <b>16,722,860</b>        | <b>1.72</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| COUPANG INC  | 240,000   | USD      | 3,550,655                | 0.37         |
| MERCADOLIBRE   | 5,600     | USD      | 8,004,483                | 0.83         |
|  |           |          | <b>11,555,138</b>        | <b>1.19</b>  |
| <b>Total Shares</b>  |           |          | <b>952,323,382</b>       | <b>98.21</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          | <b>952,323,382</b>       | <b>98.21</b> |
| <b>Other transferable securities</b>   |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Russia</b>  |           |          |                          |              |
| MAGNIT SHS   | 169,180   | USD      | 0                        | 0.00         |
|  |           |          | <b>0</b>                 | <b>0.00</b>  |
| <b>Total Shares</b>  |           |          | <b>0</b>                 | <b>0.00</b>  |
| <b>Rights</b>  |           |          |                          |              |
| <b>Brazil</b>  |           |          |                          |              |
| LOCA RENT A CAR 05/02/24 RIGHT   | 2,583     | BRL      | 9,613                    | 0.00         |
|  |           |          | <b>9,613</b>             | <b>0.00</b>  |
| <b>Total Rights</b>  |           |          | <b>9,613</b>             | <b>0.00</b>  |
| <b>Total Other transferable securities</b>   |           |          | <b>9,613</b>             | <b>0.00</b>  |
| <b>Total investment portfolio</b>  |           |          | <b>952,332,995</b>       | <b>98.21</b> |
| Acquisition cost   |           |          | 920,453,594              |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Emerging Markets

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                            |              |
|----------------------------|--------------|
| India                      | 17.06        |
| Cayman Islands             | 15.03        |
| Taiwan                     | 14.32        |
| South Korea                | 13.38        |
| People's Republic of China | 10.56        |
| Brazil                     | 5.92         |
| South Africa               | 4.62         |
| Mexico                     | 4.46         |
| Indonesia                  | 2.73         |
| Luxembourg                 | 2.68         |
| Thailand                   | 2.01         |
| Turkey                     | 1.72         |
| United States of America   | 1.19         |
| Poland                     | 0.92         |
| Hong Kong                  | 0.82         |
| Malaysia                   | 0.78         |
| Russia                     | 0.00         |
|                            | <b>98.21</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Banks and other financial institutions     | 20.66        |
| Electronics and semiconductors             | 18.05        |
| Internet and internet services             | 9.34         |
| Foods and non alcoholic drinks             | 5.23         |
| Road vehicles                              | 3.60         |
| Communication                              | 3.50         |
| Graphic art and publishing                 | 3.40         |
| Pharmaceuticals                            | 3.28         |
| Electrical engineering                     | 3.15         |
| Miscellaneous services                     | 3.13         |
| Machine and apparatus construction         | 3.06         |
| Chemicals                                  | 3.02         |
| Petroleum                                  | 2.95         |
| Insurance                                  | 2.45         |
| Precious metals and stones                 | 2.24         |
| Office supplies and computing              | 2.17         |
| Coal mining and steel industry & Chemicals | 1.86         |
| Biotechnology                              | 1.28         |
| Non ferrous metals                         | 1.23         |
| Healthcare                                 | 0.82         |
| Real estate                                | 0.77         |
| Retail trade and department stores         | 0.74         |
| Building materials                         | 0.69         |
| Aeronautic and astronautic Industry        | 0.65         |
| Tobacco and alcoholic drinks               | 0.37         |
| Transportation                             | 0.33         |
| Textiles and garments                      | 0.23         |
|  | <b>98.21</b> |

Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L EMU Innovation

Investment portfolio as at December 31, 2023

| Description  | Quantity | Currency | Market value<br>(in EUR) | % net assets |
|--|----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |          |          |                          |              |
| <b>Shares</b>  |          |          |                          |              |
| <b>Belgium</b>   |          |          |                          |              |
| KBC GROUPE SA  | 33,566   | EUR      | 1,970,996                | 4.11         |
|  |          |          | <b>1,970,996</b>         | <b>4.11</b>  |
| <b>Denmark</b>   |          |          |                          |              |
| GENMAB AS  | 2,354    | DKK      | 680,507                  | 1.42         |
|  |          |          | <b>680,507</b>           | <b>1.42</b>  |
| <b>France</b>  |          |          |                          |              |
| BIOMERIEUX SA  | 20,207   | EUR      | 2,032,824                | 4.23         |
| DASSAULT SYST.   | 50,076   | EUR      | 2,215,112                | 4.61         |
| ESSILORLUXOTTICA SA  | 7,727    | EUR      | 1,403,223                | 2.92         |
| L'OREAL SA   | 3,301    | EUR      | 1,487,596                | 3.10         |
| SANOFI   | 17,890   | EUR      | 1,605,806                | 3.35         |
| SCHNEIDER ELECTRIC SE  | 10,526   | EUR      | 1,913,416                | 3.99         |
|  |          |          | <b>10,657,977</b>        | <b>22.20</b> |
| <b>Germany</b>   |          |          |                          |              |
| BEIERSDORF AG  | 15,618   | EUR      | 2,119,363                | 4.41         |
| CARL ZEISS MEDITEC AG  | 24,906   | EUR      | 2,461,709                | 5.13         |
| INFINEON TECHNOLOGIES - REG SHS  | 19,713   | EUR      | 745,151                  | 1.55         |
| NEMETSCHEK   | 10,021   | EUR      | 786,448                  | 1.64         |
| RATIONAL NAMEN   | 1,160    | EUR      | 811,420                  | 1.69         |
| SIEMENS AG PREFERENTIAL SHARE  | 7,104    | EUR      | 1,207,112                | 2.51         |
| SIEMENS HEALTHINEERS   | 28,386   | EUR      | 1,493,104                | 3.11         |
| STRATEC N REG SHS  | 14,980   | EUR      | 682,339                  | 1.42         |
| SYMRISE AG   | 14,513   | EUR      | 1,446,075                | 3.01         |
|  |          |          | <b>11,752,721</b>        | <b>24.48</b> |
| <b>Ireland</b>   |          |          |                          |              |
| KERRY GROUP -A-  | 29,183   | EUR      | 2,295,535                | 4.78         |
| KINGSPAN GROUP   | 21,009   | EUR      | 1,647,106                | 3.43         |
|  |          |          | <b>3,942,641</b>         | <b>8.21</b>  |
| <b>Italy</b>   |          |          |                          |              |
| FINCOBANK  | 183,547  | EUR      | 2,493,486                | 5.19         |
| ILLIMITY BANK SPA - BEARER SHS   | 44,318   | EUR      | 241,755                  | 0.50         |
|  |          |          | <b>2,735,241</b>         | <b>5.70</b>  |
| <b>Luxembourg</b>  |          |          |                          |              |
| GRAND CITY PROPERTIES  | 97,011   | EUR      | 987,572                  | 2.06         |
| MIPS AB  | 10,534   | SEK      | 344,904                  | 0.72         |
|  |          |          | <b>1,332,476</b>         | <b>2.78</b>  |
| <b>Netherlands</b>   |          |          |                          |              |
| ADYEN  | 645      | EUR      | 752,457                  | 1.57         |
| ASML HOLDING NV  | 3,712    | EUR      | 2,530,471                | 5.27         |
| CORBION  | 10,252   | EUR      | 198,684                  | 0.41         |
|  |          |          | <b>3,481,612</b>         | <b>7.25</b>  |
| <b>Norway</b>  |          |          |                          |              |
| TOMRA SYSTEMS ASA  | 93,425   | NOK      | 1,028,062                | 2.14         |
|  |          |          | <b>1,028,062</b>         | <b>2.14</b>  |
| <b>Spain</b>   |          |          |                          |              |
| AMADEUS IT GROUP SA -A-  | 11,940   | EUR      | 774,667                  | 1.61         |
| INDITEX SHARE FROM SPLIT   | 59,484   | EUR      | 2,345,454                | 4.89         |
|  |          |          | <b>3,120,121</b>         | <b>6.50</b>  |
| <b>Sweden</b>  |          |          |                          |              |
| ASSA ABLOY -B- NEW I   | 18,869   | SEK      | 492,043                  | 1.02         |
| HEXAGON - REG SHS -B-  | 88,254   | SEK      | 958,843                  | 2.00         |
|  |          |          | <b>1,450,886</b>         | <b>3.02</b>  |
| <b>Switzerland</b>   |          |          |                          |              |
| DSM FIRMENICH  | 26,682   | EUR      | 2,454,744                | 5.11         |
|  |          |          | <b>2,454,744</b>         | <b>5.11</b>  |
| <b>Total Shares</b>  |          |          | <b>44,607,984</b>        | <b>92.92</b> |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L EMU Innovation

Investment portfolio as at December 31, 2023

| Description  | Quantity | Currency | Market value<br>(in EUR) | % net assets |
|--|----------|----------|--------------------------|--------------|
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |          |          | <b>44,607,984</b>        | <b>92.92</b> |
| <b>Total investment portfolio</b>  |          |          | <b>44,607,984</b>        | <b>92.92</b> |
| Acquisition cost   |          |          | 42,439,582               |              |





## Candriam Equities L EMU Innovation

### Geographical and economic breakdown of investments as at December 31, 2023

#### Geographical breakdown (in % of net assets)

|             |              |
|-------------|--------------|
| Germany     | 24.48        |
| France      | 22.20        |
| Ireland     | 8.21         |
| Netherlands | 7.25         |
| Spain       | 6.50         |
| Italy       | 5.70         |
| Switzerland | 5.11         |
| Belgium     | 4.11         |
| Sweden      | 3.02         |
| Luxembourg  | 2.78         |
| Norway      | 2.14         |
| Denmark     | 1.42         |
|             | <b>92.92</b> |

#### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Pharmaceuticals                        | 26.25        |
| Banks and other financial institutions | 16.48        |
| Electrical engineering                 | 8.19         |
| Internet and internet services         | 7.87         |
| Electronics and semiconductors         | 6.82         |
| Machine and apparatus construction     | 6.59         |
| Foods and non alcoholic drinks         | 5.20         |
| Retail trade and department stores     | 4.89         |
| Building materials                     | 3.43         |
| Chemicals                              | 3.01         |
| Real estate                            | 2.06         |
| Biotechnology                          | 1.42         |
| Miscellaneous services                 | 0.72         |
|  | <b>92.92</b> |



## Candriam Equities L Europe Innovation

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in EUR) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Denmark</b>   |           |          |                          |              |
| GENMAB AS  | 61,161    | DKK      | 17,680,739               | 1.97         |
| NOVOZYMES -B-  | 228,932   | DKK      | 11,396,619               | 1.27         |
|  |           |          | <b>29,077,358</b>        | <b>3.24</b>  |
| <b>France</b>  |           |          |                          |              |
| BIOMERIEUX SA  | 418,925   | EUR      | 42,143,855               | 4.69         |
| DASSAULT SYST.   | 930,069   | EUR      | 41,141,601               | 4.58         |
| ESSILORLUXOTTICA SA  | 97,813    | EUR      | 17,762,841               | 1.98         |
| L'OREAL SA   | 15,561    | EUR      | 7,012,565                | 0.78         |
| SANOFI   | 115,847   | EUR      | 10,398,427               | 1.16         |
| SCHNEIDER ELECTRIC SE  | 123,477   | EUR      | 22,445,649               | 2.50         |
|  |           |          | <b>140,904,938</b>       | <b>15.68</b> |
| <b>Germany</b>   |           |          |                          |              |
| BEIERSDORF AG  | 149,712   | EUR      | 20,315,919               | 2.26         |
| CARL ZEISS MEDITEC AG  | 323,281   | EUR      | 31,953,094               | 3.56         |
| DUERR AG   | 195,962   | EUR      | 4,189,668                | 0.47         |
| INFINEON TECHNOLOGIES - REG SHS  | 155,521   | EUR      | 5,878,693                | 0.65         |
| NEMETSCHEK   | 144,644   | EUR      | 11,351,661               | 1.26         |
| SIEMENS AG PREFERENTIAL SHARE  | 53,343    | EUR      | 9,064,042                | 1.01         |
| SIEMENS HEALTHINEERS   | 335,074   | EUR      | 17,624,892               | 1.96         |
| STRATEC N REG SHS  | 218,671   | EUR      | 9,960,464                | 1.11         |
| SYMRISE AG   | 180,193   | EUR      | 17,954,431               | 2.00         |
|  |           |          | <b>128,292,864</b>       | <b>14.28</b> |
| <b>Ireland</b>   |           |          |                          |              |
| KERRY GROUP -A-  | 470,706   | EUR      | 37,025,734               | 4.12         |
| KINGSPAN GROUP   | 253,186   | EUR      | 19,849,783               | 2.21         |
|  |           |          | <b>56,875,517</b>        | <b>6.33</b>  |
| <b>Italy</b>   |           |          |                          |              |
| FINECOBANK   | 2,708,733 | EUR      | 36,798,138               | 4.09         |
| ILLIMITY BANK SPA - BEARER SHS   | 889,689   | EUR      | 4,853,255                | 0.54         |
|  |           |          | <b>41,651,393</b>        | <b>4.63</b>  |
| <b>Luxembourg</b>  |           |          |                          |              |
| GRAND CITY PROPERTIES  | 977,474   | EUR      | 9,950,685                | 1.11         |
| MIPS AB  | 220,884   | SEK      | 7,232,177                | 0.80         |
|  |           |          | <b>17,182,862</b>        | <b>1.91</b>  |
| <b>Netherlands</b>   |           |          |                          |              |
| ADYEN  | 8,585     | EUR      | 10,015,261               | 1.11         |
| ASML HOLDING NV  | 36,115    | EUR      | 24,619,596               | 2.74         |
| CORBION  | 157,843   | EUR      | 3,058,997                | 0.34         |
|  |           |          | <b>37,693,854</b>        | <b>4.19</b>  |
| <b>Norway</b>  |           |          |                          |              |
| TOMRA SYSTEMS ASA  | 2,231,116 | NOK      | 24,551,524               | 2.73         |
|  |           |          | <b>24,551,524</b>        | <b>2.73</b>  |
| <b>Spain</b>   |           |          |                          |              |
| AMADEUS IT GROUP SA -A-  | 154,711   | EUR      | 10,037,650               | 1.12         |
| INDITEX SHARE FROM SPLIT   | 436,254   | EUR      | 17,201,495               | 1.91         |
|  |           |          | <b>27,239,145</b>        | <b>3.03</b>  |
| <b>Sweden</b>  |           |          |                          |              |
| ASSA ABLOY -B- NEW I   | 351,860   | SEK      | 9,175,384                | 1.02         |
| CELLAVISION  | 463,661   | SEK      | 8,829,655                | 0.98         |
| HEXAGON - REG SHS -B-  | 4,212,414 | SEK      | 45,766,133               | 5.09         |
| THULE CORP   | 253,013   | SEK      | 6,238,678                | 0.69         |
|  |           |          | <b>70,009,850</b>        | <b>7.79</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| DSM FIRMENICH  | 399,768   | EUR      | 36,778,656               | 4.09         |
| NESTLE SA PREFERENTIAL SHARE   | 394,888   | CHF      | 41,417,154               | 4.61         |
| ROCHE HOLDING LTD  | 72,338    | CHF      | 19,024,030               | 2.12         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Europe Innovation

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in EUR) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| TECAN GROUP NAM.AKT  | 86,279    | CHF      | 31,868,569               | 3.55         |
|  |           |          | <b>129,088,409</b>       | <b>14.36</b> |
| <b>United Kingdom</b>  |           |          |                          |              |
| ADMIRAL GROUP PLC  | 562,971   | GBP      | 17,437,126               | 1.94         |
| ASTRAZENECA PLC  | 155,941   | GBP      | 19,075,351               | 2.12         |
| CRODA INTL - REG SHS   | 159,458   | GBP      | 9,292,746                | 1.03         |
| HALMA PLC  | 1,619,121 | GBP      | 42,675,810               | 4.75         |
| JOHNSON MATTHEY  | 522,915   | GBP      | 10,243,473               | 1.14         |
| RECKITT BENCKISER GROUP PLC  | 325,611   | GBP      | 20,365,953               | 2.27         |
| SPIRAX-SARCO ENGIN   | 321,396   | GBP      | 38,962,149               | 4.34         |
| YOUGOV PLC   | 330,893   | GBP      | 4,505,842                | 0.50         |
|  |           |          | <b>162,558,450</b>       | <b>18.09</b> |
| <b>Total Shares</b>  |           |          | <b>865,126,164</b>       | <b>96.27</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          | <b>865,126,164</b>       | <b>96.27</b> |
| <b>Total investment portfolio</b>  |           |          | <b>865,126,164</b>       | <b>96.27</b> |
| Acquisition cost   |           |          | 838,652,783              |              |



## Candriam Equities L Europe Innovation

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                |              |
|----------------|--------------|
| United Kingdom | 18.09        |
| France         | 15.68        |
| Switzerland    | 14.36        |
| Germany        | 14.28        |
| Sweden         | 7.79         |
| Ireland        | 6.33         |
| Italy          | 4.63         |
| Netherlands    | 4.19         |
| Denmark        | 3.24         |
| Spain          | 3.03         |
| Norway         | 2.73         |
| Luxembourg     | 1.91         |
|                | <b>96.27</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Pharmaceuticals                        | 24.17        |
| Machine and apparatus construction     | 14.76        |
| Banks and other financial institutions | 9.84         |
| Foods and non alcoholic drinks         | 9.07         |
| Electronics and semiconductors         | 8.14         |
| Internet and internet services         | 6.96         |
| Chemicals                              | 4.30         |
| Electrical engineering                 | 3.51         |
| Miscellaneous consumer goods           | 2.96         |
| Biotechnology                          | 2.95         |
| Building materials                     | 2.21         |
| Insurance                              | 1.94         |
| Retail trade and department stores     | 1.91         |
| Miscellaneous services                 | 1.31         |
| Precious metals and stones             | 1.14         |
| Real estate                            | 1.11         |
|  | <b>96.27</b> |



## Candriam Equities L Europe Optimum Quality

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in EUR) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Belgium</b>   |           |          |                          |              |
| AEDIFICA SA  | 109,399   | EUR      | 6,963,246                | 1.23         |
| KBC GROUPE SA  | 309,321   | EUR      | 18,163,329               | 3.22         |
| WAREHOUSES DE PAUW SCA - REGISTERED SHS  | 244,315   | EUR      | 6,962,978                | 1.23         |
|  |           |          | <b>32,089,553</b>        | <b>5.68</b>  |
| <b>Czech Republic</b>  |           |          |                          |              |
| KOMERCNI BANKA AS  | 131,770   | CZK      | 3,866,876                | 0.68         |
|  |           |          | <b>3,866,876</b>         | <b>0.68</b>  |
| <b>Denmark</b>   |           |          |                          |              |
| CHRISTIAN HANSEN   | 37,899    | DKK      | 2,878,566                | 0.51         |
| GENMAB AS  | 38,760    | DKK      | 11,204,942               | 1.98         |
| NOVOZYMES -B-  | 173,617   | DKK      | 8,642,947                | 1.53         |
| TOPDANMARK AS  | 136,053   | DKK      | 5,884,122                | 1.04         |
| TRYG A/S   | 579,738   | DKK      | 11,424,367               | 2.02         |
| VESTAS WIND SYSTEMS - BEARER AND/OR SHS  | 165,624   | DKK      | 4,761,283                | 0.84         |
|  |           |          | <b>44,796,227</b>        | <b>7.93</b>  |
| <b>Finland</b>   |           |          |                          |              |
| NESTE  | 184,236   | EUR      | 5,934,242                | 1.05         |
|  |           |          | <b>5,934,242</b>         | <b>1.05</b>  |
| <b>France</b>  |           |          |                          |              |
| AIR LIQUIDE SA   | 64,959    | EUR      | 11,440,579               | 2.03         |
| BIOMERIEUX SA  | 191,819   | EUR      | 19,296,990               | 3.42         |
| BUREAU VERITAS SA  | 786,702   | EUR      | 17,991,875               | 3.19         |
| DASSAULT SYST.   | 388,591   | EUR      | 17,189,323               | 3.04         |
| ESSILORLUXOTTICA SA  | 61,454    | EUR      | 11,160,046               | 1.98         |
| L'OREAL SA   | 13,310    | EUR      | 5,998,152                | 1.06         |
| LVMH MOET HENNESSY LOUIS VUITTON SE  | 15,223    | EUR      | 11,167,593               | 1.98         |
| SANOFI   | 127,444   | EUR      | 11,439,373               | 2.03         |
| SCHNEIDER ELECTRIC SE  | 46,788    | EUR      | 8,505,123                | 1.51         |
|  |           |          | <b>114,189,054</b>       | <b>20.22</b> |
| <b>Germany</b>   |           |          |                          |              |
| BEIERSDORF AG  | 134,432   | EUR      | 18,242,421               | 3.23         |
| CARL ZEISS MEDITEC AG  | 89,430    | EUR      | 8,839,261                | 1.57         |
| HANNOVER RUECK SE  | 13,660    | EUR      | 2,954,658                | 0.52         |
| SIEMENS AG PREFERENTIAL SHARE  | 34,452    | EUR      | 5,854,084                | 1.04         |
| SIEMENS HEALTHINEERS   | 217,776   | EUR      | 11,455,018               | 2.03         |
| SYMRISE AG   | 53,116    | EUR      | 5,292,478                | 0.94         |
|  |           |          | <b>52,637,920</b>        | <b>9.32</b>  |
| <b>Guernsey</b>  |           |          |                          |              |
| SHURGARD SELF STORAGE LTD  | 71,661    | EUR      | 3,214,712                | 0.57         |
|  |           |          | <b>3,214,712</b>         | <b>0.57</b>  |
| <b>Ireland</b>   |           |          |                          |              |
| KERRY GROUP -A-  | 229,013   | EUR      | 18,014,163               | 3.19         |
|  |           |          | <b>18,014,163</b>        | <b>3.19</b>  |
| <b>Italy</b>   |           |          |                          |              |
| FINECOBANK   | 1,032,752 | EUR      | 14,029,936               | 2.48         |
|  |           |          | <b>14,029,936</b>        | <b>2.48</b>  |
| <b>Luxembourg</b>  |           |          |                          |              |
| GRAND CITY PROPERTIES  | 565,278   | EUR      | 5,754,530                | 1.02         |
|  |           |          | <b>5,754,530</b>         | <b>1.02</b>  |
| <b>Netherlands</b>   |           |          |                          |              |
| ALFEN NV   | 115,471   | EUR      | 6,960,592                | 1.23         |
| ASML HOLDING NV  | 22,294    | EUR      | 15,197,820               | 2.69         |
|  |           |          | <b>22,158,412</b>        | <b>3.92</b>  |
| <b>Norway</b>  |           |          |                          |              |
| TOMRA SYSTEMS ASA  | 375,473   | NOK      | 4,131,759                | 0.73         |
|  |           |          | <b>4,131,759</b>         | <b>0.73</b>  |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Europe Optimum Quality

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in EUR) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Spain</b>   |           |          |                          |              |
| AMADEUS IT GROUP SA -A-  | 43,194    | EUR      | 2,802,427                | 0.50         |
| BANKINTER SA - REG SHS   | 1,102,138 | EUR      | 6,387,992                | 1.13         |
| INDITEX SHARE FROM SPLIT   | 73,862    | EUR      | 2,912,379                | 0.52         |
|  |           |          | <b>12,102,798</b>        | <b>2.14</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| BACHEM HOLDING LTD SHARES  | 41,862    | CHF      | 2,926,783                | 0.52         |
| DSM FIRMENICH  | 193,205   | EUR      | 17,774,860               | 3.15         |
| KARDEX HOLDING AG  | 12,472    | CHF      | 2,924,487                | 0.52         |
| LONZA GROUP  | 16,118    | CHF      | 6,132,017                | 1.09         |
| NESTLE SA PREFERENTIAL SHARE   | 160,754   | CHF      | 16,860,409               | 2.99         |
| ROCHE HOLDING LTD  | 52,221    | CHF      | 13,733,500               | 2.43         |
| SIG GROUP PREFERENTIAL SHARE   | 530,708   | CHF      | 11,045,713               | 1.96         |
| TECAN GROUP NAM.AKT  | 43,747    | CHF      | 16,158,675               | 2.86         |
|  |           |          | <b>87,556,444</b>        | <b>15.50</b> |
| <b>United Kingdom</b>  |           |          |                          |              |
| ADMIRAL GROUP PLC  | 356,785   | GBP      | 11,050,845               | 1.96         |
| ASTRAZENECA PLC  | 95,300    | GBP      | 11,657,492               | 2.06         |
| BIG YELLOW GROUP PLC   | 220,000   | GBP      | 3,102,418                | 0.55         |
| COMPASS GROUP  | 468,355   | GBP      | 11,598,752               | 2.05         |
| CRODA INTL - REG SHS   | 101,745   | GBP      | 5,929,401                | 1.05         |
| GRAINGER PLC   | 2,281,939 | GBP      | 6,962,607                | 1.23         |
| HALMA PLC  | 258,106   | GBP      | 6,803,002                | 1.20         |
| INTERTEK GROUP PLC   | 177,464   | GBP      | 8,695,541                | 1.54         |
| RECKITT BENCKISER GROUP PLC  | 313,031   | GBP      | 19,579,113               | 3.47         |
| RELX PLC   | 154,609   | GBP      | 5,548,832                | 0.98         |
| RENTOKIL INITIAL PLC   | 1,151,563 | GBP      | 5,857,816                | 1.04         |
| SPIRAX-SARCO ENGIN   | 76,024    | GBP      | 9,216,227                | 1.63         |
| UNILEVER   | 46,514    | EUR      | 2,039,871                | 0.36         |
| UNILEVER   | 335,349   | GBP      | 14,705,743               | 2.60         |
| UNITE GROUP PLC  | 121,117   | GBP      | 1,459,190                | 0.26         |
|  |           |          | <b>124,206,850</b>       | <b>22.00</b> |
| <b>Total Shares</b>  |           |          | <b>544,683,476</b>       | <b>96.45</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          | <b>544,683,476</b>       | <b>96.45</b> |
| <b>Total investment portfolio</b>  |           |          | <b>544,683,476</b>       | <b>96.45</b> |
| Acquisition cost   |           |          | 540,330,420              |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Europe Optimum Quality

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                |              |
|----------------|--------------|
| United Kingdom | 22.00        |
| France         | 20.22        |
| Switzerland    | 15.50        |
| Germany        | 9.32         |
| Denmark        | 7.93         |
| Belgium        | 5.68         |
| Netherlands    | 3.92         |
| Ireland        | 3.19         |
| Italy          | 2.48         |
| Spain          | 2.14         |
| Finland        | 1.05         |
| Luxembourg     | 1.02         |
| Norway         | 0.73         |
| Czech Republic | 0.68         |
| Guernsey       | 0.57         |
|                | <b>96.45</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Pharmaceuticals                        | 22.66        |
| Banks and other financial institutions | 14.37        |
| Foods and non alcoholic drinks         | 9.14         |
| Chemicals                              | 6.63         |
| Real estate                            | 6.10         |
| Insurance                              | 5.55         |
| Miscellaneous services                 | 4.22         |
| Electronics and semiconductors         | 3.90         |
| Internet and internet services         | 3.54         |
| Textiles and garments                  | 3.52         |
| Miscellaneous consumer goods           | 3.47         |
| Machine and apparatus construction     | 2.88         |
| Electrical engineering                 | 2.54         |
| Biotechnology                          | 2.49         |
| Hotels and restaurants                 | 2.05         |
| Petroleum                              | 1.05         |
| Graphic art and publishing             | 0.98         |
| Utilities                              | 0.84         |
| Retail trade and department stores     | 0.52         |
|  | <b>96.45</b> |



## Candriam Equities L Global Demography

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in EUR) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Belgium</b>   |           |          |                          |              |
| KBC GROUPE SA  | 420,358   | EUR      | 24,683,422               | 1.57         |
|  |           |          | <b>24,683,422</b>        | <b>1.57</b>  |
| <b>Finland</b>   |           |          |                          |              |
| KONE OYJ -B-   | 363,686   | EUR      | 16,424,060               | 1.05         |
|  |           |          | <b>16,424,060</b>        | <b>1.05</b>  |
| <b>France</b>  |           |          |                          |              |
| AXA SA   | 478,447   | EUR      | 14,109,402               | 0.90         |
| CIE GENERALE DES ETABLISSEMENTS MICHELIN   | 525,176   | EUR      | 17,047,213               | 1.09         |
| LVMH MOET HENNESSY LOUIS VUITTON SE  | 37,883    | EUR      | 27,790,969               | 1.77         |
| VINCI SA   | 114,988   | EUR      | 13,074,136               | 0.83         |
|  |           |          | <b>72,021,720</b>        | <b>4.59</b>  |
| <b>Hong Kong</b>   |           |          |                          |              |
| AIA GROUP LTD  | 1,892,402 | HKD      | 14,929,479               | 0.95         |
|  |           |          | <b>14,929,479</b>        | <b>0.95</b>  |
| <b>Ireland</b>   |           |          |                          |              |
| LINDE PLC  | 55,093    | USD      | 20,432,763               | 1.30         |
|  |           |          | <b>20,432,763</b>        | <b>1.30</b>  |
| <b>Japan</b>   |           |          |                          |              |
| HOYA CORP  | 74,400    | JPY      | 8,420,151                | 0.54         |
| MITSUBISHI UFJ FINANCIAL GROUP INC   | 2,383,700 | JPY      | 18,543,548               | 1.18         |
| NINTENDO CO LTD  | 375,800   | JPY      | 17,757,973               | 1.13         |
| SMC CORP   | 25,100    | JPY      | 12,210,445               | 0.78         |
| UNI CHARM  | 553,600   | JPY      | 18,122,317               | 1.16         |
|  |           |          | <b>75,054,434</b>        | <b>4.79</b>  |
| <b>Jersey</b>  |           |          |                          |              |
| APTIV PLC  | 240,782   | USD      | 19,556,385               | 1.25         |
|  |           |          | <b>19,556,385</b>        | <b>1.25</b>  |
| <b>Netherlands Antilles</b>  |           |          |                          |              |
| SLB  | 325,891   | USD      | 15,352,707               | 0.98         |
|  |           |          | <b>15,352,707</b>        | <b>0.98</b>  |
| <b>Netherlands</b>   |           |          |                          |              |
| ASML HOLDING NV  | 36,490    | EUR      | 24,875,233               | 1.59         |
|  |           |          | <b>24,875,233</b>        | <b>1.59</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| NESTLE SA PREFERENTIAL SHARE   | 374,551   | CHF      | 39,284,143               | 2.51         |
| SIKA - REGISTERED SHS  | 28,000    | CHF      | 8,243,089                | 0.53         |
| TE CONNECTIVITY LTD - REG SHS  | 127,555   | USD      | 16,223,670               | 1.04         |
|  |           |          | <b>63,750,902</b>        | <b>4.07</b>  |
| <b>United Kingdom</b>  |           |          |                          |              |
| ANTOFAGASTA PLC  | 457,069   | GBP      | 8,858,662                | 0.57         |
| ASTRAZENECA PLC  | 139,349   | GBP      | 17,045,749               | 1.09         |
| DIAGEO PLC   | 742,472   | GBP      | 24,470,602               | 1.56         |
| RELX PLC   | 480,342   | EUR      | 17,205,850               | 1.10         |
| UNILEVER   | 558,833   | EUR      | 24,507,621               | 1.56         |
|  |           |          | <b>92,088,484</b>        | <b>5.87</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| ABBOTT LABORATORIES  | 243,701   | USD      | 24,282,958               | 1.55         |
| ADOBE INC  | 27,736    | USD      | 14,979,675               | 0.96         |
| ADVANCED MICRO DEVICES INC   | 64,745    | USD      | 8,639,895                | 0.55         |
| ALPHABET INC -A-   | 508,065   | USD      | 64,248,042               | 4.10         |
| AMAZON.COM INC   | 199,472   | USD      | 27,436,542               | 1.75         |
| AMGEN INC  | 55,538    | USD      | 14,480,654               | 0.92         |
| APPLE INC  | 562,906   | USD      | 98,109,168               | 6.26         |
| BANK OF AMERICA CORP   | 899,456   | USD      | 27,415,637               | 1.75         |
| BROADCOM INC - REGISTERED SHS  | 23,211    | USD      | 23,454,740               | 1.50         |
| BROWN AND BROWN INC  | 155,470   | USD      | 10,008,122               | 0.64         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.





## Candriam Equities L Global Demography

Investment portfolio as at December 31, 2023

| Description  | Quantity | Currency | Market value<br>(in EUR) | % net assets |
|--|----------|----------|--------------------------|--------------|
| CATERPILLAR - REG SHS  | 60,080   | USD      | 16,080,979               | 1.03         |
| CISCO SYSTEMS INC  | 273,109  | USD      | 12,490,351               | 0.80         |
| CONSOLIDATED EDISON INC  | 315,727  | USD      | 26,000,711               | 1.66         |
| COSTCO WHOLESALE CORP  | 28,000   | USD      | 16,731,309               | 1.07         |
| ELI LILLY & CO   | 25,215   | USD      | 13,305,869               | 0.85         |
| EMERSON ELECTRIC CO  | 186,657  | USD      | 16,446,228               | 1.05         |
| FORTIVE CORP   | 319,485  | USD      | 21,295,144               | 1.36         |
| HALLIBURTON  | 332,726  | USD      | 10,888,557               | 0.69         |
| HOME DEPOT INC   | 65,833   | USD      | 20,653,081               | 1.32         |
| JPMORGAN CHASE CO  | 157,080  | USD      | 24,188,031               | 1.54         |
| MARVELL TECH --- REGISTERED SHS  | 326,285  | USD      | 17,814,012               | 1.14         |
| MASTERCARD INC -A-   | 68,967   | USD      | 26,628,448               | 1.70         |
| MCDONALD'S CORP  | 75,789   | USD      | 20,343,273               | 1.30         |
| MERCK & CO INC   | 281,957  | USD      | 27,826,870               | 1.78         |
| METTLER TOLEDO INTERNATIONAL   | 7,417    | USD      | 8,144,231                | 0.52         |
| MICROSOFT CORP   | 291,066  | USD      | 99,083,382               | 6.32         |
| MONDELEZ INTERNATIONAL INC   | 231,654  | USD      | 15,189,154               | 0.97         |
| NIKE INC   | 109,212  | USD      | 10,733,849               | 0.68         |
| NVIDIA CORP  | 58,069   | USD      | 26,032,617               | 1.66         |
| OTIS WORLDWIDE CORPORATION   | 180,810  | USD      | 14,644,522               | 0.93         |
| PARKER-HANNIFIN CORP   | 19,012   | USD      | 7,929,053                | 0.51         |
| PEPSICO INC  | 119,629  | USD      | 18,392,966               | 1.17         |
| PROCTER & GAMBLE CO  | 163,555  | USD      | 21,696,782               | 1.38         |
| PROGRESSIVE CORP   | 79,237   | USD      | 11,425,220               | 0.73         |
| S&P GLOBAL INC   | 48,315   | USD      | 19,267,391               | 1.23         |
| SEMPRA ENERGY  | 223,766  | USD      | 15,137,857               | 0.97         |
| SERVICENOW INC   | 14,509   | USD      | 9,279,377                | 0.59         |
| STARBUCKS CORP   | 208,314  | USD      | 18,105,488               | 1.16         |
| STRYKER CORP   | 57,905   | USD      | 15,697,489               | 1.00         |
| THERMO FISHER SCIENT SHS   | 37,272   | USD      | 17,909,387               | 1.14         |
| TJX COS INC  | 131,702  | USD      | 11,184,506               | 0.71         |
| UNITEDHEALTH GROUP INC   | 84,592   | USD      | 40,316,073               | 2.57         |
| VALERO ENERGY CORP   | 81,210   | USD      | 9,557,145                | 0.61         |
| VISA INC -A-   | 139,015  | USD      | 32,763,821               | 2.09         |
| WALT DISNEY CO   | 90,244   | USD      | 7,376,210                | 0.47         |
| WASTE MANAGEMENT   | 180,829  | USD      | 29,318,313               | 1.87         |
|  |          |          | <b>1,042,933,129</b>     | <b>66.53</b> |
| <b>Total Shares</b>  |          |          | <b>1,482,102,718</b>     | <b>94.55</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |          |          | <b>1,482,102,718</b>     | <b>94.55</b> |
| <b>Total investment portfolio</b>  |          |          | <b>1,482,102,718</b>     | <b>94.55</b> |
| Acquisition cost   |          |          | 1,301,238,996            |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Global Demography

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                          |              |
|--------------------------|--------------|
| United States of America | 66.53        |
| United Kingdom           | 5.87         |
| Japan                    | 4.79         |
| France                   | 4.59         |
| Switzerland              | 4.07         |
| Netherlands              | 1.59         |
| Belgium                  | 1.57         |
| Ireland                  | 1.30         |
| Jersey                   | 1.25         |
| Finland                  | 1.05         |
| Netherlands Antilles     | 0.98         |
| Hong Kong                | 0.95         |
|                          | <b>94.55</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Internet and internet services         | 11.97        |
| Banks and other financial institutions | 11.22        |
| Office supplies and computing          | 8.55         |
| Electronics and semiconductors         | 8.49         |
| Pharmaceuticals                        | 7.19         |
| Foods and non alcoholic drinks         | 6.21         |
| Retail trade and department stores     | 4.85         |
| Machine and apparatus construction     | 4.29         |
| Insurance                              | 3.22         |
| Graphic art and publishing             | 2.80         |
| Utilities                              | 2.62         |
| Healthcare                             | 2.57         |
| Miscellaneous consumer goods           | 2.54         |
| Textiles and garments                  | 2.46         |
| Hotels and restaurants                 | 2.45         |
| Petroleum                              | 2.28         |
| Miscellaneous services                 | 2.09         |
| Environmental services and recycling   | 1.87         |
| Tobacco and alcoholic drinks           | 1.56         |
| Road vehicles                          | 1.25         |
| Tires and rubber                       | 1.09         |
| Electrical engineering                 | 1.05         |
| Building materials                     | 0.83         |
| Non ferrous metals                     | 0.57         |
| Chemicals                              | 0.53         |
|  | <b>94.55</b> |

Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Life Care

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Belgium</b>   |           |          |                          |              |
| ION BEAM APPLICATIONS  | 56,000    | EUR      | 713,869                  | 0.10         |
| UCB  | 50,903    | EUR      | 4,436,547                | 0.61         |
|  |           |          | <b>5,150,416</b>         | <b>0.71</b>  |
| <b>Denmark</b>   |           |          |                          |              |
| COLOPLAST -B-  | 16,230    | DKK      | 1,856,689                | 0.25         |
| NOVO NORDISK - BEARER AND/OR - REG SHS   | 289,930   | DKK      | 29,992,596               | 4.11         |
|  |           |          | <b>31,849,285</b>        | <b>4.36</b>  |
| <b>France</b>  |           |          |                          |              |
| ESSILORLUXOTTICA SA  | 37,852    | EUR      | 7,593,279                | 1.04         |
| SANOFI   | 187,794   | EUR      | 18,620,411               | 2.55         |
|  |           |          | <b>26,213,690</b>        | <b>3.59</b>  |
| <b>Germany</b>   |           |          |                          |              |
| FRESENIUS SE   | 76,281    | EUR      | 2,365,285                | 0.32         |
| MERCK KGAA   | 12,619    | EUR      | 2,008,693                | 0.28         |
| SIEMENS HEALTHINEERS   | 170,000   | EUR      | 9,877,780                | 1.35         |
|  |           |          | <b>14,251,758</b>        | <b>1.95</b>  |
| <b>Hong Kong</b>   |           |          |                          |              |
| CSPC PHARMACEUTICAL  | 4,750,000 | HKD      | 4,416,295                | 0.60         |
|  |           |          | <b>4,416,295</b>         | <b>0.60</b>  |
| <b>Ireland</b>   |           |          |                          |              |
| ALKERMES   | 137,370   | USD      | 3,810,644                | 0.52         |
| ICON PLC   | 14,891    | USD      | 4,215,195                | 0.58         |
| MEDTRONIC HLD  | 319,117   | USD      | 26,288,858               | 3.60         |
|  |           |          | <b>34,314,697</b>        | <b>4.70</b>  |
| <b>Japan</b>   |           |          |                          |              |
| CHUGAI PHARMACEUTICAL  | 61,600    | JPY      | 2,334,141                | 0.32         |
| DAIICHI SANKYO CO LTD  | 139,800   | JPY      | 3,839,592                | 0.53         |
| EISAI  | 24,900    | JPY      | 1,245,530                | 0.17         |
| OLYMPUS CORP   | 392,100   | JPY      | 5,675,132                | 0.78         |
| SHINOBI CO LTD   | 38,700    | JPY      | 1,866,099                | 0.26         |
| TAKEDA PHARMACEUTICAL  | 112,200   | JPY      | 3,226,407                | 0.44         |
|  |           |          | <b>18,186,901</b>        | <b>2.49</b>  |
| <b>Luxembourg</b>  |           |          |                          |              |
| JMDC INC   | 55,700    | JPY      | 1,684,275                | 0.23         |
| WUXI XDC CAYMAN INC  | 1,808     | HKD      | 7,409                    | 0.00         |
|  |           |          | <b>1,691,684</b>         | <b>0.23</b>  |
| <b>People's Republic of China</b>  |           |          |                          |              |
| SINOPHARM GROUP CO LTD   | 594,800   | HKD      | 1,557,730                | 0.21         |
|  |           |          | <b>1,557,730</b>         | <b>0.21</b>  |
| <b>South Africa</b>  |           |          |                          |              |
| ASPEN PHARMACARE HOLDINGS PLC  | 376,376   | ZAR      | 4,188,241                | 0.57         |
|  |           |          | <b>4,188,241</b>         | <b>0.57</b>  |
| <b>Spain</b>   |           |          |                          |              |
| ALMIRALL - BEARER SHS  | 337,885   | EUR      | 3,144,586                | 0.43         |
|  |           |          | <b>3,144,586</b>         | <b>0.43</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| ALCON - REG SHS  | 39,175    | CHF      | 3,055,339                | 0.42         |
| LONZA GROUP  | 14,454    | CHF      | 6,074,422                | 0.83         |
| NOVARTIS AG PREFERENTIAL SHARE   | 214,067   | CHF      | 21,586,677               | 2.96         |
| ROCHE HOLDING LTD  | 70,043    | CHF      | 20,348,175               | 2.79         |
| SANDOZ GROUP AG  | 189,437   | CHF      | 6,090,802                | 0.83         |
| SONOVA HOLDING NAM-AKT   | 14,192    | CHF      | 4,627,107                | 0.63         |
| TECAN GROUP NAM.AKT  | 5,817     | CHF      | 2,373,456                | 0.33         |
|  |           |          | <b>64,155,978</b>        | <b>8.79</b>  |
| <b>United Kingdom</b>  |           |          |                          |              |
| ASTRAZENECA PLC  | 105,638   | GBP      | 14,274,375               | 1.96         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



Candriam Equities L Life Care

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| CONVATEC GROUP REGD  | 1,327,574 | GBP      | 4,132,715                | 0.57         |
|  |           |          | <b>18,407,090</b>        | <b>2.52</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| ABBOTT LABORATORIES  | 144,673   | USD      | 15,924,157               | 2.18         |
| ABBVIE INC   | 113,212   | USD      | 17,544,464               | 2.40         |
| AGILENT TECHNOLOGIES   | 30,816    | USD      | 4,284,348                | 0.59         |
| ALNYLAM PHARMACEUTICALS INC  | 13,980    | USD      | 2,675,912                | 0.37         |
| AMGEN INC  | 52,782    | USD      | 15,202,272               | 2.08         |
| BECTON DICKINSON   | 63,957    | USD      | 15,594,635               | 2.14         |
| BIOGEN IDEC INC  | 11,795    | USD      | 3,052,192                | 0.42         |
| BOSTON SCIENTIF CORP   | 338,020   | USD      | 19,540,936               | 2.68         |
| BRISTOL-MYERS SQUIBB CO  | 154,753   | USD      | 7,940,376                | 1.09         |
| BRUKER BIOSCIENCES   | 97,350    | USD      | 7,153,278                | 0.98         |
| COOPER COMPANIES INC   | 9,502     | USD      | 3,595,937                | 0.49         |
| CVS HEALTH   | 222,373   | USD      | 17,558,572               | 2.41         |
| DANAHER CORP   | 83,724    | USD      | 19,368,710               | 2.65         |
| DENTSPLY SIRONA INC  | 86,184    | USD      | 3,067,289                | 0.42         |
| DEXCOM INC   | 95,881    | USD      | 11,897,873               | 1.63         |
| ELEVANCE HEALTH  | 22,001    | USD      | 10,374,792               | 1.42         |
| ELI LILLY & CO   | 59,683    | USD      | 34,790,414               | 4.77         |
| ENCOMPASS HLTH   | 62,680    | USD      | 4,182,010                | 0.57         |
| EVOLENT HEALTH -A-   | 178,663   | USD      | 5,901,239                | 0.81         |
| GILEAD SCIENCES INC  | 45,283    | USD      | 3,668,376                | 0.50         |
| GLOBUS MEDICAL -A-   | 36,834    | USD      | 1,962,884                | 0.27         |
| HCA INC  | 12,284    | USD      | 3,325,033                | 0.46         |
| HOLOGIC INC  | 44,771    | USD      | 3,198,888                | 0.44         |
| HUMANA INC   | 38,661    | USD      | 17,699,392               | 2.42         |
| ILLUMINA INC   | 31,000    | USD      | 4,316,440                | 0.59         |
| INCYTE CORP  | 22,061    | USD      | 1,385,210                | 0.19         |
| INSULET  | 11,193    | USD      | 2,428,657                | 0.33         |
| INTUITIVE SURGICAL   | 24,744    | USD      | 8,347,636                | 1.14         |
| JOHNSON & JOHNSON  | 134,668   | USD      | 21,107,862               | 2.89         |
| LABORATORY CORP OF AMERICA HOLDINGS  | 11,289    | USD      | 2,565,877                | 0.35         |
| MCKESSON CORP  | 32,173    | USD      | 14,895,456               | 2.04         |
| MERCK & CO INC   | 255,802   | USD      | 27,887,534               | 3.82         |
| MONTE ROSA THERAPEUTICS INC  | 135,000   | USD      | 762,750                  | 0.10         |
| NEUROCRINE BIOSCIENCES   | 22,386    | USD      | 2,949,579                | 0.40         |
| OPTION CARE HEALTH INC   | 220,000   | USD      | 7,411,800                | 1.02         |
| PFIZER INC   | 543,176   | USD      | 15,638,037               | 2.14         |
| PHREESIA INC   | 363,440   | USD      | 8,413,636                | 1.15         |
| QUEST DIAGNOSTICS  | 51,869    | USD      | 7,151,698                | 0.98         |
| REGENERON PHARMACEUTICALS INC  | 11,496    | USD      | 10,096,822               | 1.38         |
| SAREPTA THERAPEUTICS   | 43,445    | USD      | 4,189,401                | 0.57         |
| STRYKER CORP   | 23,465    | USD      | 7,026,829                | 0.96         |
| THERMO FISHER SCIENT SHS   | 45,668    | USD      | 24,240,118               | 3.32         |
| TREACE MEDICAL CONCEPTS INC  | 350,000   | USD      | 4,462,500                | 0.61         |
| UNITEDHEALTH GROUP INC   | 93,076    | USD      | 49,001,722               | 6.71         |
| VERTEX PHARMACEUTICALS INC   | 19,449    | USD      | 7,913,604                | 1.08         |
| ZIMMER BIOMET HLDGS SHS  | 34,633    | USD      | 4,214,836                | 0.58         |
|  |           |          | <b>485,911,983</b>       | <b>66.56</b> |
| <b>Total Shares</b>  |           |          | <b>713,440,334</b>       | <b>97.72</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          | <b>713,440,334</b>       | <b>97.72</b> |
| <b>Total investment portfolio</b>  |           |          | <b>713,440,334</b>       | <b>97.72</b> |
| Acquisition cost   |           |          | 685,249,295              |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Life Care

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                            |              |
|----------------------------|--------------|
| United States of America   | 66.56        |
| Switzerland                | 8.79         |
| Ireland                    | 4.70         |
| Denmark                    | 4.36         |
| France                     | 3.59         |
| United Kingdom             | 2.52         |
| Japan                      | 2.49         |
| Germany                    | 1.95         |
| Belgium                    | 0.71         |
| Hong Kong                  | 0.60         |
| South Africa               | 0.57         |
| Spain                      | 0.43         |
| Luxembourg                 | 0.23         |
| People's Republic of China | 0.21         |
|                            | <b>97.72</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Pharmaceuticals                        | 68.92        |
| Healthcare                             | 12.81        |
| Biotechnology                          | 4.83         |
| Electronics and semiconductors         | 3.32         |
| Machine and apparatus construction     | 2.65         |
| Banks and other financial institutions | 1.63         |
| Internet and internet services         | 1.15         |
| Chemicals                              | 0.83         |
| Miscellaneous services                 | 0.80         |
| Photographic and optics                | 0.78         |
|  | <b>97.72</b> |

Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Meta Globe

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Cayman Islands</b>  |           |          |                          |              |
| XIAOMI CORP - REGISTERED SHS -B-   | 1,214,044 | HKD      | 2,425,419                | 1.62         |
|  |           |          | <b>2,425,419</b>         | <b>1.62</b>  |
| <b>France</b>  |           |          |                          |              |
| DASSAULT SYST.   | 51,341    | EUR      | 2,508,737                | 1.68         |
|  |           |          | <b>2,508,737</b>         | <b>1.68</b>  |
| <b>Germany</b>   |           |          |                          |              |
| SIEMENS AG PREFERENTIAL SHARE  | 23,683    | EUR      | 4,445,350                | 2.98         |
|  |           |          | <b>4,445,350</b>         | <b>2.98</b>  |
| <b>Japan</b>   |           |          |                          |              |
| CAPCOM CO LTD  | 41,200    | JPY      | 1,331,446                | 0.89         |
| RENESAS ELECTRONICS  | 143,000   | JPY      | 2,585,523                | 1.73         |
| SONY CORP  | 46,200    | JPY      | 4,394,538                | 2.94         |
|  |           |          | <b>8,311,507</b>         | <b>5.56</b>  |
| <b>Luxembourg</b>  |           |          |                          |              |
| CLOUDFLARE INC   | 29,233    | USD      | 2,433,940                | 1.63         |
| GLOBANT REG SHS  | 10,085    | USD      | 2,400,028                | 1.61         |
| SNOWFLAKE INC-CLASS A  | 12,444    | USD      | 2,476,356                | 1.66         |
|  |           |          | <b>7,310,324</b>         | <b>4.89</b>  |
| <b>Netherlands</b>   |           |          |                          |              |
| UNIVERSAL MUSIC GROUP N.V.   | 86,287    | EUR      | 2,460,130                | 1.65         |
|  |           |          | <b>2,460,130</b>         | <b>1.65</b>  |
| <b>People's Republic of China</b>  |           |          |                          |              |
| GOERTEK INC. -A-   | 508,047   | CNY      | 1,505,043                | 1.01         |
|  |           |          | <b>1,505,043</b>         | <b>1.01</b>  |
| <b>South Korea</b>   |           |          |                          |              |
| NAVER  | 14,403    | KRW      | 2,505,064                | 1.68         |
| NCISOFT  | 7,267     | KRW      | 1,357,026                | 0.91         |
|  |           |          | <b>3,862,090</b>         | <b>2.59</b>  |
| <b>Sweden</b>  |           |          |                          |              |
| HEXAGON - REG SHS -B-  | 212,809   | SEK      | 2,554,041                | 1.71         |
| SURGICAL SCIENCE SWEDEN AB   | 53,663    | SEK      | 971,784                  | 0.65         |
|  |           |          | <b>3,525,825</b>         | <b>2.36</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| LOGITECH - REG SHS   | 26,648    | CHF      | 2,525,408                | 1.69         |
|  |           |          | <b>2,525,408</b>         | <b>1.69</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| ADOBE INC  | 7,131     | USD      | 4,254,355                | 2.85         |
| ADVANCED MICRO DEVICES INC   | 30,409    | USD      | 4,482,592                | 3.00         |
| AKAMAI TECHNOLOGIES  | 20,644    | USD      | 2,443,217                | 1.64         |
| ALPHABET INC -A-   | 31,103    | USD      | 4,344,778                | 2.91         |
| ANSYS INC  | 8,324     | USD      | 3,020,613                | 2.02         |
| APPLE INC  | 21,562    | USD      | 4,151,332                | 2.78         |
| ARISTA NETWORKS INC  | 10,368    | USD      | 2,441,768                | 1.63         |
| AUTODESK INC   | 10,354    | USD      | 2,520,992                | 1.69         |
| BENTLEY SYSTEMS --- REGISTERED SHS -B-   | 48,895    | USD      | 2,551,341                | 1.71         |
| BROADCOM INC - REGISTERED SHS  | 3,682     | USD      | 4,110,033                | 2.75         |
| CADENCE DESIGN SYSTEMS INC   | 9,053     | USD      | 2,465,766                | 1.65         |
| CROWDSTRIKE HOLDINGS INC   | 9,530     | USD      | 2,433,200                | 1.63         |
| ELECTRONIC ARTS - REGSHS   | 17,930    | USD      | 2,453,003                | 1.64         |
| EQUINIX INC  | 3,073     | USD      | 2,474,963                | 1.66         |
| GENERAL ELECTRI  | 34,162    | USD      | 4,360,096                | 2.92         |
| IBM CORP   | 25,954    | USD      | 4,244,777                | 2.84         |
| INTUITIVE SURGICAL   | 12,861    | USD      | 4,338,787                | 2.91         |
| KEYSIGHT TECHNOLOGIES  | 15,508    | USD      | 2,467,168                | 1.65         |
| LIVE NATION ENT  | 26,547    | USD      | 2,484,799                | 1.66         |
| MICRON TECHNOLOGY INC  | 30,358    | USD      | 2,590,752                | 1.73         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Meta Globe

Investment portfolio as at December 31, 2023

| Description  | Quantity | Currency | Market value<br>(in USD) | % net assets |
|--|----------|----------|--------------------------|--------------|
| MICROSOFT CORP   | 11,475   | USD      | 4,315,059                | 2.89         |
| NVIDIA CORP  | 8,352    | USD      | 4,136,077                | 2.77         |
| OKTA -A-   | 29,354   | USD      | 2,657,418                | 1.78         |
| PAYPAL HOLDINGS  | 40,281   | USD      | 2,473,656                | 1.66         |
| PTC INC  | 14,568   | USD      | 2,548,817                | 1.71         |
| QUALCOMM INC   | 29,819   | USD      | 4,312,722                | 2.89         |
| SKYWORKS SOLUTIONS INC   | 20,968   | USD      | 2,357,223                | 1.58         |
| TAIWAN SEMICONDUCTOR CO ADR (REPR 5 SHS)   | 41,656   | USD      | 4,332,224                | 2.90         |
| TAKE TWO INTERACTIVE SOFTWARE INC  | 15,615   | USD      | 2,513,234                | 1.68         |
| UNITY SOFTWARE INC   | 62,988   | USD      | 2,575,579                | 1.72         |
| WALT DISNEY CO   | 44,922   | USD      | 4,056,007                | 2.72         |
| ZSCALER INC  | 11,125   | USD      | 2,464,855                | 1.65         |
| <b>Total Shares</b>  |          |          | <b>103,377,203</b>       | <b>69.22</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |          |          | <b>142,257,036</b>       | <b>95.25</b> |
| <b>Total investment portfolio</b>  |          |          | <b>142,257,036</b>       | <b>95.25</b> |
| Acquisition cost   |          |          | 124,001,738              |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Meta Globe

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                            |              |
|----------------------------|--------------|
| United States of America   | 69.22        |
| Japan                      | 5.56         |
| Luxembourg                 | 4.89         |
| Germany                    | 2.98         |
| South Korea                | 2.59         |
| Sweden                     | 2.36         |
| Switzerland                | 1.69         |
| France                     | 1.68         |
| Netherlands                | 1.65         |
| Cayman Islands             | 1.62         |
| People's Republic of China | 1.01         |
|                            | <b>95.25</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Internet and internet services         | 40.87        |
| Electronics and semiconductors         | 16.66        |
| Office supplies and computing          | 10.06        |
| Electrical engineering                 | 8.56         |
| Banks and other financial institutions | 3.25         |
| Pharmaceuticals                        | 2.91         |
| Communication                          | 2.89         |
| Graphic art and publishing             | 2.72         |
| Machine and apparatus construction     | 1.71         |
| Hotels and restaurants                 | 1.66         |
| Miscellaneous services                 | 1.66         |
| Real estate                            | 1.66         |
| Healthcare                             | 0.65         |
|  | <b>95.25</b> |





## Candriam Equities L Oncology Impact

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Cayman Islands</b>  |           |          |                          |              |
| BEIGENE - REG SHS  | 1,924,215 | HKD      | 27,131,184               | 1.46         |
| LEGEND BIOTECH CORP  | 130,000   | USD      | 7,822,100                | 0.42         |
|  |           |          | <b>34,953,284</b>        | <b>1.88</b>  |
| <b>Denmark</b>   |           |          |                          |              |
| COLOPLAST -B-  | 206,000   | DKK      | 23,566,104               | 1.27         |
| GENMAB AS  | 116,583   | DKK      | 37,229,377               | 2.00         |
|  |           |          | <b>60,795,481</b>        | <b>3.27</b>  |
| <b>Germany</b>   |           |          |                          |              |
| MERCK KGAA   | 260,742   | EUR      | 41,504,929               | 2.23         |
| MORPHOSYS  | 151,796   | EUR      | 5,701,169                | 0.31         |
| SIEMENS HEALTHINEERS   | 1,630,212 | EUR      | 94,722,799               | 5.09         |
|  |           |          | <b>141,928,897</b>       | <b>7.63</b>  |
| <b>Ireland</b>   |           |          |                          |              |
| ICON PLC   | 68,000    | USD      | 19,248,760               | 1.03         |
|  |           |          | <b>19,248,760</b>        | <b>1.03</b>  |
| <b>Japan</b>   |           |          |                          |              |
| ASTELLAS PHARMA  | 800,000   | JPY      | 9,567,315                | 0.51         |
| DAIICHI SANKYO CO LTD  | 1,082,400 | JPY      | 29,727,997               | 1.60         |
| OLYMPUS CORP   | 2,999,600 | JPY      | 43,415,265               | 2.33         |
|  |           |          | <b>82,710,577</b>        | <b>4.44</b>  |
| <b>Luxembourg</b>  |           |          |                          |              |
| LANTHEUS HOLDINGS INC  | 356,000   | USD      | 22,072,000               | 1.19         |
| REVOLUTION MEDICINES INC   | 353,376   | USD      | 10,134,824               | 0.54         |
| SPRINGWORKS THERAPEUTICS INC   | 200,619   | USD      | 7,322,594                | 0.39         |
| SYNDAX PHARMACEUTICALS INC   | 656,000   | USD      | 14,176,160               | 0.76         |
|  |           |          | <b>53,705,578</b>        | <b>2.89</b>  |
| <b>Netherlands</b>   |           |          |                          |              |
| IMMATICS NV  | 295,000   | USD      | 3,106,350                | 0.17         |
| MERUS - REG SHS  | 338,076   | USD      | 9,297,090                | 0.50         |
|  |           |          | <b>12,403,440</b>        | <b>0.67</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| LONZA GROUP  | 42,748    | CHF      | 17,965,228               | 0.97         |
| NOVARTIS AG PREFERENTIAL SHARE   | 860,000   | CHF      | 86,723,045               | 4.66         |
| ROCHE HOLDING LTD  | 433,697   | CHF      | 125,993,211              | 6.77         |
| SANDOZ GROUP AG  | 453,000   | CHF      | 14,564,912               | 0.78         |
| TECAN GROUP NAM.AKT  | 37,899    | CHF      | 15,463,575               | 0.83         |
|  |           |          | <b>260,709,971</b>       | <b>14.01</b> |
| <b>United Kingdom</b>  |           |          |                          |              |
| ASTRAZENECA PLC  | 854,508   | GBP      | 115,465,719              | 6.20         |
| BICYCLE THERAPEUTICS PLC   | 580,934   | USD      | 10,503,287               | 0.56         |
| IMMUNOCORE HOLDINGS PLC-ADR  | 89,000    | USD      | 6,080,480                | 0.33         |
|  |           |          | <b>132,049,486</b>       | <b>7.09</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| AGILENT TECHNOLOGIES   | 144,660   | USD      | 20,112,080               | 1.08         |
| AMGEN INC  | 186,468   | USD      | 53,706,513               | 2.89         |
| ARCELLX INC  | 242,000   | USD      | 13,431,000               | 0.72         |
| ARVINAS - REG SHS  | 348,254   | USD      | 14,334,135               | 0.77         |
| BIO RAD LABORATORIES -A-   | 40,012    | USD      | 12,919,475               | 0.69         |
| BLACK DIAMOND - REG SHS  | 540,000   | USD      | 1,517,400                | 0.08         |
| BLUEPRINT MEDICINES CORP   | 30,063    | USD      | 2,773,011                | 0.15         |
| CARIBOU BIOSCIEN   | 860,000   | USD      | 4,927,800                | 0.26         |
| COGENT BIOSCIENCES INC   | 232,449   | USD      | 1,366,800                | 0.07         |
| CRINETIC PHARMA - REG SHS  | 208,000   | USD      | 7,400,640                | 0.40         |
| DANAHER CORP   | 269,878   | USD      | 62,433,577               | 3.35         |
| DAY ONE BIOPHARMACEUTICALS INC   | 290,000   | USD      | 4,234,000                | 0.23         |
| ELI LILLY & CO   | 44,160    | USD      | 25,741,747               | 1.38         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Oncology Impact

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| EXACT SCIENCES CORP  | 200,000   | USD      | 14,796,000               | 0.79         |
| EXELIXIS   | 326,641   | USD      | 7,836,118                | 0.42         |
| GILEAD SCIENCES INC  | 720,000   | USD      | 58,327,200               | 3.13         |
| GUARDANT HEALTH --- REGISTERED SHS   | 291,123   | USD      | 7,874,877                | 0.42         |
| HALOZYME THERAPEUT -SHS-   | 90,138    | USD      | 3,331,500                | 0.18         |
| HOLOGIC INC  | 1,214,424 | USD      | 86,770,595               | 4.66         |
| IDEAYA BIOSCIENCES INC   | 315,000   | USD      | 11,207,700               | 0.60         |
| ILLUMINA INC   | 38,235    | USD      | 5,323,841                | 0.29         |
| IMMUNOGEN INC  | 782,876   | USD      | 23,212,273               | 1.25         |
| INCYTE CORP  | 387,120   | USD      | 24,307,265               | 1.31         |
| IOVANCE BIOTHERAPEUTICS INC  | 961,403   | USD      | 7,816,206                | 0.42         |
| IQVIA HOLDINGS INC   | 213,883   | USD      | 49,488,249               | 2.66         |
| KARM THES INC  | 530,630   | USD      | 458,995                  | 0.02         |
| KEROS THERAPEUTICS INC   | 356,981   | USD      | 14,193,565               | 0.76         |
| KURA ONCOLOGY - REGISTERED   | 366,996   | USD      | 5,277,402                | 0.28         |
| KYMERA THERAPEUTICS INC  | 157,815   | USD      | 4,017,970                | 0.22         |
| MERCK & CO INC   | 1,588,089 | USD      | 173,133,462              | 9.30         |
| NATERA   | 167,000   | USD      | 10,460,880               | 0.56         |
| NEOGENOMICS-REGISTERED SHS   | 205,000   | USD      | 3,316,900                | 0.18         |
| NURIX THERAPETC - REG SHS  | 563,096   | USD      | 5,811,151                | 0.31         |
| NUVALENT INC-A SHARES  | 162,000   | USD      | 11,921,580               | 0.64         |
| OLEMA PHARMA --- REGISTERED SHS  | 215,000   | USD      | 3,016,450                | 0.16         |
| REGENERON PHARMACEUTICALS INC  | 100,834   | USD      | 88,561,494               | 4.76         |
| RELAY THERAPTCS - REGISTERED SHS   | 368,400   | USD      | 4,056,084                | 0.22         |
| SEAGEN INC   | 256,015   | USD      | 58,627,435               | 3.15         |
| SUTRO BIOPHARMA INC  | 550,369   | USD      | 2,361,083                | 0.13         |
| THERMO FISHER SCIENT SHS   | 172,082   | USD      | 91,339,405               | 4.91         |
| VERACYTE - REGISTERED SHS  | 610,898   | USD      | 16,805,804               | 0.90         |
| XENCOR INC   | 366,667   | USD      | 7,784,340                | 0.42         |
| ZAI LAB AMERICAN DEPOSITARY RECEIPT REPR   | 325,000   | USD      | 8,882,250                | 0.48         |
|  |           |          | <b>1,035,216,252</b>     | <b>55.62</b> |
| <b>Total Shares</b>  |           |          | <b>1,833,721,726</b>     | <b>98.52</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          | <b>1,833,721,726</b>     | <b>98.52</b> |
| <b>Total investment portfolio</b>  |           |          | <b>1,833,721,726</b>     | <b>98.52</b> |
| Acquisition cost   |           |          | 1,732,747,548            |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Oncology Impact

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                          |              |
|--------------------------|--------------|
| United States of America | 55.62        |
| Switzerland              | 14.01        |
| Germany                  | 7.63         |
| United Kingdom           | 7.09         |
| Japan                    | 4.44         |
| Denmark                  | 3.27         |
| Luxembourg               | 2.89         |
| Cayman Islands           | 1.88         |
| Ireland                  | 1.03         |
| Netherlands              | 0.67         |
|                          | <b>98.52</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Pharmaceuticals                        | 55.62        |
| Biotechnology                          | 27.10        |
| Electronics and semiconductors         | 4.91         |
| Machine and apparatus construction     | 3.35         |
| Banks and other financial institutions | 2.96         |
| Photographic and optics                | 2.33         |
| Chemicals                              | 0.97         |
| Healthcare                             | 0.71         |
| Miscellaneous services                 | 0.56         |
|  | <b>98.52</b> |



## Candriam Equities L Risk Arbitrage Opportunities

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in EUR) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b>       |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Belgium</b>   |           |          |                          |              |
| EURONAV NV   | 115,460   | EUR      | 1,843,896                | 3.71         |
| INTERVEST OFFICES  | 88,754    | EUR      | 1,837,208                | 3.70         |
|  |           |          | <b>3,681,104</b>         | <b>7.42</b>  |
| <b>Finland</b>   |           |          |                          |              |
| MUSTI GROUP OYJ  | 111,982   | EUR      | 2,924,970                | 5.89         |
|  |           |          | <b>2,924,970</b>         | <b>5.89</b>  |
| <b>Germany</b>   |           |          |                          |              |
| COVESTRO AG  | 3,349     | EUR      | 176,425                  | 0.36         |
| TELEFONICA - REG SHS   | 1,153,273 | EUR      | 2,712,498                | 5.46         |
|  |           |          | <b>2,888,923</b>         | <b>5.82</b>  |
| <b>Portugal</b>  |           |          |                          |              |
| GREENVOLT ER   | 84,534    | EUR      | 691,488                  | 1.39         |
|  |           |          | <b>691,488</b>           | <b>1.39</b>  |
| <b>Spain</b>   |           |          |                          |              |
| APPLUS SERVICES S.A.   | 219,866   | EUR      | 2,198,660                | 4.43         |
|  |           |          | <b>2,198,660</b>         | <b>4.43</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| EHOSTAR HOLDING - WHEN ISSUED  | 145,918   | USD      | 2,188,803                | 4.41         |
| IROBOT   | 8,196     | USD      | 287,136                  | 0.58         |
|  |           |          | <b>2,475,939</b>         | <b>4.99</b>  |
| <b>Total Shares</b>  |           |          | <b>14,861,084</b>        | <b>29.94</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          | <b>14,861,084</b>        | <b>29.94</b> |
| <b>Undertakings for Collective Investment</b>  |           |          |                          |              |
| <b>Shares/Units in investment funds</b>  |           |          |                          |              |
| <b>France</b>  |           |          |                          |              |
| CANDRIAM MONÉTAIRE SICAV Z C   | 3,018     | EUR      | 4,622,460                | 9.31         |
|  |           |          | <b>4,622,460</b>         | <b>9.31</b>  |
| <b>Total Shares/Units in investment funds</b>  |           |          | <b>4,622,460</b>         | <b>9.31</b>  |
| <b>Total Undertakings for Collective Investment</b>  |           |          | <b>4,622,460</b>         | <b>9.31</b>  |
| <b>Total investment portfolio</b>  |           |          | <b>19,483,544</b>        | <b>39.25</b> |
| Acquisition cost   |           |          | 19,094,547               |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Risk Arbitrage Opportunities

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                          |              |
|--------------------------|--------------|
| France                   | 9.31         |
| Belgium                  | 7.42         |
| Finland                  | 5.89         |
| Germany                  | 5.82         |
| United States of America | 4.99         |
| Spain                    | 4.43         |
| Portugal                 | 1.39         |
|                          | <b>39.25</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Miscellaneous services                 | 10.32        |
| Investments funds                      | 9.31         |
| Communication                          | 5.46         |
| Banks and other financial institutions | 4.41         |
| Transportation                         | 3.71         |
| Real estate                            | 3.70         |
| Utilities                              | 1.39         |
| Miscellaneous consumer goods           | 0.58         |
| Chemicals                              | 0.36         |
|  | <b>39.25</b> |



## Candriam Equities L Robotics & Innovative Technology

Investment portfolio as at December 31, 2023

| Description  | Quantity  | Currency | Market value<br>(in USD) | % net assets |
|--|-----------|----------|--------------------------|--------------|
| <b>Transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |           |          |                          |              |
| <b>Shares</b>  |           |          |                          |              |
| <b>Cayman Islands</b>  |           |          |                          |              |
| AMBARELLA INC  | 232,785   | USD      | 14,267,393               | 0.78         |
|  |           |          | <b>14,267,393</b>        | <b>0.78</b>  |
| <b>France</b>  |           |          |                          |              |
| SCHNEIDER ELECTRIC SE  | 227,471   | EUR      | 45,676,922               | 2.49         |
|  |           |          | <b>45,676,922</b>        | <b>2.49</b>  |
| <b>Germany</b>   |           |          |                          |              |
| SAP AG   | 236,818   | EUR      | 36,488,108               | 1.99         |
| SIEMENS AG PREFERENTIAL SHARE  | 269,506   | EUR      | 50,586,850               | 2.76         |
|  |           |          | <b>87,074,958</b>        | <b>4.75</b>  |
| <b>Japan</b>   |           |          |                          |              |
| DAIFUKU CO   | 1,266,100 | JPY      | 25,617,466               | 1.40         |
| FANUC CORP SHS   | 702,200   | JPY      | 20,655,579               | 1.13         |
| KEYENCE CORP   | 110,900   | JPY      | 48,865,855               | 2.66         |
| RENESAS ELECTRONICS  | 1,060,100 | JPY      | 19,167,222               | 1.05         |
| SMC CORP   | 73,900    | JPY      | 39,712,471               | 2.17         |
|  |           |          | <b>154,018,593</b>       | <b>8.40</b>  |
| <b>Jersey</b>  |           |          |                          |              |
| APTIV PLC  | 375,753   | USD      | 33,712,559               | 1.84         |
|  |           |          | <b>33,712,559</b>        | <b>1.84</b>  |
| <b>Netherlands</b>   |           |          |                          |              |
| ASML HOLDING NV  | 67,497    | EUR      | 50,827,934               | 2.77         |
| STMICROELECTRONICS NV  | 649,743   | EUR      | 32,449,068               | 1.77         |
|  |           |          | <b>83,277,002</b>        | <b>4.54</b>  |
| <b>Switzerland</b>   |           |          |                          |              |
| TECAN GROUP NAM.AKT  | 63,491    | CHF      | 25,905,640               | 1.41         |
|  |           |          | <b>25,905,640</b>        | <b>1.41</b>  |
| <b>United States of America</b>  |           |          |                          |              |
| ADOBE INC  | 64,908    | USD      | 38,724,113               | 2.11         |
| ADVANCED MICRO DEVICES INC   | 548,611   | USD      | 80,870,748               | 4.41         |
| ALPHABET INC -A-   | 763,599   | USD      | 106,667,144              | 5.82         |
| ANSYS INC  | 89,324    | USD      | 32,413,893               | 1.77         |
| APPLIED MATERIALS INC  | 239,999   | USD      | 38,896,638               | 2.12         |
| AUTODESK INC   | 154,802   | USD      | 37,691,191               | 2.05         |
| CADENCE DESIGN SYSTEMS INC   | 126,439   | USD      | 34,438,190               | 1.88         |
| CROWDSTRIKE HOLDINGS INC   | 152,974   | USD      | 39,057,322               | 2.13         |
| DATADOG INC  | 243,954   | USD      | 29,611,137               | 1.61         |
| EMERSON ELECTRIC CO  | 537,256   | USD      | 52,291,126               | 2.85         |
| INTUITIVE SURGICAL   | 138,189   | USD      | 46,619,441               | 2.54         |
| KEYSIGHT TECHNOLOGIES  | 255,243   | USD      | 40,606,609               | 2.21         |
| LAM RESEARCH CORP  | 57,817    | USD      | 45,285,743               | 2.47         |
| MARVELL TECH --- REGISTERED SHS  | 532,529   | USD      | 32,116,824               | 1.75         |
| MICRON TECHNOLOGY INC  | 446,708   | USD      | 38,122,061               | 2.08         |
| MICROSOFT CORP   | 261,826   | USD      | 98,457,049               | 5.37         |
| MONGODB INC  | 44,870    | USD      | 18,345,100               | 1.00         |
| NVIDIA CORP  | 114,041   | USD      | 56,475,384               | 3.08         |
| ON SEMICONDUCTOR CORP  | 288,873   | USD      | 24,129,562               | 1.32         |
| PALO ALTO NETWORKS   | 230,766   | USD      | 68,048,278               | 3.71         |
| PTC INC  | 329,734   | USD      | 57,690,261               | 3.15         |
| ROCKWELL AUTOMATION  | 140,739   | USD      | 43,696,645               | 2.38         |
| SALESFORCE INC   | 215,677   | USD      | 56,753,246               | 3.09         |
| SERVICENOW INC   | 88,806    | USD      | 62,740,551               | 3.42         |
| SILICON LABORATORIES INC   | 145,810   | USD      | 19,286,289               | 1.05         |
| TAIWAN SEMICONDUCTOR CO ADR (REPR 5 SHS)   | 419,310   | USD      | 43,608,240               | 2.38         |
| TRIMBLE  | 514,497   | USD      | 27,371,240               | 1.49         |
| UNIVERSAL DISPLAY  | 165,366   | USD      | 31,627,901               | 1.72         |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Robotics & Innovative Technology

Investment portfolio as at December 31, 2023

| Description  | Quantity | Currency | Market value<br>(in USD) | % net assets |
|--|----------|----------|--------------------------|--------------|
| VEEVA SYSTEMS -A-  | 178,197  | USD      | 34,306,486               | 1.87         |
|  |          |          | <b>1,335,948,412</b>     | <b>72.84</b> |
| <b>Total Shares</b>  |          |          | <b>1,779,881,479</b>     | <b>97.04</b> |
| <b>Total transferable securities admitted to an official stock exchange listing or dealt in another regulated market</b> |          |          | <b>1,779,881,479</b>     | <b>97.04</b> |
| <b>Total investment portfolio</b>  |          |          | <b>1,779,881,479</b>     | <b>97.04</b> |
| Acquisition cost   |          |          | 1,442,029,281            |              |

The accompanying notes form an integral part of the financial statements.  
Any differences in the percentage of Net Assets are the result of roundings.



## Candriam Equities L Robotics & Innovative Technology

Geographical and economic breakdown of investments as at December 31, 2023

### Geographical breakdown (in % of net assets)

|                          |              |
|--------------------------|--------------|
| United States of America | 72.84        |
| Japan                    | 8.40         |
| Germany                  | 4.75         |
| Netherlands              | 4.54         |
| France                   | 2.49         |
| Jersey                   | 1.84         |
| Switzerland              | 1.41         |
| Cayman Islands           | 0.78         |
|                          | <b>97.04</b> |

### Economic breakdown (in % of net assets)

|  |              |
|--|--------------|
| Internet and internet services         | 40.97        |
| Electronics and semiconductors         | 31.15        |
| Electrical engineering                 | 13.82        |
| Pharmaceuticals                        | 3.95         |
| Machine and apparatus construction     | 3.56         |
| Road vehicles                          | 1.84         |
| Banks and other financial institutions | 1.75         |
|  | <b>97.04</b> |





## Notes to the financial statements - Schedule of derivative instruments

### Forward foreign exchange contracts

As at December 31, 2023, the following forward foreign exchange contracts were outstanding:

#### Candriam Equities L Biotechnology

| Currency purchased | Quantity purchased | Currency sold | Quantity sold | Maturity date | Counterparty             | Unrealised (in USD) |
|--------------------|--------------------|---------------|---------------|---------------|--------------------------|---------------------|
| CHF                | 979,577            | USD           | 1,125,228     | 16/01/2024    | CACEIS Bank, Lux. Branch | 40,417              |
| EUR                | 119,484,126        | USD           | 129,491,824   | 16/01/2024    | CACEIS Bank, Lux. Branch | 2,570,994           |
| USD                | 17,722             | CHF           | 15,157        | 16/01/2024    | CACEIS Bank, Lux. Branch | (313)               |
| USD                | 3,853,587          | EUR           | 3,519,406     | 16/01/2024    | CACEIS Bank, Lux. Branch | (36,304)            |
|                    |                    |               |               |               |                          | <b>2,574,794</b>    |

#### Candriam Equities L Emerging Markets

| Currency purchased | Quantity purchased | Currency sold | Quantity sold | Maturity date | Counterparty             | Unrealised (in EUR) |
|--------------------|--------------------|---------------|---------------|---------------|--------------------------|---------------------|
| USD                | 95,100             | EUR           | 88,035        | 16/01/2024    | CACEIS Bank, Lux. Branch | (2,135)             |
|                    |                    |               |               |               |                          | <b>(2,135)</b>      |

#### Candriam Equities L Europe Innovation

| Currency purchased | Quantity purchased | Currency sold | Quantity sold | Maturity date | Counterparty             | Unrealised (in EUR) |
|--------------------|--------------------|---------------|---------------|---------------|--------------------------|---------------------|
| USD                | 2,241,475          | EUR           | 2,070,940     | 16/01/2024    | CACEIS Bank, Lux. Branch | (42,960)            |
|                    |                    |               |               |               |                          | <b>(42,960)</b>     |

#### Candriam Equities L Oncology Impact

| Currency purchased | Quantity purchased | Currency sold | Quantity sold | Maturity date | Counterparty             | Unrealised (in USD) |
|--------------------|--------------------|---------------|---------------|---------------|--------------------------|---------------------|
| CHF                | 8,084              | JPY           | 1,326,452     | 12/01/2024    | Société Générale         | 191                 |
| DKK                | 7,145              | JPY           | 150,968       | 12/01/2024    | J.P. Morgan AG           | (13)                |
| DKK                | 17,174             | JPY           | 361,264       | 12/01/2024    | BNP Paribas Paris        | (20)                |
| DKK                | 18,424             | JPY           | 382,874       | 12/01/2024    | Société Générale         | 11                  |
| EUR                | 20,653             | JPY           | 3,231,480     | 12/01/2024    | BNP Paribas Paris        | (134)               |
| EUR                | 224,258,748        | USD           | 242,675,544   | 16/01/2024    | CACEIS Bank, Lux. Branch | 5,192,043           |
| GBP                | 4,704              | JPY           | 848,120       | 12/01/2024    | BNP Paribas Paris        | (28)                |
| HKD                | 16,590             | JPY           | 301,082       | 12/01/2024    | J.P. Morgan AG           | (14)                |
| HKD                | 9,941              | JPY           | 182,473       | 12/01/2024    | BNP Paribas Paris        | (23)                |
| JPY                | 589,324            | CHF           | 3,560         | 12/01/2024    | J.P. Morgan AG           | (48)                |
| JPY                | 57,731,811         | CHF           | 344,028       | 12/01/2024    | Société Générale         | 949                 |
| JPY                | 390,395            | DKK           | 18,483        | 12/01/2024    | J.P. Morgan AG           | 33                  |
| JPY                | 15,520,369         | DKK           | 731,751       | 12/01/2024    | Société Générale         | 1,770               |
| JPY                | 35,010,397         | EUR           | 221,339       | 12/01/2024    | BNP Paribas Paris        | 4,122               |
| JPY                | 1,088,569          | EUR           | 7,013         | 12/01/2024    | Société Générale         | (16)                |
| JPY                | 327,417            | GBP           | 1,806         | 12/01/2024    | J.P. Morgan AG           | 24                  |
| JPY                | 952,478            | GBP           | 5,257         | 12/01/2024    | BNP Paribas Paris        | 65                  |
| JPY                | 26,385,448         | GBP           | 143,337       | 12/01/2024    | Société Générale         | 4,713               |
| JPY                | 518,858            | HKD           | 28,275        | 12/01/2024    | J.P. Morgan AG           | 64                  |
| JPY                | 1,443,794          | HKD           | 79,455        | 12/01/2024    | BNP Paribas Paris        | 80                  |
| JPY                | 4,679,716          | HKD           | 249,882       | 12/01/2024    | Société Générale         | 1,237               |
| JPY                | 4,456,560          | USD           | 31,480        | 12/01/2024    | BNP Paribas Paris        | 181                 |
| JPY                | 264,909,898        | USD           | 1,814,364     | 12/01/2024    | Société Générale         | 67,547              |
| USD                | 4,641,319          | EUR           | 4,227,691     | 16/01/2024    | CACEIS Bank, Lux. Branch | (31,424)            |
| USD                | 60,450             | JPY           | 8,665,523     | 12/01/2024    | BNP Paribas Paris        | (1,111)             |
| USD                | 19,135             | JPY           | 2,787,328     | 12/01/2024    | Société Générale         | (666)               |
|                    |                    |               |               |               |                          | <b>5,239,533</b>    |

#### Candriam Equities L Risk Arbitrage Opportunities

| Currency purchased | Quantity purchased | Currency sold | Quantity sold | Maturity date | Counterparty              | Unrealised (in EUR) |
|--------------------|--------------------|---------------|---------------|---------------|---------------------------|---------------------|
| EUR                | 116,543            | GBP           | 100,000       | 12/01/2024    | Société Générale          | 1,182               |
| EUR                | 451,105            | USD           | 500,000       | 12/01/2024    | Barclays Bank Ireland Plc | (1,348)             |
| EUR                | 2,114,575          | USD           | 2,300,000     | 12/01/2024    | Société Générale          | 33,304              |
| EUR                | 723,781            | USD           | 789,381       | 15/03/2024    | Barclays Bank Ireland Plc | 11,281              |
| EUR                | 3,147,369          | USD           | 3,433,858     | 15/03/2024    | Société Générale          | 47,944              |
| USD                | 1,300,712          | EUR           | 1,211,794     | 15/03/2024    | J.P. Morgan AG            | (37,819)            |
| USD                | 777,601            | EUR           | 723,781       | 15/03/2024    | Barclays Bank Ireland Plc | (21,945)            |
|                    |                    |               |               |               |                           | <b>32,599</b>       |



## Notes to the financial statements - Schedule of derivative instruments

### Forward foreign exchange contracts (continued)

#### Candriam Equities L Robotics & Innovative Technology

| Currency purchased | Quantity purchased | Currency sold | Quantity sold | Maturity date | Counterparty             | Unrealised (in USD) |
|--------------------|--------------------|---------------|---------------|---------------|--------------------------|---------------------|
| EUR                | 18,430,665         | USD           | 19,959,671    | 16/01/2024    | CACEIS Bank, Lux. Branch | 411,282             |
| GBP                | 272,739            | USD           | 342,241       | 16/01/2024    | CACEIS Bank, Lux. Branch | 5,465               |
| USD                | 580,504            | EUR           | 528,462       | 16/01/2024    | CACEIS Bank, Lux. Branch | (3,589)             |
| USD                | 7,511              | GBP           | 5,932         | 16/01/2024    | CACEIS Bank, Lux. Branch | (52)                |
|                    |                    |               |               |               |                          | <b>413,106</b>      |

Please refer to Note 14 for collateral received/posted in relation with the forward foreign exchange contracts. These operations on forward foreign exchange contracts are mainly allocated to the classes of shares hedged against exchange risk.



## Notes to the financial statements - Schedule of derivative instruments

### Futures

As at December 31, 2023, the following futures contracts were outstanding:

#### Candriam Equities L Europe Optimum Quality

| Quantity<br>(purchase/(sale)) | Description         | Currency | Counterparty   | Commitment<br>(in EUR)<br>(in absolute value) | Unrealised<br>(in EUR) |
|-------------------------------|---------------------|----------|----------------|---|------------------------|
| <b>Futures on index</b>       |                     |          |                |   |                        |
| (5,550)                       | DJ EURO STOX 202403 | EUR      | J.P. Morgan AG | 250,951,575                                   | 2,636,250              |
|                               |                     |          |                |   | <b>2,636,250</b>       |

#### Candriam Equities L Risk Arbitrage Opportunities

| Quantity<br>(purchase/(sale)) | Description          | Currency | Counterparty   | Commitment<br>(in EUR)<br>(in absolute value) | Unrealised<br>(in EUR) |
|-------------------------------|----------------------|----------|----------------|---|------------------------|
| <b>Futures on index</b>       |                      |          |                |   |                        |
| (38)                          | DJ.STOXX600 ./202403 | EUR      | J.P. Morgan AG | 373,616                                       | 7,980                  |
| (12)                          | FTSE 250 Y2 /202403  | GBP      | J.P. Morgan AG | 545,325                                       | (28,929)               |
| (8)                           | DJ EURO STOX 202403  | EUR      | J.P. Morgan AG | 361,732                                       | 3,040                  |
| (5)                           | DJ EURO STOX /202403 | EUR      | J.P. Morgan AG | 190,178                                       | 1,165                  |
| (3)                           | DJ.STOXX600 /202403  | EUR      | J.P. Morgan AG | 194,412                                       | (4,625)                |
| (2)                           | NASDAQ 100 E /202403 | USD      | J.P. Morgan AG | 609,276                                       | (20,414)               |
| (1)                           | S&P 500 EMIN /202403 | USD      | J.P. Morgan AG | 215,898                                       | (6,167)                |
|                               |                      |          |                |   | <b>(47,950)</b>        |

Please refer to Note 13 about Cash at broker related to futures.



## Notes to the financial statements - Schedule of derivative instruments

### Contracts for difference

As at December 31, 2023, the following CFD contracts were outstanding:

#### Candriam Equities L Risk Arbitrage Opportunities

| Quantity  | Long / Short position | Currency | Underlying                       | Counterparty                        | Commitment (in EUR) (in absolute value) | Unrealised (in EUR) |
|-----------|-----------------------|----------|----------------------------------|-------------------------------------|---|---------------------|
| 13,393    | Long                  | USD      | ABENGOA YIELD PL                 | J.P. Morgan SE                      | 260,670                                 | 22,066              |
| 186,643   | Long                  | GBP      | LEARNING TECHNOLOGIES GROUP PLC  | J.P. Morgan SE                      | 174,463                                 | 16,692              |
| 132,682   | Long                  | GBP      | LEARNING TECHNOLOGIES GROUP PLC  | Citibank Europe plc, Germany Branch | 124,023                                 | 10,412              |
| 32,799    | Long                  | NOK      | CRAYON GROUP HOLDING ASA         | Barclays Bank Ireland PLC           | 247,633                                 | 2,924               |
| 1,147     | Short                 | USD      | IROBOT                           | J.P. Morgan SE                      | 0                                       | 0                   |
| 5,014     | Long                  | SEK      | SWEDENCARE AB                    | Barclays Bank Ireland PLC           | 27,456                                  | 1,284               |
| 11,905    | Long                  | USD      | PIONER NATURAL R                 | UBS Europe SE Frankfurt             | 2,423,570                               | (78,350)            |
| 123,853   | Long                  | GBP      | NETWORK INTERNAT                 | Barclays Bank Ireland PLC           | 557,128                                 | (2,573)             |
| 1,115     | Short                 | EUR      | OHB AG                           | UBS Europe SE Frankfurt             | 47,276                                  | (502)               |
| 9,980     | Long                  | USD      | BLUEGREEN VACTN                  | Barclays Bank Ireland PLC           | 0                                       | 0                   |
| 11,824    | Long                  | USD      | CARRIAGE SERVICE                 | J.P. Morgan SE                      | 29,025                                  | 2,159               |
| 148,169   | Long                  | GBP      | NETWORK INTERNAT                 | J.P. Morgan SE                      | 666,508                                 | (3,078)             |
| 14,677    | Long                  | GBP      | ELECTROCOMPONENTS                | Barclays Bank Ireland PLC           | 138,818                                 | 10,704              |
| 27,658    | Short                 | USD      | EXXON MOBIL CORP XNYS US         | UBS Europe SE Frankfurt             | 2,503,279                               | 75,364              |
| 13,788    | Long                  | CHF      | SOFTWONE HLDG -                  | UBS Europe SE Frankfurt             | 243,222                                 | (20,318)            |
| 13,633    | Short                 | USD      | BROOKFIELD --- R                 | UBS Europe SE Frankfurt             | 495,757                                 | (50,723)            |
| 90,692    | Long                  | USD      | ENGAGESMART INC                  | UBS Europe SE Frankfurt             | 1,880,095                               | 5,747               |
| 31,480    | Long                  | USD      | RAMCO-GERSHENSON PROPERTIES      | J.P. Morgan SE                      | 367,347                                 | 22,810              |
| 21,325    | Short                 | EUR      | OHB SE                           | UBS Europe SE Frankfurt             | 913,243                                 | 640                 |
| 414,621   | Short                 | USD      | DISH NETWORK -A-                 | J.P. Morgan SE                      | 2,165,721                               | (454,587)           |
| 18,973    | Short                 | USD      | KIMCO REALTY                     | J.P. Morgan SE                      | 366,012                                 | (21,641)            |
| 1,772,837 | Long                  | GBP      | RESTAURANT GROUP PLC             | UBS Europe SE Frankfurt             | 1,329,807                               | 8,183               |
| 143,637   | Long                  | NOK      | ADEVINTA ASA ---                 | Barclays Bank Ireland PLC           | 1,439,123                               | 4,264               |
| 28,218    | Long                  | USD      | MICHAEL KORS --- REGISTERED SHS  | UBS Europe SE Frankfurt             | 1,283,368                               | 46,491              |
| 46,506    | Long                  | USD      | STRATASYS LTD                    | Barclays Bank Ireland PLC           | 601,191                                 | 86,581              |
| 31,540    | Long                  | USD      | ENFUSION --- REG                 | UBS Europe SE Frankfurt             | 276,955                                 | (11,421)            |
| 64,300    | Long                  | JPY      | JSR CORP XTKS JP                 | UBS Europe SE Frankfurt             | 1,659,796                               | (14,038)            |
| 66,236    | Long                  | USD      | ROVER GROUP ---                  | J.P. Morgan SE                      | 652,376                                 | (4,197)             |
| 1,959     | Long                  | USD      | SHOCKWAVE MED --                 | UBS Europe SE Frankfurt             | 337,941                                 | 14,826              |
| 15,516    | Long                  | USD      | ORCHARD THERAPEU                 | J.P. Morgan SE                      | 231,058                                 | 3,371               |
| 27,427    | Long                  | USD      | AMERICAN EQUITY INVT LIFE HOLDIN | UBS Europe SE Frankfurt             | 1,385,440                               | 5,462               |
| 51,169    | Long                  | USD      | TEXTAINER GROUP                  | UBS Europe SE Frankfurt             | 2,279,016                               | (2,316)             |
| 39,402    | Long                  | USD      | STANDARD PARKING CORP            | UBS Europe SE Frankfurt             | 1,828,047                               | 9,987               |
| 52,284    | Long                  | SEK      | NORDIC WATERPROO                 | J.P. Morgan SE                      | 2,923,285                               | 24,894              |
| 50,434    | Long                  | USD      | AMEDISYS INC                     | UBS Europe SE Frankfurt             | 2,159,707                               | 45,751              |
| 15,491    | Long                  | USD      | HESS CORP                        | J.P. Morgan SE                      | 2,021,620                               | 86,151              |
| 108,503   | Long                  | GBP      | SMART METERING XLON GB           | UBS Europe SE Frankfurt             | 1,176,999                               | (9,920)             |
| 15,872    | Short                 | USD      | CHEVRON CORP XNY                 | J.P. Morgan SE                      | 2,143,183                               | (85,081)            |
| 3,563     | Long                  | USD      | HAWAIIAN HOLDINGS                | Barclays Bank Ireland PLC           | 0                                       | 0                   |
| 1,130,621 | Long                  | EUR      | TELECOM ITALIA SPA               | Citibank Europe plc, Germany Branch | 332,629                                 | 34,936              |
| 54,302    | Long                  | USD      | IMMUNOGEN INC                    | Citibank Europe plc, Germany Branch | 1,457,524                               | 0                   |
| 42,622    | Short                 | GBP      | DECHARA PHARMACL                 | Barclays Bank Ireland PLC           | 0                                       | 0                   |
| 380       | Short                 | USD      | AMEDISYS INC                     | Barclays Bank Ireland PLC           | 2,159,707                               | 45,751              |
| 38,615    | Long                  | USD      | POINT BIOPHARMA                  | J.P. Morgan SE                      | 0                                       | 0                   |
| 31,304    | Long                  | USD      | SOVOS BRANDS INC                 | Barclays Bank Ireland PLC           | 150,290                                 | 750                 |
| 49,169    | Long                  | EUR      | VIVENDI SA                       | Citibank Europe plc, Germany Branch | 475,759                                 | 31,960              |
| 294,514   | Long                  | SEK      | NORDIC WATERPROO                 | Barclays Bank Ireland PLC           | 2,923,285                               | 24,894              |
| 9,980     | Short                 | USD      | BLUEGREEN VACTN                  | UBS Europe SE Frankfurt             | 0                                       | 0                   |
| 3,196     | Long                  | USD      | KARUNA THERAPEUT                 | UBS Europe SE Frankfurt             | 915,734                                 | (2,209)             |
| 6,006     | Short                 | USD      | CARRIAGE SERVICE                 | UBS Europe SE Frankfurt             | 29,025                                  | 2,159               |
|           |                       |          |                                  |                                     |   | <b>(113,741)</b>    |

Please refer to Note 13 about Cash at broker related to CFD contracts.



## Other notes to the financial statements

### Note 1 - General Information

Candriam Equities L (hereafter the "SICAV" or "the Fund") was incorporated for an indefinite period on April 27, 1994 under the name "BIL Equities" in the form of a Société d'Investissement à Capital Variable (SICAV) in accordance with the provisions of the part I of the law of December 17, 2010, as amended, relating to undertakings for collective investment and the Law of August 10, 1915, as amended, on commercial undertakings. Its minimum capital is EUR 1,250,000.

The Articles of Incorporation of the SICAV were published in the "Mémorial, Recueil des Sociétés et Associations" dated June 9, 1994. They have been modified several times, in particular, for the last time on April 6, 2020. The corresponding modifications were published in the "Recueil Electronique des Sociétés et Associations" ("RESA"). The SICAV is registered in the Luxembourg Commercial and Companies Register under the number B-47449.

The following sub-funds are currently available to investors:

| <u>Sub-funds</u>                                     | <u>Reference currency</u> |
|--|---------------------------|
| Candriam Equities L Australia                        | AUD                       |
| Candriam Equities L Biotechnology                    | USD                       |
| Candriam Equities L Emerging Markets                 | EUR                       |
| Candriam Equities L EMU Innovation                   | EUR                       |
| Candriam Equities L Europe Innovation                | EUR                       |
| Candriam Equities L Europe Optimum Quality           | EUR                       |
| Candriam Equities L Global Demography                | EUR                       |
| Candriam Equities L Life Care                        | USD                       |
| Candriam Equities L Meta Globe                       | USD                       |
| Candriam Equities L Oncology Impact                  | USD                       |
| Candriam Equities L Risk Arbitrage Opportunities     | EUR                       |
| Candriam Equities L Robotics & Innovative Technology | USD                       |

The structure of multiple sub-funds offers investors not only the advantage of being able to choose between different sub-funds but also of being able to switch between these sub-funds if allowed. Within each sub-fund, the SICAV may issue different share classes which differ in particular in terms of the fees and commissions payable or in terms of their distribution policy.

The issued share classes are the following:

- The **BF class** is reserved for Belgian-law feeder UCIs approved by the Management Company and managed by an entity of the Candriam group.
- The **C class** is offered to individuals and companies.
- The **CB class** is reserved only for certain bank distributors approved by the Management Company.
- The **I class** is restricted exclusively to institutional investors whose initial minimum subscription is EUR 250,000. This minimum may be modified at the discretion of the Board of Directors, on condition that equal treatment of shareholders is ensured on the same valuation day. For the sub-fund Candriam Equities L Oncology Impact, the Board of Directors decided to close the share class I Distribution (ISIN: LU1864482432) with effect from July 11, 2022, since no further commercial interest has been identified for such a share class.
- The **I2 class** is a share class with no performance fee that is reserved solely for institutional investors with a minimum initial subscription of EUR 250,000, or the equivalent in foreign currencies for the classes denominated in foreign currencies (the Board of Directors may adjust this minimum at its discretion provided all shareholders are treated equally on a given valuation day).
- The **LOCK class** (hereinafter "L class") is a share class linked to a mechanism aimed at limiting the capital risk taken. This mechanism is offered only by Belfius Banque S.A., the sole distributor authorized to distribute these shares. By investing in this class, the investor agrees that the shares be automatically sold as soon as the net asset value has reached a predetermined amount (activation price). Thus when Belfius Banque S.A. ascertains that the net asset value is equal to or lower than the activation price, a redemption order is automatically generated and executed as soon as possible. The sale order will be globalized at the first cut-off date (closing date for receipt of orders) following the date on which the net asset value that gave rise to the automatic triggering of the redemption order was calculated. Given the specific nature of this class, potential investors are invited, before subscribing, to obtain information from their financial adviser at Belfius Banque S.A. in order to familiarize themselves with the technical and operational requirements related to this mechanism.
- The **N class** is restricted to distributors especially authorised by the Management Company.
- The **P class** is reserved for (i) occupational retirement pension institutions and/or similar investment vehicles, established at the initiative of one or more employers for the benefit of their employees and (ii) groups of one or more employers investing the funds that they hold in order to provide retirement benefits to their employees. The minimum initial subscription is EUR 15,000,000.



## Other notes to the financial statements

### Note 1 - General Information (Continued)

- The **PI class** is reserved for institutional investors which subscribe before the sub-fund has reached a critical size in terms of assets under management. The minimum initial subscription is EUR 1,000,000, or the equivalent amount in the relevant currency for classes denominated in other currencies (the Board of Directors may adjust this minimum at its discretion provided all shareholders are treated equally on a given valuation day). This class will remain open to subscriptions until one of the following events occurs: (i) the period set by the Board of Directors has expired; (ii) the sub-fund has reached a critical size in terms of assets under management, as defined by the Board of Directors; (iii) the Board of Directors has decided, on justified grounds, to close this class to subscriptions. The Board of Directors has the option of re-opening this share class at its discretion, without being obliged to inform investors beforehand.
- The **R class** is reserved for financial intermediaries (including distributors and platforms) which:
  - have separate arrangements with their clients for the provision of investment services related to the sub-fund, and
  - are not entitled to accept and retain from the Management Company and to retain, on account of their applicable laws and regulations or further to agreements with their clients, any fees, commissions or other monetary benefits in connection with the provision of the above-mentioned investment service.
- The **R2 class** is reserved:
  - for distributors and/or intermediaries approved by the Management Company and which do not receive, for investments in this class, any form of remuneration from an entity of the Candriam Group when the final investments in the shares are made in the context of a mandate.
  - for UCIs approved by the Management Company.
- The **S class** is a share class reserved exclusively for institutional investors which have been especially approved by the Management Company.
- The **SF2 class** is reserved for feeder funds approved by the Management Company and managed by delegation by an entity of the Candriam group. The minimum holding in this class is EUR 200,000,000 or the equivalent in foreign currencies for classes denominated in foreign currencies. This amount may be changed at the discretion of the Board of Directors provided that shareholders are treated equally.
- The **V class** is restricted exclusively to institutional investors whose initial minimum subscription is EUR 15,000,000 or its equivalent in foreign currencies for the classes denominated in foreign currencies (this minimum amount may be modified at the discretion of the Board of Directors, on condition that equal treatment of shareholders is ensured on the same valuation day).
- The **V2 class** is a share class with no performance fee and is restricted to institutional/professional investors, distributors and/or intermediaries approved by the Management Company, and whose initial minimum subscription is EUR 15,000,000 or the equivalent in foreign currencies for the classes denominated in foreign currencies (this amount can be reviewed at the directors' discretion; in this case, equal treatment of shareholders must be ensured on the same valuation day).
- The **Y class** is a share class reserved exclusively for institutional investors which have been especially approved by the Management Company.
- The **Z class** is reserved:
  - for institutional/professional investors approved by the Management Company. Since the portfolio management activity for this class is remunerated directly via the contract concluded with the investor, no portfolio management fee will be charged on the assets of this class.
  - for UCIs approved by the Management Company and managed by an entity of the Candriam Group.
- The **ZF class** is reserved for feeder UCIs approved by the Management Company and managed by an entity of the Candriam group.

The assets of the various classes are pooled within a single account.

Furthermore, a currency hedging process may be applied to the share classes:

- **Base currency hedged share classes:**  
These hedged share classes aim to reduce the effect of exchange rate fluctuations between the base currency of the sub-fund and the currency in which the hedged share class is denominated.  
The aim of this type of hedging is for the performance of the hedged share class to be reasonably comparable (after adjusting for the difference in interest rates between the two currencies) to the performance of a share class denominated in the sub-fund's base currency. This type of hedging is identified with the suffix H added in the denomination of the share class.
- **Asset hedged share classes:**  
These hedged share classes aim to reduce the effect of exchange rate fluctuations between the currencies in which a sub-fund's investments are held and the currency of the hedged share class. This type of hedging is identified with the suffix AH added in the denomination of the share class.

The shares issued are described in detail in the section "Statistics" of the various sub-funds.

In the frame of the Sustainable Finance Disclosure Regulation (SFDR), information on environmental and/or social characteristics and/or sustainable investments is available in the relevant annexes under the (unaudited) Sustainable Finance Disclosure Regulation section.



## Other notes to the financial statements

### Note 2 - Principal accounting policies

The financial statements of the SICAV are prepared in accordance with Luxembourg regulations relating to Undertakings for Collective Investment. Some small discrepancies might appear in some totals or sub-totals in the financial statements due to rounding rules.

The net asset values used for the purpose of the financial statements are dated:

- Sub-fund Candriam Equities L Australia: the net asset value has been calculated on December 31, 2023 on the basis of the closing stock market prices dated December 29, 2023;
- Sub-fund Candriam Equities L Emerging Markets : the net asset values has been calculated on December 31, 2023 on the basis of the stock market prices dated December 29, 2023 for Asian markets opened at that date and on the basis of the stock market prices dated December 28, 2023 for the other markets;
- For the other sub-funds of the SICAV, the net asset values dated December 31, 2023 have been calculated on January 2, 2024 on the basis of the last known prices at the time of the valuation.

This annual report is prepared on the basis of the last unofficial technical net asset values, calculated for the purpose of the financial statements as at December 31, 2023.

#### a) Valuation of each sub-fund's portfolio

The valuation of any security admitted for trading to an official listing or any other normally operating regulated market which is recognised and open to the public is based on the last price known in Luxembourg on the valuation date or, if this stock is traded on several markets, on the last known price on the principal market on which it is traded. If the last known price is not representative, the valuation shall be based on the probable realisation value as estimated by the Board of Directors with prudence and good faith. Securities which are neither quoted nor traded on a stock market or any other normally operating regulated market which is recognised and open to the public shall be valued on the basis of the probable realisation value as estimated with due prudence and good faith. All other assets shall be valued by the directors on the basis of the probable realisation value which must be estimated in good faith and according to generally accepted principles and procedures.

#### b) Net realised profits or losses on sales of investments

The realised profits or losses realised on sales of investments from each sub-fund are calculated based on the average cost of the investments sold.

#### c) Foreign currency translation

The values expressed in a currency other than the reference currency of each sub-fund are translated into that currency at the exchange rate prevailing at closing date.

Income and expenses in a currency other than the reference currency of each sub-fund are translated into that currency at the exchange rates prevailing at the transaction date.

The acquisition cost of securities in each sub-fund expressed in a currency other than the reference currency of the sub-fund is translated into that currency at the exchange rates prevailing at the day of purchase.

For the sub-funds Candriam Equities L Biotechnology, Candriam Equities L EMU Innovation, Candriam Equities L Europe Innovation, Candriam Equities L Europe Optimum Quality, Candriam Equities L Global Demography, Candriam Equities L Life Care, Candriam Equities L Oncology Impact, Candriam Equities L Robotics & Innovative Technology, Candriam Equities L Risk Arbitrage Opportunities, Candriam Equities L Meta Globe, the exchange rates used as at December 31, 2023 are as follows:

|         |          |     |         |           |     |         |             |     |         |           |     |
|---------|----------|-----|---------|-----------|-----|---------|-------------|-----|---------|-----------|-----|
| 1 EUR = | 1.618900 | AUD | 1 EUR = | 24.688500 | CZK | 1 EUR = | 155.733550  | JPY | 1 EUR = | 4.343750  | PLN |
| 1 EUR = | 1.456600 | CAD | 1 EUR = | 7.454550  | DKK | 1 EUR = | 1422.678800 | KRW | 1 EUR = | 11.132500 | SEK |
| 1 EUR = | 0.929700 | CHF | 1 EUR = | 0.866550  | GBP | 1 EUR = | 11.218500   | NOK | 1 EUR = | 1.104650  | USD |
| 1 EUR = | 7.834400 | CNY | 1 EUR = | 8.625750  | HKD | 1 EUR = | 1.744700    | NZD | 1 EUR = | 20.201300 | ZAR |

For the sub-funds Candriam Equities L Australia, Candriam Equities L Emerging Markets, the exchange rates used as at December 31, 2023 are as follows:

|         |           |     |         |              |     |         |           |     |         |           |     |
|---------|-----------|-----|---------|--------------|-----|---------|-----------|-----|---------|-----------|-----|
| 1 EUR = | 1.619380  | AUD | 1 EUR = | 0.868070     | GBP | 1 EUR = | 18.757800 | MXN | 1 EUR = | 33.838300 | TWD |
| 1 EUR = | 5.374200  | BRL | 1 EUR = | 8.645400     | HKD | 1 EUR = | 5.079100  | MYR | 1 EUR = | 1.106500  | USD |
| 1 EUR = | 1.464970  | CAD | 1 EUR = | 382.320000   | HUF | 1 EUR = | 4.337100  | PLN | 1 EUR = | 20.484900 | ZAR |
| 1 EUR = | 0.931070  | CHF | 1 EUR = | 17039.760000 | IDR | 1 EUR = | 1.459100  | SGD |         |           |     |
| 1 EUR = | 7.851200  | CNY | 1 EUR = | 91.998900    | INR | 1 EUR = | 37.889500 | THB |         |           |     |
| 1 EUR = | 24.711000 | CZK | 1 EUR = | 1428.640000  | KRW | 1 EUR = | 32.714500 | TRY |         |           |     |





## Other notes to the financial statements

### Note 2 - Principal accounting policies (Continued)

#### d) Combined financial statements of the SICAV

The combined statement of the SICAV's net assets and the combined statement of changes in net assets which are expressed in EUR are the sum of the statement of net assets, the statement of changes in net assets of each sub-fund converted into the currency of the SICAV using exchange rates prevailing at the closing date.

#### e) Valuation of options and futures

The valuation of options and futures admitted to an official listing or any other organised market is based on the last known price or, if the option is traded on more than one market, on the basis of the last known price in the market on which the contract was concluded by the SICAV. Options and futures that are not traded on a stock exchange or any other organised market will be valued at their probable market value estimated conservatively and in good faith. The market value of options is included in the statement of net assets under the heading "options (long position) / (short position) at market value".

The realised gains / (losses) and change in unrealised appreciation / depreciation on options are disclosed in the statement of changes in net assets respectively under the headings "Net realised gain / (loss) on options" and "Change in net unrealised appreciation / depreciation on options".

The unrealised appreciation / (depreciation) on future contracts is disclosed in the statement of net assets under "Net unrealised appreciation / (depreciation) on futures". Changes in the market value of open future contracts are recorded as unrealised appreciation / (depreciation) in the statement of changes in net assets under "Change in net unrealised appreciation / depreciation on futures". Realised gains or losses, representing the difference between the value of the contract at the time it was opened and the value at the time it was closed, are reported at the closing or expiration of futures contracts in the statement of changes in net assets under "Net realised gain / (loss) on futures".

For the details of outstanding options or financial futures, if any, please refer to the section "Notes to the financial statements - Schedule of derivative instruments".

#### f) Valuation of Contracts for difference ("CFD")

Contracts for difference are valued at fair value based respectively on the last known spread curve, rates curve and last known closing price of the underlying asset.

The unrealised appreciation / (depreciation) on CFD is disclosed in the statement of net assets under "Net unrealised appreciation / (depreciation) on CFD". Realised gains / (losses) and change in unrealised appreciation / depreciation resulting there from are included in the statement of changes in net assets respectively under "Net realised gain / (loss) on CFD" and "Change in net unrealised appreciation / depreciation on CFD".

For the details of outstanding CFD contracts, if any, please refer to the section "Notes to the report - Schedule of derivative instruments".

#### g) Valuation of forward foreign exchange contracts

The forward foreign exchange contracts are valued on the basis of forward exchange rates prevailing at the closing date and applicable to the remaining period until the expiration date. The unrealised appreciation / (depreciation) on forward foreign exchange contracts is disclosed in the statement of net assets under "Net unrealised appreciation / (depreciation) on forward foreign exchange contracts".

Realised gains / (losses) and change in unrealised appreciation / depreciation resulting there from are included in the statement of changes in net assets respectively under "Net realised gain / (loss) on forward foreign exchanges contracts" and "Change in net unrealised appreciation / depreciation on forward foreign exchange contracts".

For the details of outstanding forward foreign exchange contracts, if any, please refer to the section "Notes to the financial statements - Schedule of derivative instruments".

#### h) Repurchase agreements

Each sub-fund may enter into repurchase agreements, which involve the sale and purchase of securities whose terms grant the seller the right to repurchase the securities at a price and terms stipulated by the parties at the time the contract is established.

#### i) Formation expenses

Formation expenses are amortised using the straight-line method over 5 years at 20% per annum.

#### j) Transaction costs

For the year ended December 31, 2023, the SICAV incurred transaction costs and broker's charges related to the purchase and sale of transferable securities, money market instruments, other eligible assets and derivatives instruments. Those charges are disclosed in the statement of changes in net assets under the heading "Transaction costs".

#### k) Income

Interest income is accrued pursuant to the terms of the underlying investment. Income is recorded net of respective withholding taxes, if any. Dividends are recognised on ex-date.

#### l) Abbreviations used in investment portfolios

A: Annual  
 FL.R: Floating Rate Notes  
 Q: Quarterly  
 S: Semi-Annual  
 XX: Perpetual Bonds  
 ZCP or U: Zero Coupon





## Other notes to the financial statements

### Note 3 - Management fees

Candriam, a partnership limited by shares under Luxembourg law whose registered office is located at SERENITY - Bloc B, 19-21, Route d'Arlon, L-8009 Strassen, has been appointed Management Company. An agreement to that effect was entered into for an unlimited term. Either party is entitled to terminate the agreement at any time by registered letter (with signed receipt requested) sent to the other party, subject to 90 days' notice.

Candriam is a subsidiary of Candriam Group, an entity of the New York Life Insurance Company group.

It is authorised as a Management Company of Chapter 15 of the law of December 17, 2010, concerning UCITS and is authorised to exercise the activities of collective portfolio management, investment portfolio management and to provide investment advisory services.

The Management Company is vested with the widest powers to carry out all actions relating to the management and administration of the SICAV within the scope of this purpose, in accordance with its articles of association. It is responsible for the portfolio management activities, administration activities (Administrative Agent, Transfer Agent (including the Register holding business)) and marketing activities (distribution).

The portfolio management function is performed directly by Candriam and/or by one or more of its branches : Candriam-Belgian Branch, Candriam - Succursale française, Candriam - UK Establishment.

The Management Company delegated, under its supervision, responsibility and expense, the implementation of portfolio management for the Candriam Equities L Australia sub-fund to Ausbil Management Limited via a delegation agreement entered into for an unlimited term. This agreement may be terminated by either party subject to advance written notice of 90 days.

The Management Company receives management fees as payment for its services, expressed as an annual percentage of the average net asset value. These fees are payable by the SICAV at the end of each month.

The rates applicable as at December 31, 2023 are as follows:

| Sub-funds                            | Share class         | Share type     | ISIN         | Management fee |
|--------------------------------------|---------------------|----------------|--------------|----------------|
| Candriam Equities L Australia        | C                   | Capitalisation | LU0078775011 | 1.50%          |
|                                      | C                   | Distribution   | LU0078775284 | 1.50%          |
|                                      | C - EUR - Unhedged  | Capitalisation | LU0256780106 | 1.50%          |
|                                      | I                   | Capitalisation | LU0133348622 | 0.55%          |
|                                      | I - EUR - Unhedged  | Capitalisation | LU0256781096 | 0.55%          |
|                                      | N                   | Capitalisation | LU0133347731 | 2.00%          |
|                                      | N - EUR - Unhedged  | Capitalisation | LU0256780874 | 2.00%          |
|                                      | R                   | Capitalisation | LU0942225839 | 0.70%          |
|                                      | V                   | Capitalisation | LU0317020385 | 0.35%          |
|                                      | Z                   | Capitalisation | LU0240973742 | 0.00%          |
| Candriam Equities L Biotechnology    | C                   | Capitalisation | LU0108459040 | 1.60%          |
|                                      | C                   | Distribution   | LU0108459552 | 1.60%          |
|                                      | C - EUR - Hedged    | Capitalisation | LU1120766206 | 1.60%          |
|                                      | C - EUR - Unhedged  | Capitalisation | LU1120766388 | 1.60%          |
|                                      | I                   | Capitalisation | LU0133360163 | 0.60%          |
|                                      | I - CHF - Hedged    | Capitalisation | LU2478813442 | 0.60%          |
|                                      | I - EUR - Hedged    | Capitalisation | LU1006082199 | 0.60%          |
|                                      | I - EUR - Unhedged  | Capitalisation | LU1120766032 | 0.60%          |
|                                      | I - GBP - Unhedged  | Capitalisation | LU1269737059 | 0.60%          |
|                                      | L                   | Capitalisation | LU0574798848 | 1.60%          |
|                                      | N                   | Capitalisation | LU0133359157 | 2.00%          |
|                                      | R                   | Capitalisation | LU0942225912 | 0.80%          |
|                                      | R - CHF - Hedged    | Capitalisation | LU1269736754 | 0.80%          |
|                                      | R - EUR - Hedged    | Capitalisation | LU1708110975 | 0.80%          |
|                                      | R - EUR - Unhedged  | Capitalisation | LU1269736838 | 0.80%          |
|                                      | R - GBP - Unhedged  | Capitalisation | LU1269736911 | 0.80%          |
|                                      | R2                  | Capitalisation | LU1397644557 | 0.38%          |
|                                      | R2                  | Distribution   | LU1397644631 | 0.38%          |
|                                      | R2 - EUR - Unhedged | Capitalisation | LU1397644805 | 0.38%          |
|                                      | S - JPY - Unhedged  | Capitalisation | LU1820816558 | 0.50%          |
|                                      | V                   | Capitalisation | LU0317020203 | 0.45%          |
|                                      | V2                  | Capitalisation | LU2026682919 | 0.65%          |
|                                      | Z                   | Capitalisation | LU0240982651 | 0.00%          |
| Candriam Equities L Emerging Markets | BF                  | Capitalisation | LU1904319164 | 0.00%          |
|                                      | BF                  | Distribution   | LU1397645364 | 0.00%          |
|                                      | C                   | Capitalisation | LU0056052961 | 1.60%          |
|                                      | C                   | Distribution   | LU0056053001 | 1.60%          |
|                                      | C - USD - Hedged    | Capitalisation | LU1293437023 | 1.60%          |
|                                      | I                   | Capitalisation | LU0133355080 | 0.65%          |
|                                      | I                   | Distribution   | LU1269737562 | 0.65%          |
|                                      | I - GBP - Unhedged  | Capitalisation | LU1269737489 | 0.65%          |
|                                      | I2 - USD - Unhedged | Capitalisation | LU1774694167 | 0.85%          |
|                                      | L                   | Capitalisation | LU0574798921 | 1.60%          |
|                                      | N                   | Capitalisation | LU0133352731 | 2.00%          |
|                                      | P                   | Capitalisation | LU0596238260 | 0.25%          |
|                                      | R                   | Capitalisation | LU0942226134 | 0.85%          |
|                                      | R - GBP - Unhedged  | Capitalisation | LU1269737307 | 0.85%          |
|                                      | R2                  | Capitalisation | LU1397645018 | 0.40%          |
|                                      | R2                  | Distribution   | LU1397645109 | 0.40%          |
|                                      | V                   | Capitalisation | LU0317020112 | 0.35%          |
|                                      | V2                  | Capitalisation | LU1397645281 | 0.44%          |
|                                      | Z                   | Capitalisation | LU0240980523 | 0.00%          |



## Other notes to the financial statements

### Note 3 - Management fees (Continued)

| Sub-funds                                  | Share class                           | Share type     | ISIN           | Management fee |       |
|--|---------------------------------------|----------------|----------------|----------------|-------|
| Candriam Equities L EMU Innovation         | C                                     | Capitalisation | LU0317020898   | 1.50%          |       |
|  | I                                     | Capitalisation | LU0317021433   | 0.55%          |       |
|  | R                                     | Capitalisation | LU1293437379   | 0.70%          |       |
|  | S                                     | Capitalisation | LU0317021276   | 0.25%          |       |
|  | Z                                     | Capitalisation | LU0317021359   | 0.00%          |       |
| Candriam Equities L Europe Innovation      | C                                     | Capitalisation | LU0344046155   | 1.60%          |       |
|  | C                                     | Distribution   | LU0344046239   | 1.60%          |       |
|  | C - USD - Hedged                      | Capitalisation | LU1293437882   | 1.60%          |       |
|  | I                                     | Capitalisation | LU0344046668   | 0.60%          |       |
|  | I - USD - Hedged                      | Capitalisation | LU1293437965   | 0.60%          |       |
|  | L                                     | Capitalisation | LU0654531002   | 1.60%          |       |
|  | N                                     | Capitalisation | LU0344046312   | 2.00%          |       |
|  | R                                     | Capitalisation | LU1293438005   | 0.80%          |       |
|  | R2                                    | Capitalisation | LU1397646503   | 0.38%          |       |
|  | R2                                    | Distribution   | LU1397646685   | 0.38%          |       |
|  | S                                     | Capitalisation | LU2026683057   | 0.45%          |       |
|  | V                                     | Capitalisation | LU0344046403   | 0.35%          |       |
|  | V2                                    | Capitalisation | LU2026683131   | 0.45%          |       |
| Z  | Capitalisation                        | LU0344046585   | 0.00%          |                |       |
| Candriam Equities L Europe Optimum Quality | C                                     | Capitalisation | LU0304859712   | 1.60%          |       |
|  | C                                     | Distribution   | LU0304860058   | 1.60%          |       |
|  | I                                     | Capitalisation | LU0304860645   | 0.55%          |       |
|  | I                                     | Distribution   | LU1269737729   | 0.55%          |       |
|  | L                                     | Capitalisation | LU0574799226   | 1.60%          |       |
|  | N                                     | Capitalisation | LU0304860561   | 2.00%          |       |
|  | R                                     | Capitalisation | LU1293438187   | 0.70%          |       |
|  | R2                                    | Capitalisation | LU1397646842   | 0.38%          |       |
|  | R2                                    | Distribution   | LU1397646925   | 0.38%          |       |
|  | V                                     | Capitalisation | LU0317019536   | 0.35%          |       |
|  | Z                                     | Capitalisation | LU0317112661   | 0.00%          |       |
|  | Candriam Equities L Global Demography | C              | Capitalisation | LU0654531184   | 1.60% |
|  |                                       | C              | Distribution   | LU0654531267   | 1.60% |
| I  |                                       | Capitalisation | LU0654531341   | 0.60%          |       |
| I - USD - Unhedged                         |                                       | Capitalisation | LU2328285445   | 0.60%          |       |
| L  |                                       | Capitalisation | LU0654531697   | 1.60%          |       |
| N  |                                       | Capitalisation | LU0654531424   | 2.00%          |       |
| R  |                                       | Capitalisation | LU1598288089   | 0.80%          |       |
| R2   |                                       | Capitalisation | LU1397647733   | 0.38%          |       |
| R2   |                                       | Distribution   | LU1397647816   | 0.38%          |       |
| V2 - USD - Unhedged                        |                                       | Capitalisation | LU2439121216   | 0.35%          |       |
| Z  |                                       | Capitalisation | LU1397647907   | 0.00%          |       |
| Candriam Equities L Life Care              | BF                                    | Capitalisation | LU2223682787   | 0.00%          |       |
|  | BF                                    | Distribution   | LU2223682860   | 0.00%          |       |
|  | C                                     | Capitalisation | LU2223680658   | 1.50%          |       |
|  | I                                     | Capitalisation | LU2223680815   | 0.80%          |       |
|  | I - EUR - Unhedged                    | Capitalisation | LU2346867125   | 0.80%          |       |
|  | R                                     | Capitalisation | LU2223681201   | 0.80%          |       |
|  | R2                                    | Capitalisation | LU2223681896   | 0.40%          |       |
|  | V                                     | Capitalisation | LU2223682274   | 0.48%          |       |
|  | Z                                     | Capitalisation | LU2223682357   | 0.00%          |       |
| Candriam Equities L Meta Globe             | BF - EUR - Unhedged                   | Capitalisation | LU2476791202   | 0.00%          |       |
|  | BF - EUR - Unhedged                   | Distribution   | LU2476793323   | 0.00%          |       |
|  | C                                     | Capitalisation | LU2476793240   | 1.60%          |       |
|  | I                                     | Capitalisation | LU2476792861   | 0.80%          |       |
|  | R                                     | Capitalisation | LU2476792432   | 0.80%          |       |
|  | V                                     | Capitalisation | LU2476791467   | 0.48%          |       |
|  | Z                                     | Capitalisation | LU2476791384   | 0.00%          |       |
| Candriam Equities L Oncology Impact        | BF - EUR - Unhedged                   | Capitalisation | LU1940963215   | 0.00%          |       |
|  | BF - EUR - Unhedged                   | Distribution   | LU1940963306   | 0.00%          |       |
|  | C                                     | Capitalisation | LU1864481467   | 1.60%          |       |
|  | C                                     | Distribution   | LU1864481541   | 1.60%          |       |
|  | C - EUR - Hedged                      | Capitalisation | LU1864481624   | 1.60%          |       |
|  | C - EUR - Unhedged                    | Capitalisation | LU1864484214   | 1.60%          |       |
|  | I                                     | Capitalisation | LU1864482358   | 0.80%          |       |
|  | I                                     | Distribution   | LU1864482432   | 0.80%          |       |
|  | I - EUR - Hedged                      | Capitalisation | LU2015349330   | 0.80%          |       |
|  | I - GBP - Unhedged                    | Capitalisation | LU1864482515   | 0.80%          |       |
|  | N                                     | Capitalisation | LU2346866234   | 2.00%          |       |
|  | N - EUR - Hedged                      | Capitalisation | LU1864482606   | 2.00%          |       |
|  | N - EUR - Unhedged                    | Capitalisation | LU2346866317   | 2.00%          |       |
|  | PI                                    | Capitalisation | LU1864483836   | 0.40%          |       |
|  | R                                     | Capitalisation | LU1864482788   | 0.80%          |       |
|  | R                                     | Distribution   | LU1864482861   | 0.80%          |       |
|  | R - EUR - Hedged                      | Capitalisation | LU1864483083   | 0.80%          |       |
|  | R - EUR - Unhedged                    | Capitalisation | LU1864483166   | 0.80%          |       |



## Other notes to the financial statements

### Note 3 - Management fees (Continued)

| Sub-funds  | Share class            | Share type     | ISIN         | Management fee |
|--|------------------------|----------------|--------------|----------------|
| Candriam Equities L Oncology Impact (Continued)      | R - GBP - Unhedged     | Capitalisation | LU1864482945 | 0.80%          |
|  | R2                     | Capitalisation | LU1864483240 | 0.40%          |
|  | R2                     | Distribution   | LU1864483323 | 0.40%          |
|  | R2 - EUR - Hedged      | Distribution   | LU1864483596 | 0.40%          |
|  | S - JPY - Asset Hedged | Distribution   | LU2015349090 | 0.38%          |
|  | S - JPY - Unhedged     | Distribution   | LU2015348522 | 0.50%          |
|  | SF2 - EUR - Unhedged   | Capitalisation | LU2295688928 | 0.18%          |
|  | V                      | Capitalisation | LU1864483752 | 0.48%          |
|  | V - GBP - Unhedged     | Capitalisation | LU2425425506 | 0.48%          |
|  | Z                      | Capitalisation | LU1864483919 | 0.00%          |
| Candriam Equities L Risk Arbitrage Opportunities     | C                      | Capitalisation | LU2223682944 | 1.50%          |
|  | I                      | Capitalisation | LU2223683082 | 1.00%          |
|  | PI                     | Capitalisation | LU2223683678 | 0.50%          |
|  | R                      | Capitalisation | LU2223683322 | 1.00%          |
|  | S                      | Capitalisation | LU2223683751 | 0.25%          |
|  | V                      | Capitalisation | LU2223683835 | 0.80%          |
|  | Z                      | Capitalisation | LU2223683918 | 0.00%          |
| Candriam Equities L Robotics & Innovative Technology | BF                     | Capitalisation | LU2226954738 | 0.00%          |
|  | BF                     | Distribution   | LU2226954902 | 0.00%          |
|  | C                      | Capitalisation | LU1502282558 | 1.60%          |
|  | C                      | Distribution   | LU1502282715 | 1.60%          |
|  | C - EUR - Hedged       | Capitalisation | LU1806526718 | 1.60%          |
|  | C - EUR - Unhedged     | Capitalisation | LU1502282632 | 1.60%          |
|  | I                      | Capitalisation | LU1502282806 | 0.80%          |
|  | I - EUR - Unhedged     | Capitalisation | LU1613213971 | 0.80%          |
|  | N - EUR - Hedged       | Capitalisation | LU1806526809 | 2.00%          |
|  | R                      | Capitalisation | LU1502282988 | 0.80%          |
|  | R                      | Distribution   | LU1708110629 | 0.80%          |
|  | R - EUR - Hedged       | Capitalisation | LU1613220596 | 0.80%          |
|  | R - EUR - Unhedged     | Capitalisation | LU1598284849 | 0.80%          |
|  | R - GBP - Hedged       | Capitalisation | LU1613217964 | 0.80%          |
|  | V - EUR - Unhedged     | Capitalisation | LU2402073626 | 0.48%          |
|  | Z                      | Capitalisation | LU1502283010 | 0.00%          |

The table hereafter reflects the maximum Management fee's annual rate applied to UCITS invested into by Candriam Equities L different sub-funds as at December 31, 2023.

| Target fund                  | Maximum rate |
|------------------------------|--------------|
| CANDRIAM MONÉTAIRE SICAV Z C | 0.15%        |

### Note 4 - Distribution fees

The rates of the specific distribution fee for the Lock share class are as follows:

| Sub-funds                                  | Share class | Share type     | ISIN         | Annual rate |
|--|-------------|----------------|--------------|-------------|
| Candriam Equities L Biotechnology          | L           | Capitalisation | LU0574798848 | 0.10%       |
| Candriam Equities L Emerging Markets       | L           | Capitalisation | LU0574798921 | 0.10%       |
| Candriam Equities L Europe Innovation      | L           | Capitalisation | LU0654531002 | 0.10%       |
| Candriam Equities L Europe Optimum Quality | L           | Capitalisation | LU0574799226 | 0.10%       |
| Candriam Equities L Global Demography      | L           | Capitalisation | LU0654531697 | 0.10%       |

### Note 5 - Operating and Administrative Expenses

The SICAV bears the current operating and administrative expenses incurred to cover all the overheads and variable expenses, the charges, fees and other expenses, as defined below ("Operating and Administrative Expenses").

The Operating and Administrative Expenses cover, but are not limited to, the following expenses:

a) the expenditures incurred directly by the SICAV, including, inter alia, the Depositary Bank's fees and charges, the fees and expenses of the approved independent auditors, the cost of share class hedging, including that invoiced by the Management Company, the fees paid to the Directors and the reasonable expenses and outlays incurred by or for the Directors;



Other notes to the financial statements

**Note 5 - Operating and Administrative Expenses (Continued)**

b) a "service fee" paid to the Management Company and including the remaining sum of the Operating and Administrative Expenses after deduction of the expenses detailed in section (a) above, that is, inter alia, the fees and expenses of the Domiciliary Agent, the Administrative Agent, the Transfer Agent and Registrar Holding and the Principal Paying Agent, the costs related to registration and maintenance of the registration in all the jurisdictions (such as the fees charged by the supervisory authorities concerned, the translation expenses and the remuneration of the Representatives abroad and the local paying agents), the stock exchange registration and renewal expenses, the cost of publishing the share prices, the postal and telecommunication charges, preparation cost, printing, translating and distributing the prospectuses, key investor information documents, notices to shareholders, financial reports or of any other document intended for the shareholders, the legal fees and expenses, the charges and expenses related to the taking out of any subscription/licence or any other use of fee-paying information or data, the expenses incurred by the use of a registered trademark by the SICAV, the expenses and fees payable to the Management Company and/or its delegates and/or to any other agent appointed by the SICAV itself and/or to the independent experts.

The Operating and Administrative Expenses are expressed as an annual percentage of the average net asset value of each share class and are payable monthly.

At the end of a given period, if the actual charges and expenses were to be higher than the percentage of Operating and Administrative Expenses set for a share class, then the Management Company would pay for the difference itself. Conversely, if the actual charges and expenses were to turn out to be lower than the percentage of Operating and Administrative Expenses set for a share class, then the Management Company would retain the difference.

The Management Company shall be entitled to instruct the SICAV to proceed to settle all or part of the expenses as listed above directly from its assets.

In such a case, the amount of the Operating and Administrative Expenses would be reduced accordingly.

The maximum rates applicable as at December 31, 2023 are as follows:

| Sub-funds                            | Share class         | Share type     | ISIN         | Maximum rate |
|--------------------------------------|---------------------|----------------|--------------|--------------|
| Candriam Equities L Australia        | C                   | Distribution   | LU0078775284 | 0.40%        |
|                                      | C                   | Capitalisation | LU0078775011 | 0.40%        |
|                                      | C - EUR - Unhedged  | Capitalisation | LU0256780106 | 0.40%        |
|                                      | I                   | Capitalisation | LU0133348622 | 0.30%        |
|                                      | I - EUR - Unhedged  | Capitalisation | LU0256781096 | 0.30%        |
|                                      | N                   | Capitalisation | LU0133347731 | 0.40%        |
|                                      | N - EUR - Unhedged  | Capitalisation | LU0256780874 | 0.40%        |
|                                      | R                   | Capitalisation | LU0942225839 | 0.40%        |
|                                      | V                   | Capitalisation | LU0317020385 | 0.30%        |
|                                      | Z                   | Capitalisation | LU0240973742 | 0.30%        |
| Candriam Equities L Biotechnology    | C                   | Distribution   | LU0108459552 | 0.40%        |
|                                      | C                   | Capitalisation | LU0108459040 | 0.40%        |
|                                      | C - EUR - Hedged    | Capitalisation | LU1120766206 | 0.40%        |
|                                      | C - EUR - Unhedged  | Capitalisation | LU1120766388 | 0.40%        |
|                                      | I                   | Capitalisation | LU0133360163 | 0.30%        |
|                                      | I - CHF - Hedged    | Capitalisation | LU2478813442 | 0.30%        |
|                                      | I - EUR - Hedged    | Capitalisation | LU1006082199 | 0.30%        |
|                                      | I - EUR - Unhedged  | Capitalisation | LU1120766032 | 0.30%        |
|                                      | I - GBP - Unhedged  | Capitalisation | LU1269737059 | 0.30%        |
|                                      | L                   | Capitalisation | LU0574798848 | 0.40%        |
|                                      | N                   | Capitalisation | LU0133359157 | 0.40%        |
|                                      | R                   | Capitalisation | LU0942225912 | 0.40%        |
|                                      | R - CHF - Hedged    | Capitalisation | LU1269736754 | 0.40%        |
|                                      | R - EUR - Hedged    | Capitalisation | LU1708110975 | 0.40%        |
|                                      | R - EUR - Unhedged  | Capitalisation | LU1269736838 | 0.40%        |
|                                      | R - GBP - Unhedged  | Capitalisation | LU1269736911 | 0.40%        |
|                                      | R2                  | Distribution   | LU1397644631 | 0.40%        |
|                                      | R2                  | Capitalisation | LU1397644557 | 0.40%        |
|                                      | R2 - EUR - Unhedged | Capitalisation | LU1397644805 | 0.40%        |
|                                      | S - JPY - Unhedged  | Capitalisation | LU1820816558 | 0.30%        |
| V                                    | Capitalisation      | LU0317020203   | 0.30%        |              |
| V2                                   | Capitalisation      | LU2026682919   | 0.30%        |              |
| Z                                    | Capitalisation      | LU0240982651   | 0.30%        |              |
| Candriam Equities L Emerging Markets | BF                  | Distribution   | LU1397645364 | 0.46%        |
|                                      | BF                  | Capitalisation | LU1904319164 | 0.46%        |
|                                      | C                   | Distribution   | LU0056053001 | 0.55%        |
|                                      | C                   | Capitalisation | LU0056052961 | 0.55%        |
|                                      | C - USD - Hedged    | Capitalisation | LU1293437023 | 0.55%        |
|                                      | I                   | Distribution   | LU1269737562 | 0.46%        |
|                                      | I                   | Capitalisation | LU0133355080 | 0.46%        |
|                                      | I - GBP - Unhedged  | Capitalisation | LU1269737489 | 0.46%        |
|                                      | I2 - USD - Unhedged | Capitalisation | LU1774694167 | 0.46%        |
|                                      | L                   | Capitalisation | LU0574798921 | 0.55%        |
|                                      | N                   | Capitalisation | LU0133352731 | 0.55%        |
|                                      | P                   | Capitalisation | LU0596238260 | 0.46%        |
|                                      | R                   | Capitalisation | LU0942226134 | 0.55%        |
|                                      | R - GBP - Unhedged  | Capitalisation | LU1269737307 | 0.55%        |
|                                      | R2                  | Distribution   | LU1397645109 | 0.55%        |
|                                      | R2                  | Capitalisation | LU1397645018 | 0.55%        |
|                                      | V                   | Capitalisation | LU0317020112 | 0.46%        |



## Other notes to the financial statements

### Note 5 - Operating and Administrative Expenses (Continued)

| Sub-funds  | Share class                           | Share type     | ISIN           | Maximum rate |       |
|--|---------------------------------------|----------------|----------------|--------------|-------|
| Candriam Equities L Emerging Markets (Continued) | V2                                    | Capitalisation | LU1397645281   | 0.46%        |       |
|  | Z                                     | Capitalisation | LU0240980523   | 0.46%        |       |
| Candriam Equities L EMU Innovation               | C                                     | Capitalisation | LU0317020898   | 0.40%        |       |
|  | I                                     | Capitalisation | LU0317021433   | 0.30%        |       |
|  | R                                     | Capitalisation | LU1293437379   | 0.40%        |       |
|  | S                                     | Capitalisation | LU0317021276   | 0.30%        |       |
|  | Z                                     | Capitalisation | LU0317021359   | 0.30%        |       |
| Candriam Equities L Europe Innovation            | C                                     | Distribution   | LU0344046239   | 0.40%        |       |
|  | C                                     | Capitalisation | LU0344046155   | 0.40%        |       |
|  | C - USD - Hedged                      | Capitalisation | LU1293437882   | 0.40%        |       |
|  | I                                     | Capitalisation | LU0344046668   | 0.30%        |       |
|  | I - USD - Hedged                      | Capitalisation | LU1293437965   | 0.30%        |       |
|  | L                                     | Capitalisation | LU0654531002   | 0.40%        |       |
|  | N                                     | Capitalisation | LU0344046312   | 0.40%        |       |
|  | R                                     | Capitalisation | LU1293438005   | 0.40%        |       |
|  | R2                                    | Distribution   | LU1397646685   | 0.40%        |       |
|  | R2                                    | Capitalisation | LU1397646503   | 0.40%        |       |
|  | S                                     | Capitalisation | LU2026683057   | 0.30%        |       |
|  | V                                     | Capitalisation | LU0344046403   | 0.30%        |       |
|  | V2                                    | Capitalisation | LU2026683131   | 0.30%        |       |
|  | Z                                     | Capitalisation | LU0344046585   | 0.30%        |       |
| Candriam Equities L Europe Optimum Quality       | C                                     | Distribution   | LU0304860058   | 0.40%        |       |
|  | C                                     | Capitalisation | LU0304859712   | 0.40%        |       |
|  | I                                     | Distribution   | LU1269737729   | 0.30%        |       |
|  | I                                     | Capitalisation | LU0304860645   | 0.30%        |       |
|  | L                                     | Capitalisation | LU0574799226   | 0.40%        |       |
|  | N                                     | Capitalisation | LU0304860561   | 0.40%        |       |
|  | R                                     | Capitalisation | LU1293438187   | 0.40%        |       |
|  | R2                                    | Distribution   | LU1397646925   | 0.40%        |       |
|  | R2                                    | Capitalisation | LU1397646842   | 0.40%        |       |
|  | V                                     | Capitalisation | LU0317019536   | 0.30%        |       |
|  | Z                                     | Capitalisation | LU0317112661   | 0.30%        |       |
|  | Candriam Equities L Global Demography | C              | Distribution   | LU0654531267 | 0.40% |
|  |                                       | C              | Capitalisation | LU0654531184 | 0.40% |
| I  |                                       | Capitalisation | LU0654531341   | 0.30%        |       |
| I - USD - Unhedged                               |                                       | Capitalisation | LU2328285445   | 0.30%        |       |
| L  |                                       | Capitalisation | LU0654531697   | 0.40%        |       |
| N  |                                       | Capitalisation | LU0654531424   | 0.40%        |       |
| R  |                                       | Capitalisation | LU1598288089   | 0.40%        |       |
| R2   |                                       | Distribution   | LU1397647816   | 0.40%        |       |
| R2   |                                       | Capitalisation | LU1397647733   | 0.40%        |       |
| V2 - USD - Unhedged                              |                                       | Capitalisation | LU2439121216   | 0.30%        |       |
| Z  |                                       | Capitalisation | LU1397647907   | 0.30%        |       |
| Candriam Equities L Life Care                    | BF                                    | Distribution   | LU2223682860   | 0.30%        |       |
|  | BF                                    | Capitalisation | LU2223682787   | 0.30%        |       |
|  | C                                     | Capitalisation | LU2223680658   | 0.40%        |       |
|  | I                                     | Capitalisation | LU2223680815   | 0.30%        |       |
|  | I - EUR - Unhedged                    | Capitalisation | LU2346867125   | 0.30%        |       |
|  | R                                     | Capitalisation | LU2223681201   | 0.40%        |       |
|  | R2                                    | Capitalisation | LU2223681896   | 0.40%        |       |
|  | V                                     | Capitalisation | LU2223682274   | 0.30%        |       |
|  | Z                                     | Capitalisation | LU2223682357   | 0.30%        |       |
| Candriam Equities L Meta Globe                   | BF - EUR - Unhedged                   | Distribution   | LU2476793323   | 0.30%        |       |
|  | BF - EUR - Unhedged                   | Capitalisation | LU2476791202   | 0.30%        |       |
|  | C                                     | Capitalisation | LU2476793240   | 0.40%        |       |
|  | I                                     | Capitalisation | LU2476792861   | 0.30%        |       |
|  | R                                     | Capitalisation | LU2476792432   | 0.40%        |       |
|  | V                                     | Capitalisation | LU2476791467   | 0.30%        |       |
|  | Z                                     | Capitalisation | LU2476791384   | 0.30%        |       |
| Candriam Equities L Oncology Impact              | BF - EUR - Unhedged                   | Distribution   | LU1940963306   | 0.30%        |       |
|  | BF - EUR - Unhedged                   | Capitalisation | LU1940963215   | 0.30%        |       |
|  | C                                     | Distribution   | LU1864481541   | 0.40%        |       |
|  | C                                     | Capitalisation | LU1864481467   | 0.40%        |       |
|  | C - EUR - Hedged                      | Capitalisation | LU1864481624   | 0.40%        |       |
|  | C - EUR - Unhedged                    | Capitalisation | LU1864484214   | 0.40%        |       |
|  | I                                     | Distribution   | LU1864482432   | 0.30%        |       |
|  | I                                     | Capitalisation | LU1864482358   | 0.30%        |       |
|  | I - EUR - Hedged                      | Capitalisation | LU2015349330   | 0.30%        |       |
|  | I - GBP - Unhedged                    | Capitalisation | LU1864482515   | 0.30%        |       |
|  | N                                     | Capitalisation | LU2346866234   | 0.40%        |       |
|  | N - EUR - Hedged                      | Capitalisation | LU1864482606   | 0.40%        |       |
|  | N - EUR - Unhedged                    | Capitalisation | LU2346866317   | 0.40%        |       |
|  | PI                                    | Capitalisation | LU1864483836   | 0.30%        |       |
|  | R                                     | Distribution   | LU1864482861   | 0.40%        |       |
|  | R                                     | Capitalisation | LU1864482788   | 0.40%        |       |
|  | R - EUR - Hedged                      | Capitalisation | LU1864483083   | 0.40%        |       |
|  | R - EUR - Unhedged                    | Capitalisation | LU1864483166   | 0.40%        |       |
|  | R - GBP - Unhedged                    | Capitalisation | LU1864482945   | 0.40%        |       |



## Other notes to the financial statements

### Note 5 - Operating and Administrative Expenses (Continued)

| Sub-funds  | Share class            | Share type     | ISIN         | Maximum rate |
|--|------------------------|----------------|--------------|--------------|
| Candriam Equities L Oncology Impact (Continued)      | R2                     | Distribution   | LU1864483323 | 0.40%        |
|  | R2                     | Capitalisation | LU1864483240 | 0.40%        |
|  | R2 - EUR - Hedged      | Distribution   | LU1864483596 | 0.40%        |
|  | S - JPY - Asset Hedged | Distribution   | LU2015349090 | 0.30%        |
|  | S - JPY - Unhedged     | Distribution   | LU2015348522 | 0.30%        |
|  | SF2 - EUR - Unhedged   | Capitalisation | LU2295688928 | 0.30%        |
|  | V                      | Capitalisation | LU1864483752 | 0.30%        |
|  | V - GBP - Unhedged     | Capitalisation | LU2425425506 | 0.30%        |
|  | Z                      | Capitalisation | LU1864483919 | 0.30%        |
| Candriam Equities L Risk Arbitrage Opportunities     | C                      | Capitalisation | LU2223682944 | 0.40%        |
|  | I                      | Capitalisation | LU2223683082 | 0.30%        |
|  | PI                     | Capitalisation | LU2223683678 | 0.30%        |
|  | R                      | Capitalisation | LU2223683322 | 0.40%        |
|  | S                      | Capitalisation | LU2223683751 | 0.30%        |
|  | V                      | Capitalisation | LU2223683835 | 0.30%        |
|  | Z                      | Capitalisation | LU2223683918 | 0.30%        |
| Candriam Equities L Robotics & Innovative Technology | BF                     | Distribution   | LU2226954902 | 0.30%        |
|  | BF                     | Capitalisation | LU2226954738 | 0.30%        |
|  | C                      | Distribution   | LU1502282715 | 0.40%        |
|  | C                      | Capitalisation | LU1502282558 | 0.40%        |
|  | C - EUR - Hedged       | Capitalisation | LU1806526718 | 0.40%        |
|  | C - EUR - Unhedged     | Capitalisation | LU1502282632 | 0.40%        |
|  | I                      | Capitalisation | LU1502282806 | 0.30%        |
|  | I - EUR - Unhedged     | Capitalisation | LU1613213971 | 0.30%        |
|  | N - EUR - Hedged       | Capitalisation | LU1806526809 | 0.40%        |
|  | R                      | Distribution   | LU1708110629 | 0.40%        |
|  | R                      | Capitalisation | LU1502282988 | 0.40%        |
|  | R - EUR - Hedged       | Capitalisation | LU1613220596 | 0.40%        |
|  | R - EUR - Unhedged     | Capitalisation | LU1598284849 | 0.40%        |
|  | R - GBP - Hedged       | Capitalisation | LU1613217964 | 0.40%        |
|  | V - EUR - Unhedged     | Capitalisation | LU2402073626 | 0.30%        |
| Z  | Capitalisation         | LU1502283010   | 0.30%        |              |

### Note 6 - Performance fees

In payment for its portfolio management activity, the Management Company also receives performance fees on certain share classes of certain sub-funds (see table below with concerned share classes and related index).

The method of calculating the performance commission is detailed in the various technical specifications attached to the Prospectus of the SICAV in force at the time.

#### Candriam Equities L Biotechnology

| Share class        | Class type     | Currency | Performance fee rate | Amount of performance fee charged for the year | % on the Share Class NAV of performance fee charges for the year |
|--------------------|----------------|----------|----------------------|--|--|
| I                  | Capitalisation | USD      | 20.00%               | 256,378  | 0.88%  |
| I - CHF - Hedged   | Capitalisation | CHF      | 20.00%               | 2,923  | 1.09%  |
| I - EUR - Hedged   | Capitalisation | EUR      | 20.00%               | 216,370  | 0.97%  |
| I - EUR - Unhedged | Capitalisation | EUR      | 20.00%               | 403,882  | 0.80%  |
| I - GBP - Unhedged | Capitalisation | GBP      | 20.00%               | 7,175  | 1.07%  |
| V                  | Capitalisation | USD      | 20.00%               | 1,242,222                                      | 1.08%  |

The performance fee charged during the year ended December 31, 2023 amounted to USD 2,128,950.

#### Candriam Equities L Emerging Markets

| Share class        | Class type     | Currency | Performance fee rate | Amount of performance fee charged for the year | % on the Share Class NAV of performance fee charges for the year |
|--------------------|----------------|----------|----------------------|--|--|
| I                  | Distribution   | EUR      | 20.00%               | 0  | 0.00%  |
| I                  | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| I - GBP - Unhedged | Capitalisation | GBP      | 20.00%               | 0  | 0.00%  |
| V                  | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |

No performance was charged during the year ended December 31, 2023.

#### Candriam Equities L EMU Innovation

| Share class | Class type     | Currency | Performance fee rate | Amount of performance fee charged for the year | % on the Share Class NAV of performance fee charges for the year |
|-------------|----------------|----------|----------------------|--|--|
| I           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |

No performance was charged during the year ended December 31, 2023.





Other notes to the financial statements

**Note 6 - Performance fees (Continued)**

**Candriam Equities L Europe Innovation**

| Share class      | Class type     | Currency | Performance fee rate | Amount of performance fee charged for the year | % on the Share Class NAV of performance fee charges for the year |
|------------------|----------------|----------|----------------------|--|--|
| I                | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| I - USD - Hedged | Capitalisation | USD      | 20.00%               | 0  | 0.00%  |
| V                | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |

No performance was charged during the year ended December 31, 2023.

**Candriam Equities L Europe Optimum Quality**

| Share class | Class type     | Currency | Performance fee rate | Amount of performance fee charged for the year | % on the Share Class NAV of performance fee charges for the year |
|-------------|----------------|----------|----------------------|--|--|
| I           | Distribution   | EUR      | 20.00%               | 0  | 0.00%  |
| I           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| V           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |

No performance was charged during the year ended December 31, 2023.

**Candriam Equities L Global Demography**

| Share class        | Class type     | Currency | Performance fee rate | Amount of performance fee charged for the year | % on the Share Class NAV of performance fee charges for the year |
|--------------------|----------------|----------|----------------------|--|--|
| I                  | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| I - USD - Unhedged | Capitalisation | USD      | 20.00%               | 0  | 0.00%  |

No performance was charged during the year ended December 31, 2023.

**Candriam Equities L Risk Arbitrage Opportunities**

| Share class | Class type     | Currency | Performance fee rate | Amount of performance fee charged for the year | % on the Share Class NAV of performance fee charges for the year |
|-------------|----------------|----------|----------------------|--|--|
| C           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| I           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| PI          | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| R           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| V           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |
| Z           | Capitalisation | EUR      | 20.00%               | 0  | 0.00%  |

No performance was charged during the year ended December 31, 2023.

**Note 7 - Subscription tax**

The SICAV is governed by the Luxembourg tax laws.

By virtue of the legislation and regulations currently in force, the SICAV is subject in Luxembourg to an annual tax of 0.05% of the net asset value of the SICAV; this rate is reduced to 0.01% for the classes reserved for institutional investors. This tax is payable quarterly on the basis of the net asset value of the SICAV calculated at the end of the quarter to which the tax relates.

The Belgian government enacted a law to tax once a year the net asset value of foreign investment funds registered in Belgium. This annual tax is calculated on the net amounts defined as invested in Belgium by Belgian financial intermediaries. In the absence of a sufficient declaration relating to these figures, the tax authority will be entitled to calculate the tax on the entirety of the assets of these sub-funds. The Belgian law of June 17, 2013 comprising fiscal and financial provisions and provisions relating to sustainable development set the rate of the annual tax for Undertakings for Collective Investment at 0.0925% with effect from January 1, 2014.

As a precautionary measure, the SICAV filed a claim with the Belgian tax authority and the Brussels Court of First Instance for the tax to be refunded. At this stage, it is not possible to prejudge the outcome of the dispute or any reimbursement in favour of the SICAV. In a similar case, the Belgian State appealed to the Court of Cassation against the Court of Appeal's rulings in favour of the plaintiff.

The management company was informed that the Court of Cassation ruled against the plaintiff on March 25, 2022. The Court of Cassation (French-speaking chamber) considers that the Brussels Court of Appeal wrongly qualified the Belgian subscription tax as a wealth tax covered by the double taxation convention between Belgium and Luxembourg (which convention attributes the right to tax Luxembourg SICAVs only by Luxembourg and not by Belgium, which justified the claim for reimbursement of the Belgian subscription tax).

The case is referred back to the Court of Appeal of Liège which will be bound by the assessment taken by the Court of Cassation.

Another decision of the Court of Cassation (Dutch-speaking chamber) of April 21, 2022 does not dispute that the Belgian subscription tax is a wealth tax, but considers that the double taxation convention between Belgium and Luxembourg (unlike the one signed with the Netherlands) does not cover in its scope a wealth tax levied in Belgium.

The prospect of a refund is therefore limited and will in any case not be possible in the short term.



## Other notes to the financial statements

### Note 8 – Capital Gain Tax

Certain revenues of the SICAV in terms of realized gains on securities from asset sources outside Luxembourg may be liable to taxes in the source country at variable rates. Such taxes are generally deducted at source or paid upon the filing of a tax return in the foreign country.

In particular, for the sub-fund Candriam Equities L Emerging Markets, under current law of India, short term capital gains are taxed at 15% while long term capital gains are taxed at 10% if the gain is above 100,000 Indian rupees.

Considering potential impact of the Indian capital gain tax on the net assets, the SICAV is accruing such tax including unrealized gains on securities traded on the Indian stock exchange.

In Luxembourg, no tax is payable on the capital gains realized or unrealized capital appreciation on the assets of the SICAV in accordance with the Law and current practice.

### Note 9 - Reverse repurchase agreements

As at December 31, 2023, the following reverse repurchase agreements were outstanding:

#### Candriam Equities L Risk Arbitrage Opportunities

| Currency | Nominal   | Maturity date | Description                     | Counterparty             | Receivable on reverse repurchase agreements (in EUR) |
|----------|-----------|---------------|---------------------------------|--------------------------|--|
| EUR      | 6,172,000 | 04/10/2040    | EURO UNIO BILL 0.1 20-40 04/10A | CACEIS Bank, Lux. Branch | 3,518,040  |
| EUR      | 7,000,000 | 22/06/2029    | BELGIUM 0.9 19-29 22/06A        | CACEIS Bank, Lux. Branch | 6,188,000  |
| EUR      | 6,301,556 | 25/05/2032    | FRANCE 0.00 22-32 25/05A        | CACEIS Bank, Lux. Branch | 4,803,046  |
| EUR      | 3,080,588 | 15/07/2033    | NETHERLANDS 2.5 23-33 15/07A    | CACEIS Bank, Lux. Branch | 3,000,000  |
| EUR      | 3,500,000 | 15/04/2024    | BEI 4.125 07-24 15/04A          | CACEIS Bank, Lux. Branch | 3,591,000  |
|          |           |               |                                 |                          | <b>21,100,086</b>                                    |

### Note 10 - Securities lending

The implementation of the securities lending and borrowing transactions is performed directly by Candriam and/or by one or more of its branches and is partly delegated to CACEIS Bank, Luxembourg Branch.

As at December 31, 2023, the composition of the securities lent was as follows:

| Sub-funds                                  | Currency | Market value of securities lent | Collateral Securities |
|--|----------|---------------------------------|-----------------------|
| Candriam Equities L Biotechnology          | USD      | 61,253,469                      | 71,042,392            |
| Candriam Equities L Europe Innovation      | EUR      | 60,058,985                      | 61,229,200            |
| Candriam Equities L Europe Optimum Quality | EUR      | 43,788,706                      | 44,059,468            |
| Candriam Equities L Life Care              | USD      | 152,972                         | 153,065               |

The types of financial guarantees permitted are as follows:

- cash denominated in the reference currency of the sub-fund concerned;
- good-quality debt securities (rated at least BBB-/Baa3 or equivalent by one of the rating agencies) issued by a public-sector issuer of an OECD country (states, supranationals, etc.) and whose issue size is a minimum of EUR 250 million;
- good-quality debt securities (rated at least BBB-/Baa3 or equivalent by one of the rating agencies) issued by a private-sector issuer of an OECD country and whose issue size is a minimum of EUR 250 million;
- shares listed or traded on a regulated market of a Member State of the European Union or on a securities exchange of a State belonging to the OECD, provided that these shares are included in a major index;
- shares or units of undertakings for collective investment offering adequate liquidity and investing in money market instruments, good-quality bonds or in shares that meet the conditions listed above.

The securities lent are valued on the basis of the last-known price. The securities and the related interest receivable are shown in the Statement of net assets.

The amounts of the interest received in connection with this securities lending are included in the item "Interest on securities lending" of the statement of changes in net assets.

The counterparties related to the open positions of securities lending are BNP Paribas, BNP Paribas Securities Services SCA, Natixis SA, Morgan Stanley Europe S.E., Barclays Bank PLC - Ireland - LC, Scotiabank and Société Générale S.A., UBS Europe SE.





## Other notes to the financial statements

### Note 10 - Securities lending (Continued)

The following items of income were recorded in the accounts during the year ended December 31, 2023:

| Sub-funds  | Currency | Total gross amount of securities lending income | Direct-indirect costs and fees deducted from gross securities lending income | Total net amount of securities lending income |
|--|----------|---|--|---|
| Candriam Equities L Biotechnology                    | USD      | 145,758   | 58,303   | 87,455  |
| Candriam Equities L Emerging Markets                 | EUR      | 22,647  | 9,059  | 13,588  |
| Candriam Equities L EMU Innovation                   | EUR      | 2,020   | 808  | 1,212   |
| Candriam Equities L Europe Innovation                | EUR      | 170,092   | 68,037   | 102,055                                       |
| Candriam Equities L Europe Optimum Quality           | EUR      | 69,443  | 27,777   | 41,666  |
| Candriam Equities L Global Demography                | EUR      | 518   | 207  | 311   |
| Candriam Equities L Life Care                        | USD      | 4,263   | 1,705  | 2,558   |
| Candriam Equities L Robotics & Innovative Technology | USD      | 52  | 21   | 31  |

The Income net of cost and fees, and agent's commissions are received by the SICAV.

Direct and indirect costs and fees received by Candriam France and Candriam amount to respectively 19% and 1% for all the sub-funds. The commissions received by CACEIS Bank, Luxembourg Branch amount to 20% of the gross income.

Candriam – Succursale française and Candriam are related parties of the SICAV.

### Note 11 - Dividends

The SICAV distributed the following dividends during the year ended December 31, 2023:

| Sub-funds  | Share class            | Currency | Dividend   | Ex-date    |
|--|------------------------|----------|------------|------------|
| Candriam Equities L Australia                        | C                      | AUD      | 21.46      | 27/04/2023 |
| Candriam Equities L Biotechnology                    | C                      | USD      | 3.92       | 27/04/2023 |
|  | R2                     | USD      | 1.20       | 27/04/2023 |
| Candriam Equities L Emerging Markets                 | BF                     | EUR      | 33.68      | 27/04/2023 |
|  | C                      | EUR      | 13.98      | 27/04/2023 |
|  | I                      | EUR      | 40.00      | 27/04/2023 |
|  | R2                     | EUR      | 3.90       | 27/04/2023 |
| Candriam Equities L Europe Innovation                | C                      | EUR      | 6.33       | 27/04/2023 |
|  | R2                     | EUR      | 5.13       | 27/04/2023 |
| Candriam Equities L Europe Optimum Quality           | C                      | EUR      | 2.51       | 27/04/2023 |
|  | I                      | EUR      | 43.72      | 27/04/2023 |
|  | R2                     | EUR      | 4.85       | 27/04/2023 |
| Candriam Equities L Global Demography                | C                      | EUR      | 3.63       | 27/04/2023 |
|  | R2                     | EUR      | 3.69       | 27/04/2023 |
| Candriam Equities L Life Care                        | BF                     | USD      | 19.84      | 27/04/2023 |
| Candriam Equities L Oncology Impact                  | BF - EUR - Unhedged    | EUR      | 34.47      | 27/04/2023 |
|  | C                      | USD      | 3.39       | 27/04/2023 |
|  | R                      | USD      | 2.69       | 27/04/2023 |
|  | R2                     | USD      | 3.49       | 27/04/2023 |
|  | R2 - EUR - Hedged      | EUR      | 2.59       | 27/04/2023 |
|  | S - JPY - Asset Hedged | JPY      | 305.41     | 27/04/2023 |
| S - JPY - Unhedged                                   | JPY                    | 330.48   | 27/04/2023 |            |
| Candriam Equities L Robotics & Innovative Technology | BF                     | USD      | 19.84      | 27/04/2023 |
|  | C                      | USD      | 5.16       | 27/04/2023 |
|  | R                      | USD      | 3.88       | 27/04/2023 |

### Note 12 - Swing Pricing

For all the sub-funds of the SICAV, provision has been made for the following measure:

On the valuation days on which the difference between the amount of subscriptions and the amount of redemptions in a sub-fund (that is, the net transactions) exceeds a threshold previously set by the Board of Directors (partial Swing), the Board reserves the right to determine the net asset value by adding to the assets (in the case of net subscriptions) or by deducting from the assets (in the case of net redemptions) a flat-rate percentage of fees and expenses corresponding to market practices in the case of purchases or sales of securities for Candriam Equities L Australia, Candriam Equities L Biotechnology, Candriam Equities L Emerging Markets, Candriam Equities L EMU Innovation, Candriam Equities L Europe Innovation, Candriam Equities L Europe Optimum Quality, Candriam Equities L Global Demography, Candriam Equities L Life Care, Candriam Equities L Oncology Impact, Candriam Equities L Robotics & Innovative Technology and Candriam Equities L Meta Globe.

As at December 31, 2023, no swing was applied.

The swing factor is the amount by which the NAV is swung when the swing pricing process is triggered after net subscriptions or redemptions exceed the swing threshold. The factors to consider when setting the swinging factor include:



## Other notes to the financial statements

### Note 12 - Swing Pricing (Continued)

For equity method:

- Net broker commissions paid by the sub-fund
- Fiscal charges (e.g. stamp duty and sales tax)

| Sub-funds  | Maximum swing factor<br>Inflow rate (in %) | Maximum swing factor<br>Outflow rate (in %) |
|--|--|---|
| Candriam Equities L Australia                        | 0.02                                       | 0.02  |
| Candriam Equities L Biotechnology                    | 0.04                                       | 0.05  |
| Candriam Equities L Emerging Markets                 | 0.06                                       | 0.16  |
| Candriam Equities L EMU Innovation                   | 0.18                                       | 0.04  |
| Candriam Equities L Europe Innovation                | 0.24                                       | 0.04  |
| Candriam Equities L Europe Optimum Quality           | 0.24                                       | 0.04  |
| Candriam Equities L Global Demography                | 0.08                                       | 0.05  |
| Candriam Equities L Life Care                        | 0.07                                       | 0.04  |
| Candriam Equities L Meta Globe                       | 0.03                                       | 0.06  |
| Candriam Equities L Oncology Impact                  | 0.08                                       | 0.04  |
| Candriam Equities L Robotics & Innovative Technology | 0.03                                       | 0.05  |

### Note 13 - Cash at bank and broker

The Cash at bank and broker in the statement of net assets comprises the cash accounts and the cash at broker accounts on future contracts and CFD. The counterparty is J.P. Morgan AG.

The part relating to the cash at broker accounts in Cash at bank and broker included in the statement of net assets as at December 31, 2023 is as follows:

| Sub-funds  | Currency | Cash at broker |
|--|----------|----------------|
| Candriam Equities L Europe Optimum Quality       | EUR      | 14,510,250     |
| Candriam Equities L Risk Arbitrage Opportunities | EUR      | 182,266        |

### Note 14 - Collateral

In relation with the OTC derivative instruments, cash collateral has been received from Barclays Bank PLC - Ireland - LC, Caceis Bank France S.A., Citigroup Global Markets Europe AG - Germany - LC, JP Morgan AG - Germany - LC and UBS Europe SE (Brexit / ongoing) amounting to:

| Sub-funds  | Currency | Cash Collateral Posted | Cash Collateral held |
|--|----------|------------------------|----------------------|
| Candriam Equities L Biotechnology                    | USD      | 0                      | 3,280,000            |
| Candriam Equities L Oncology Impact                  | USD      | 0                      | 6,500,000            |
| Candriam Equities L Risk Arbitrage Opportunities     | EUR      | (3,090,000)            | 0                    |
| Candriam Equities L Robotics & Innovative Technology | USD      | 0                      | 520,000              |

### Note 15 - Changes in portfolio composition

A list including the transactions (sales and purchases) in the investment portfolios is available free of charge at the SICAV's registered office.

### Note 16 - Subsequent events

There is no subsequent event.



Additional unaudited information

**Global Risk Exposure**

As required by the CSSF Circular 11/512, the Board of Directors of the Company must determine the Company risk management method, using either the commitment approach or the VaR approach.

The Board of Directors of the Company has chosen to adopt the commitment approach for all the sub-funds as the method for determining overall risk, except for Candriam Equities L Risk Arbitrage Opportunities.

The Company uses the absolute “Value at Risk” (VaR) approach, the historical method of calculating the aggregate risk of the sub-fund Candriam Equities L Risk Arbitrage Opportunities. The Euro Short Term Rate (€STR) capitalised index is used as the benchmark for the Relative VaR. As an indication, the leverage of this sub-fund is a maximum of 400% of net assets. The sub-fund could, however, be exposed temporarily to a higher leverage.

This approach measures the maximum potential loss for a given confidence threshold (probability) over a specific time period under normal market conditions. These calculations are performed on the basis of the following parameters: a confidence interval of 99%, a holding period of one day (converted into a holding period of 20 days).

The results of the calculation of the relative VaR for the exercise from January 1, 2023 to December 31, 2023 are:

| Sub-fund   | Value at risk 99% (20D) |                |                    |
|--|-------------------------|----------------|--------------------|
|  | Min Var (in %)          | Max var (in %) | Average Var (in %) |
| Candriam Equities L Risk Arbitrage Opportunities | 3.43                    | 9.15           | 6.42               |

The expected leverage of this sub-fund will be a maximum of 400%. This leverage is calculated for each derivative product on the basis of the commitment method and is added to the securities portfolio of the sub-fund. The sub-fund may nevertheless be exposed to higher leverages.

The levels of leverage for the year from January 1, 2023 to December 31, 2023 are:

| Sub-fund   | Average leverage (in %) |
|--|-------------------------|
| Candriam Equities L Risk Arbitrage Opportunities | 94.95                   |



## Additional unaudited information

### Engagement & voting policies, use of voting rights

Candriam exercises voting rights for the considered funds.

For all engagement matters, please refer to the engagement policy and to the associated reports, all available under Candriam website <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>.

### Proxy Voting

Since January 1, 2004, Candriam has decided to actively exercise the voting rights attached to the shares of top-tier European companies that it manages on behalf of its clients. This decision indicates Candriam's determination to assume its responsibilities in the context of corporate governance, and to fully exercise its voting rights in companies in which it invests. The details of the voting are available on the web site <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>.

Non voted meetings result from operational / technical burdens defined in our voting policy (for more details please refer to Candriam voting policy) or others encountered at our third party levels and for which remediation plans have been defined.

The voting rights are exercised for each sub-fund of the SICAV on the basis of its positions in the portfolio except for Candriam Equities L Risk Arbitrage Opportunities for which no voting rights is exercised.

As announced above, details of the voting are available on the web site <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>. All General Assembly Meetings the Management company attended or was represented at are detailed, as well as the voted resolutions, effective votes and associated rationales when votes against management were registered.

Other non voted meetings result from either the defined voting scope itself (for more details please refer to Candriam voting policy) or from delays in reception of needed powers of attorney.

Candriam has formulated and implemented a voting policy based on four principles of corporate governance. Voting decisions are taken in accordance with these principles:

1. Protection of all shareholders' rights in accordance with the "one share – one vote – one dividend" rule.
2. Guaranteed equality of treatment of shareholders, including minority and foreign shareholders.
3. Communication of accurate and transparent financial information.
4. Accountability and independence of the Board of Directors and the external auditors.

As part of its voting decisions, Candriam satisfies itself that it has obtained all the information required for the decision to be taken. Candriam's ESG and financial analysts examine the resolutions presented to the shareholders, taking into account the voting recommendations provided by external corporate governance advisors. Candriam does, however, retain total independence as regards its votes.

This voting policy is available under Candriam website (\*) and notably details:

- The definition of the voting scope,
- How conflict of interest are identified and managed,
- The Role of proxy Advisers.

In addition, a Proxy Voting Committee has been established within Candriam, Its role is to evaluate the voting policy and make changes to it when deemed appropriate.

The Committee consists of internal representatives from the Management, Operations, Risk and ESG Research & Stewardship Teams. Representatives of the Legal department may attend meetings upon request.

For funds with securities lending programs, a minimum of 20% of every position is systematically reserved for voting (except for those which trade in 'share blocking' markets, where the reserved proportion may be smaller).

For more information on the way the management company deals with securities lending activities in the voting period, please refer to our Voting policy under <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>.

(\*) <https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>



## Additional unaudited information

### European directive on shareholders' rights (SRD II) (1)

In accordance with the transparency rules set out in the "Shareholders' Rights" European directive and related to annual disclosures to institutional investors, you can obtain additional information on the investment strategy implemented by Candriam and the contribution of this strategy to the medium to long-term performance of the fund.

You may submit your request to the following address: <https://www.candriam.fr/contact/>.

- (1) *Directive (EU) 2017/828 of the European Parliament and of the Council amending Directive 2007/36/EC as regards the encouragement of long-term shareholder engagement.*

| Sub-Funds  | Portfolio Turnover<br>Rate (in %)* |
|--|------------------------------------|
| Candriam Equities L Australia                        | 2.92                               |
| Candriam Equities L Biotechnology                    | 28.51                              |
| Candriam Equities L Emerging Markets                 | 81.76                              |
| Candriam Equities L EMU Innovation                   | 59.64                              |
| Candriam Equities L Europe Innovation                | 9.25                               |
| Candriam Equities L Europe Optimum Quality           | 59.74                              |
| Candriam Equities L Global Demography                | 160.3                              |
| Candriam Equities L Life Care                        | 123.08                             |
| Candriam Equities L Meta Globe                       | 64.79                              |
| Candriam Equities L Oncology Impact                  | 28.67                              |
| Candriam Equities L Robotics & Innovative Technology | 37.07                              |

\* *Formula used: [(Total purchases + total sales) - (total subscriptions + total redemptions)] / Average of net assets during the year under review*



## Additional unaudited information

### Information concerning the remuneration policy

European Directive 2014/91/EU amending Directive 2009/65/EC on undertakings for collective investment in transferable securities, which is applicable to the SICAV, came into force on 18 March 2016. It is implemented in national law under the Luxembourg Act of 10 May 2016 implementing Directive 2014/91/EU. Due to these new regulations, the SICAV is required to publish information relating to the remuneration of identified employees within the meaning of the Act in the annual report.

Candriam holds a double license, first, as a management company in accordance with section 15 of the Law of December 17, 2010 on undertakings for collective investment and, second, as a manager of alternative investment funds in accordance with the Law of July 12, 2013 relating to alternative investment fund managers. The responsibilities incumbent on Candriam under these two laws are relatively similar and Candriam considers that its personnel is remunerated in the same manner for tasks relating to administration of UCITS and of alternative investment funds.

During its financial year ended on December 31, 2023, Candriam paid the following amounts to its personnel:

- Total gross amount of fixed remunerations paid (excluding payments or benefits that can be considered to be part of a general and nondiscretionary policy and to have no incentive effect on risk management): EUR 17,425,254.
- Total gross amount of variable remunerations paid: EUR 6,348,617.
- Number of beneficiaries: 146.

Aggregate amount of remunerations, broken down between senior management and the members of the personnel of the investment manager whose activities have a significant impact on the funds risk profile. The systems of Candriam do not permit such an identification for each fund under management. The numbers below also show the aggregate amount of overall remunerations at Candriam.

- Aggregate amount of the remunerations of the senior management: EUR 5,155,684.
- Aggregate amount of the remunerations of the members of the personnel of Candriam whose activities have a significant impact on the risk profile of the funds of which it is the management company (excluding senior management): EUR 2,015,066.

Remunerations paid by Candriam to the personnel of its Belgian branch (i.e. Candriam – Belgian Branch), acting as investment manager, during the financial year ended on December 31, 2023:

- Total gross amount of fixed remunerations paid (excluding payments or benefits that can be considered to be part of a general and nondiscretionary policy and to have no incentive effect on risk management): EUR 25,071,403.
- Total gross amount of variable remunerations paid: EUR 8,188,525.
- Number of beneficiaries: 245.

Aggregate amount of remunerations, broken down between senior management and the members of the personnel of the investment manager whose activities have a significant impact on the funds risk profile. The systems of the investment manager do not permit such an identification for each fund under management. The numbers below also show the aggregate amount of overall remunerations at the level of the investment manager.

- Aggregate amount of the remunerations of the senior management: EUR: 6,214,566
- Aggregate amount of the remunerations of the members of the personnel of the investment manager whose activities have a significant impact on the risk profile of the funds of which it is the investment manager (excluding senior management): EUR 4,602,623.

Remunerations paid by Candriam to the personnel of its French branch (i.e. Candriam – Succursale française), acting as investment manager(s), during the financial year ended on December 31, 2023:

- Total gross amount of fixed remunerations paid (excluding payments or benefits that can be considered to be part of a general and nondiscretionary policy and to have no incentive effect on risk management): EUR 19,094,936.
- Total gross amount of variable remunerations paid: EUR 6,255,350.
- Number of beneficiaries: 202.

Aggregate amount of remunerations, broken down between senior management and the members of the personnel of the investment manager whose activities have a significant impact on the funds risk profile. The systems of the investment manager do not permit such an identification for each fund under management. The numbers below also show the aggregate amount of overall remunerations at the level of the investment manager.

- Aggregate amount of the remunerations of the senior management: EUR 4,298,365.
- Aggregate amount of the remunerations of the members of the personnel of the investment manager whose activities have a significant impact on the risk profile of the funds of which it is the investment manager (excluding senior management): EUR 3,422,966.

The remuneration policy was last reviewed by the remuneration committee of Candriam on January 29, 2021 and was adopted by the Board of Directors of Candriam



## Additional unaudited information

### Transparency of Securities Financing Transactions of Reuse and amending Regulation (SFTR) (EU) N°648/2012

#### a) Global data

With respect to securities lending transactions and total return swaps, the total market value of securities on loan at December 31, 2023 is as follows

- Securities lending**

| Sub-fund                                   | Currency | Market value (in absolute terms) | % of total lendable assets | % total net asset value |
|--|----------|----------------------------------|----------------------------|-------------------------|
| Candriam Equities L Biotechnology          | USD      | 61,253,469                       | 4.06                       | 3.86                    |
| Candriam Equities L Europe Innovation      | EUR      | 60,058,985                       | 6.94                       | 6.68                    |
| Candriam Equities L Europe Optimum Quality | EUR      | 43,788,706                       | 8.04                       | 7.75                    |
| Candriam Equities L Life Care              | USD      | 152,972                          | 0.02                       | 0.02                    |

- Reverse repurchase agreement**

| Sub-fund   | Currency | Market value (in absolute terms) | % total net asset value |
|--|----------|----------------------------------|-------------------------|
| Candriam Equities L Risk Arbitrage Opportunities | EUR      | 21,100,086                       | 42.51                   |

#### b) Concentration data

- Securities lending**

The 10 largest counterparties across all securities lending transactions as at December 31, 2023 are as follows:

##### Candriam Equities L Biotechnology

| Counterparty | Gross volumes for open trades |
|--------------|-------------------------------|
| BP2S         | 51,699,314                    |
| NATIXIS      | 5,175,315                     |
| UBS EQUITIES | 4,158,479                     |
| BARC EQTY    | 220,227                       |
| BNPSASS      | 134                           |

##### Candriam Equities L Europe Innovation

| Counterparty              | Gross volumes for open trades |
|---------------------------|-------------------------------|
| BARC EQTY                 | 40,080,161                    |
| BNPSASS                   | 8,596,194                     |
| BP2S                      | 7,571,182                     |
| UBS EQUITIES              | 2,604,168                     |
| SOCIETE GENERALE EQUITIES | 1,095,499                     |
| NATIXIS                   | 111,780                       |

##### Candriam Equities L Europe Optimum Quality

| Counterparty              | Gross volumes for open trades |
|---------------------------|-------------------------------|
| BNPSASS                   | 22,349,866                    |
| BARC EQTY                 | 11,231,352                    |
| SOCIETE GENERALE EQUITIES | 6,312,168                     |
| UBS EQUITIES              | 1,632,960                     |
| BANK OF NOVA SCOTIA       | 1,270,080                     |
| MORGAN STANLEY EUROPE SE  | 665,280                       |
| BP2S                      | 327,000                       |

##### Candriam Equities L Life Care

| Counterparty | Gross volumes for open trades |
|--------------|-------------------------------|
| UBS EQUITIES | 152,972                       |



Additional unaudited information

Transparency of Securities Financing Transactions of Reuse and amending Regulation (SFTR) (EU) N°648/2012 (Continued)

The 10 largest issuers of collateral received from securities lending activities as at December 31, 2023 are as follows:

**Candriam Equities L Biotechnology**

| Counterparty       | Gross volumes for open trades |
|--------------------|-------------------------------|
| TELE SE 5.75 11-31 | 10,476,848                    |
| BARC 3.375 04-25   | 6,990,539                     |
| LYFT INC-A         | 5,169,929                     |
| INTERACTIVE BROK   | 5,169,928                     |
| ALCOA CORP         | 5,169,927                     |
| ANTERO RESOURCES   | 5,169,911                     |
| WAYFAIR INC- A     | 5,169,880                     |
| WORKDAY INC-A      | 5,169,697                     |
| MERCADOLIBRE INC   | 5,169,262                     |
| TOLL BROTHERS      | 1,958,421                     |

**Candriam Equities L Europe Innovation**

| Counterparty        | Gross volumes for open trades |
|---------------------|-------------------------------|
| NEW SOU 2.0 03-33   | 13,713,816                    |
| AUST GO 0.25 11-24  | 5,740,458                     |
| HERMES INTL         | 3,629,760                     |
| ROSS STORES INC     | 3,628,664                     |
| MEDTRONIC PLC       | 3,392,158                     |
| ENEL SPA            | 3,281,802                     |
| ABN AMR 6.339 09-27 | 2,944,018                     |
| ING GRO 3.0 02-26   | 2,601,012                     |
| UNILEVER PLC        | 2,215,164                     |
| BANK NY MELLON      | 1,784,377                     |

**Candriam Equities L Europe Optimum Quality**

| Counterparty        | Gross volumes for open trades |
|---------------------|-------------------------------|
| ABN AMR 6.339 09-27 | 7,761,503                     |
| NOUV 2.75 04-25     | 3,930,859                     |
| TREA CO 2.0 09-35   | 3,930,639                     |
| UBS GROUP AG        | 2,866,188                     |
| UNICREDIT SPA       | 2,866,181                     |
| AENA SME SA         | 2,866,047                     |
| IBERDROLA SA        | 2,770,419                     |
| MEDTRONIC PLC       | 2,234,967                     |
| AMADEUS IT GROUP    | 2,234,953                     |
| INTESA SANPAOLO     | 1,214,655                     |

**Candriam Equities L Life Care**

| Counterparty     | Gross volumes for open trades |
|------------------|-------------------------------|
| SMART METERING S | 15,292                        |
| STOLT-NIELSEN    | 15,289                        |
| LAGERCRANTZ-B SH | 15,288                        |
| BW LPG LTD       | 15,286                        |
| LIGHTSPEED COMME | 15,286                        |
| VICAT            | 15,269                        |
| SOMPO HOLDINGS I | 15,269                        |
| NASDAQ INC       | 15,248                        |
| WALMART INC      | 15,230                        |
| DEME GROUP       | 15,189                        |

• **Reverse repurchase agreement**

The 10 largest counterparties across all reverse repurchase agreements as at December 31, 2023 are as follows:

**Candriam Equities L Risk Arbitrage Opportunities**

| Counterparty             | Concentration data for open trades |
|--------------------------|------------------------------------|
| Caceis Bank, Lux. Branch | 21,100,086                         |

The 10 largest issuers of collateral received from reverse repurchase agreements activities as at December 31, 2023 are as follows:





## Additional unaudited information

### Transparency of Securities Financing Transactions of Reuse and amending Regulation (SFTR) (EU) N°648/2012 (Continued)

#### Candriam Equities L Risk Arbitrage Opportunities

| Counterparty             | Total amount of collateral |
|--------------------------|----------------------------|
| Caceis Bank, Lux. Branch | 21,100,086                 |

There is no reuse of collateral related to Total Return Swaps transactions.

#### c) Safekeeping of collateral received

Each sub-fund has CACEIS Bank, Luxembourg Branch as depositary for collateral received. There is no reuse of collateral related to securities lending transactions.

- Securities lending

| Sub-Funds                                  | Currency | Cash | Bonds      | Equity     | Total amount of collateral |
|--|----------|------|------------|------------|----------------------------|
| Candriam Equities L Biotechnology          | USD      | 0    | 20,058,725 | 50,983,568 | 71,042,293                 |
| Candriam Equities L Europe Innovation      | EUR      | 0    | 26,586,266 | 34,642,934 | 61,229,200                 |
| Candriam Equities L Europe Optimum Quality | EUR      | 0    | 17,628,873 | 26,430,596 | 44,059,469                 |
| Candriam Equities L Life Care              | USD      | 0    | 0          | 153,063    | 153,063                    |

#### d) Aggregate transaction data

The maturity tenor of the collateral related to SFTs are the following

- Securities lending

| Sub-funds                                  | Currency | From 1 month to 3 months | From 3 months to 1 year | More than 1 year | Open maturity | Total amount of collateral |
|--|----------|--------------------------|-------------------------|------------------|---------------|----------------------------|
| Candriam Equities L Biotechnology          | USD      | 0                        | 0                       | 20,058,824       | 50,983,568    | 71,042,392                 |
| Candriam Equities L Europe Innovation      | EUR      | 0                        | 0                       | 26,586,266       | 34,642,934    | 61,229,200                 |
| Candriam Equities L Europe Optimum Quality | EUR      | 0                        | 0                       | 17,628,873       | 26,430,596    | 44,059,468                 |
| Candriam Equities L Life Care              | USD      | 0                        | 0                       | 2                | 153,063       | 153,065                    |

- Reverse repurchase agreement

| Sub-funds  | Currency | From 1 month to 3 months | From 3 months to 1 year | More than 1 year | Open maturity | Total amount of collateral |
|--|----------|--------------------------|-------------------------|------------------|---------------|----------------------------|
| Candriam Equities L Risk Arbitrage Opportunities | EUR      | 0                        | 3,591,000               | 17,509,086       | 0             | 21,100,086                 |



## Additional unaudited information

### **Sustainable Finance Disclosure Regulation (SFDR)**

#### **Candriam Equities L Australia, Candriam Equities L Risk Arbitrage Opportunities:**

The above-mentioned sub-funds are classified as article 6 under SFDR.

They do not integrate systematically ESG characteristics in the management framework. Nevertheless, sustainability risks are taken into account in investment decisions by Candriam exclusion Policy which exclude some controversial activities.

### **Taxonomy (Article 6)**

The investments underlying of this financial product do not take into account the EU criteria for environmentally sustainable economic activities and as such the sub-fund should not publish information on alignment with the Taxonomy.

## Environmental and/or social characteristics

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 91.85% of sustainable investments
  - with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### ● How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name  | Portfolio | Benchmark | New indicator |
|--|-----------|-----------|---------------|
| SDGs - Corporate (fund level) - Higher than absolute threshold | 6.80      |           | X             |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 92.69%                    | 90.32%                    |
| #2 Other                            | 7.31%                     | 9.67%                     |
| #1A Sustainable                     | 91.85%                    | 90.00%                    |
| #1B Other E/S characteristics       | 0.84%                     | 0.32%                     |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 0.82%                     | 0.00%                     |
| Social                              | 91.04%                    | 90.00%                    |

## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

### ***How were the indicators for adverse impacts on sustainability factors taken into account?***

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

### ***Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:***

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions. ,

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 106 meetings: for 96.23 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 3 of which we supported 100 %.

In addition, and for any voted director-election items (462 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 25 resolutions were filed by shareholders and we supported 32 % of them.

More specifically 1 were Human Rights, Climate or Diversity & Inclusion related: we supported 100 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 86 financial product's issuers targeted, 25.58% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 31 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 22 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI10

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations

Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 1" company exclusion policy, companies that have committed the most serious violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

**PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|-------|-----------------------------------|--|
| 3 - GHG intensity of investee companies   | 25.47 | 91.14%                            | 96.97%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00% | 96.76%                            | 96.98%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00% | 96.90%                            | 96.98%   |





## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments           | Sector                             | % of Assets | Country |
|-------------------------------|------------------------------------|-------------|---------|
| VERTEX PHARMACEUTICALS INC    | Biotechnology                      | 7.02%       | USA     |
| REGENERON PHARMACEUTICALS INC | Biotechnology                      | 6.76%       | USA     |
| GILEAD SCIENCES INC           | Biotechnology                      | 6.05%       | USA     |
| AMGEN INC                     | Pharmaceuticals                    | 5.99%       | USA     |
| BIOGEN IDEC INC               | Pharmaceuticals                    | 3.62%       | USA     |
| ALNYLAM PHARMACEUTICALS INC   | Pharmaceuticals                    | 3.41%       | USA     |
| ASTRAZENECA PLC               | Pharmaceuticals                    | 3.03%       | GBR     |
| SEAGEN INC                    | Biotechnology                      | 3.00%       | USA     |
| MODERNA INC                   | Biotechnology                      | 2.65%       | USA     |
| NEUROCRINE BIOSCIENCES        | Biotechnology                      | 2.14%       | USA     |
| BIOMARIN PHARMACEUTICAL INC   | Biotechnology                      | 1.86%       | USA     |
| SANOFI                        | Pharmaceuticals                    | 1.63%       | FRA     |
| DANAHER CORP                  | Machine and apparatus construction | 1.58%       | USA     |
| GENMAB AS                     | Biotechnology                      | 1.57%       | DNK     |
| THERMO FISHER SCIENT SHS      | Electronics and semiconductors     | 1.55%       | USA     |


*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



● **In which economic sectors were the investments made?**

| <b>Top sector</b>                      | <b>% of Assets</b> |
|--|--------------------|
| Biotechnology                          | 50.10%             |
| Pharmaceuticals                        | 40.99%             |
| Banks and other financial institutions | 4.76%              |
| Machine and apparatus construction     | 1.58%              |
| Electronics and semiconductors         | 1.55%              |
| Miscellaneous services                 | 0.61%              |
| Healthcare                             | 0.42%              |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

**Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>**

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

 **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 0.82% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**

The Sub-fund had a share of investments with a social objective of 91.04%

 **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 7.31% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.

 **What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve an average financial product SDG score higher than an absolute threshold (> 5).

Over the period, the financial product displays an average score of 6.8.

The financial product has achieved its objective by allocating a higher proportion of investments in issuers with stronger SDG scores.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Environmental and/or social characteristics

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 67.39% of sustainable investments
- with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 10%). The proportion of sustainable investments in the Fund

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 47.52     | 168.60    |               |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 2022 | 25.41     | 167.82    |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 93.18%                    | 94.02%                    |
| #2 Other                            | 6.82%                     | 6.08%                     |
| #1A Sustainable                     | 67.39%                    | 73.05%                    |
| #1B Other E/S characteristics       | 25.79%                    | 20.97%                    |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 24.66%                    | 23.27%                    |
| Social                              | 42.73%                    | 49.78%                    |



## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 10%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

### ***How were the indicators for adverse impacts on sustainability factors taken into account?***

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

### ***Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:***

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions. ,

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 187 meetings: for 57.75 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 1 of which we supported 0 %.

In addition, and for any voted director-election items (376 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 35 resolutions were filed by shareholders and we supported 74.29 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

1 issuers in the financial product are actually part of the priority targets of Candriam Net Zero Engagement campaign.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 95 financial product's issuers targeted, 58.95% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. Such initiatives targeted 5 issuer(s) of the financial product. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 64 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 37 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI10

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations

Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 1" company exclusion policy, companies that have committed the most serious violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

**PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value  | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|--------|-----------------------------------|--|
| 2 - Carbon Footprint  | 47.52  | 96.33%                            | 97.91%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 7.10%* | 97.78%                            | 97.91%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00%  | 97.87%                            | 97.91%   |

\* The fund has complied with the exclusion policy in accordance with the prospectus. The companies included in the figures of PAI 10 do not present both significant and severe structural risks and that are not the most seriously in breach of the normative principles, taking account of their practices with regard to environmental and social issues and of adherence to norms such as the UN Global Compact and the OECD Guidelines for Multinational Enterprises.



## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments                | Sector                                 | % of Assets | Country |
|------------------------------------|--|-------------|---------|
| TAIWAN SEMICONDUCTOR CO            | Electronics and semiconductors         | 8.09%       | TWN     |
| TENCENT HOLDINGS LTD               | Internet and internet services         | 3.77%       | CYM     |
| ALIBABA GROUP                      | Internet and internet services         | 3.18%       | CYM     |
| SAMSUNG ELECTRONICS CO LTD         | Electronics and semiconductors         | 2.56%       | KOR     |
| RELIANCE INDUSTRIES DEMATERIALIZED | Chemicals                              | 2.13%       | IND     |
| SK HYNIX INC                       | Electronics and semiconductors         | 2.10%       | KOR     |
| PING AN INS (GRP) CO -H-           | Insurance                              | 1.80%       | CHN     |
| AXIS BANK                          | Banks and other financial institutions | 1.63%       | IND     |
| BHARTI AIRTEL LTD(DEMATIALIZED)    | Communication                          | 1.57%       | IND     |
| GRUPO FINANCIERO BANORTE -O-       | Banks and other financial institutions | 1.43%       | MEX     |
| LG CHEM                            | Chemicals                              | 1.36%       | KOR     |
| MEITUAN - SHS 114A/REG S           | Internet and internet services         | 1.35%       | CYM     |
| AMERICA MOVIL SAB DE CV            | Communication                          | 1.35%       | MEX     |
| BANK OF JIANGSU CO LTD             | Banks and other financial institutions | 1.34%       | CHN     |
| ACCTON TECHNOLOGY CORPORATION      | Office supplies and computing          | 1.27%       | TWN     |


Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



**#1 Aligned with E/S characteristics** includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

**#2 Other** includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● **In which economic sectors were the investments made?**

| <b>Top sector</b>                          | <b>% of Assets</b> |
|--|--------------------|
| Banks and other financial institutions     | 21.63%             |
| Electronics and semiconductors             | 16.09%             |
| Internet and internet services             | 14.28%             |
| Foods and non alcoholic drinks             | 4.91%              |
| Electrical engineering                     | 4.41%              |
| Chemicals                                  | 3.56%              |
| Machine and apparatus construction         | 3.22%              |
| Pharmaceuticals                            | 3.18%              |
| Road vehicles                              | 3.10%              |
| Communication                              | 3.04%              |
| Insurance                                  | 2.65%              |
| Coal mining and steel industry & Chemicals | 2.48%              |
| Petroleum                                  | 2.19%              |
| Office supplies and computing              | 1.95%              |
| Retail trade and department stores         | 1.61%              |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

**Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>**

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.



● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as null.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

 **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 24.66% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**

The Sub-fund had a share of investments with a social objective of 42.73%

 **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 6.82% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.



**What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve a carbon footprint that is lower than the Benchmark.

Over the reference period, the financial product emitted 47.52 Tons CO<sub>2</sub>eq per million € invested, 71.82% lower than the benchmark.

The financial product has achieved its objective by favouring issuers with lower carbon footprint. More precisely, the financial product divested from 1 issuer(s) in Steel with deteriorating carbon footprint.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Environmental and/or social characteristics

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 93.11% of sustainable investments
  - with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 17.43     | 87.43     |               |
| ESG Score - Corporate - Higher than bench                   | 59.74     | 53.23     |               |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 2022 | 22.20     | 94.48     |
| ESG Score - Corporate - Higher than bench                   | 2022 | 60.16     | 53.34     |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 93.11%                    | 97.09%                    |
| #2 Other                            | 6.89%                     | 2.91%                     |
| #1A Sustainable                     | 93.11%                    | 97.09%                    |
| #1B Other E/S characteristics       | 0.00%                     | 0.00%                     |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 29.48%                    | 34.67%                    |
| Social                              | 63.62%                    | 62.41%                    |

## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

### ***How were the indicators for adverse impacts on sustainability factors taken into account?***

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

### ***Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:***

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions.

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 37 meetings: for 97.3 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 3 of which we supported 100 %.

More specifically, 1 proposals were related to climate (100 % support).

In addition, and for any voted director-election items (116 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 4 resolutions were filed by shareholders and we supported 75 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

4 issuers in the financial product are actually part of the priority targets of Candriam Net Zero Engagement campaign.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 31 financial product's issuers targeted, 96.77% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. Such initiatives targeted 1 issuer(s) of the financial product. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 23 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 24 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI3

In addition to companies involved in the thermal coal, oil and gas activities (PAI 4), electricity-generating companies with a carbon intensity greater than 354 gCO<sub>2</sub>/kWh (PAI 3), are considered risky for inclusion in sustainable investments, even if they are not universally controversial. Given that emissions vary according to electricity generation sources, it is important to assess the carbon footprint per kilowatt-hour (kWh) to determine how closely companies are aligned with the 2 degrees Celsius trajectory.

This is why Candriam includes the carbon intensity of energy producers in our sustainability assessment. Where carbon intensity data is not available, Candriam's ESG analysts use other indicators to assess alignment with the Paris Agreement, such as progress in the energy transition in line with Paris Agreement targets and integration of a 1.5D limit scenario, taking into account investment plans and the credibility of carbon neutrality targets. These indicators are forward-looking and evolve over time to reflect the progress made by companies in their transition.

The carbon intensity (PAI 3) threshold for the product in 2023 was established at 354 gCO<sub>2</sub>/kWh. Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding this threshold, in addition to those previously excluded.

#### **PAI4**

Exposure to fossil fuels (PAI 4) undergoes stringent exclusions across all Candriam sustainable funds. Thermal coal, recognized for its detrimental impact and serious financial and sustainability implications, poses systemic and reputational risks that financial benefits cannot outweigh.

Companies deriving more than 5% of their sales from coal mining, coal-fired power generation, and coal-related operations such as exploration, processing, transport, and distribution are automatically excluded.

Additionally, companies exceeding a 5% threshold of revenue from conventional oil and gas activities, including exploration, extraction, refining, and transportation, are ineligible for investment. Similarly, entities with over 5% exposure to unconventional oil and gas activities are also excluded.

Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding the 5% threshold of exposure to thermal coal activities, supplementing the previously excluded entities.

Furthermore, no additional issuer(s) lost their eligibility due to surpassing the 5% threshold of exposure to conventional oil and gas activities, while no additional issuer(s) lost their eligibility for exceeding the 5% threshold of exposure to unconventional oil and gas activities.

#### **PAI10**

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 3" SRI exclusion policy, companies with severe to very severe violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

#### **PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value  | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|--------|-----------------------------------|--|
| Scope 1 GHG Emissions   | 476.46 | 93.10%                            | 93.10%   |
| Scope 2 GHG Emissions   | 321.21 | 93.10%                            | 93.10%   |
| Total GHG Emissions   | 797.67 | 93.10%                            | 93.10%   |
| 2 - Carbon Footprint  | 17.43  | 93.10%                            | 93.10%   |
| 3 - GHG intensity of investee companies   | 47.25  | 93.10%                            | 93.10%   |
| 4 - Exposure to companies active in fossil fuel sector  | 0.00%  | 90.55%                            | 93.09%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00%  | 93.10%                            | 93.10%   |
| 13 - Board gender diversity   | 40.05% | 91.83%                            | 93.09%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00%  | 93.10%                            | 93.10%   |





## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments      | Sector                                 | % of Assets | Country |
|--------------------------|--|-------------|---------|
| FINECOBANK               | Banks and other financial institutions | 4.98%       | ITA     |
| DASSAULT SYST.           | Internet and internet services         | 4.89%       | FRA     |
| KERRY GROUP -A-          | Foods and non alcoholic drinks         | 4.83%       | IRL     |
| CARL ZEISS MEDITEC AG    | Pharmaceuticals                        | 4.77%       | DEU     |
| BIOMERIEUX SA            | Pharmaceuticals                        | 4.73%       | FRA     |
| SCHNEIDER ELECTRIC SE    | Electrical engineering                 | 4.61%       | FRA     |
| ASML HOLDING NV          | Electronics and semiconductors         | 4.10%       | NLD     |
| INDITEX SHARE FROM SPLIT | Retail trade and department stores     | 4.02%       | ESP     |
| BEIERSDORF AG            | Pharmaceuticals                        | 3.90%       | DEU     |
| SYMRISE AG               | Chemicals                              | 3.66%       | DEU     |
| SANOFI                   | Pharmaceuticals                        | 3.57%       | FRA     |
| DSM FIRMENICH            | Banks and other financial institutions | 3.41%       | CHE     |
| SIEMENS HEALTHINEERS     | Pharmaceuticals                        | 3.30%       | DEU     |
| KINGSPAN GROUP           | Building materials                     | 3.25%       | IRL     |
| L'OREAL SA               | Pharmaceuticals                        | 3.17%       | FRA     |


Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



**#1 Aligned with E/S characteristics** includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

**#2 Other** includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● **In which economic sectors were the investments made?**

| Top sector                             | % of Assets |
|--|-------------|
| Pharmaceuticals                        | 25.52%      |
| Banks and other financial institutions | 21.64%      |
| Internet and internet services         | 9.53%       |
| Electrical engineering                 | 9.18%       |
| Machine and apparatus construction     | 6.57%       |
| Electronics and semiconductors         | 5.67%       |
| Chemicals                              | 5.61%       |
| Foods and non alcoholic drinks         | 5.34%       |
| Retail trade and department stores     | 4.02%       |
| Building materials                     | 3.25%       |
| Real estate                            | 1.74%       |
| Biotechnology                          | 1.53%       |
| Miscellaneous services                 | 0.38%       |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

**Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>**

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

 **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 29.48% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**


The Sub-fund had a share of investments with a social objective of 63.62%

 **What investments were included under "other", what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 6.89% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.

 **What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve a carbon footprint that is lower than the Benchmark.

Over the reference period, the financial product emitted 17.43 Tons CO2eq per million € invested, 80.07% lower than the benchmark.

Compared to the previous year, the financial product's carbon footprint has decreased by 21.5%.

The financial product has achieved its objective by favouring issuers with lower carbon footprint.

The financial product aims to achieve an ESG score, based on Candriam's proprietary ESG methodology, higher than its benchmark.

Over the reference period, the financial product displayed an ESG score of 59.74, 12.23% higher compared to its benchmark.

The financial product has achieved its objective by selectively favouring issuers that display a stronger ESG profile. The financial product invested in 1 issuer(s) in Specialty Chemicals with improving ESG profiles.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Environmental and/or social characteristics

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 94.03% of sustainable investments
  - with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund

**Sustainability indicators** measure how the environmental or social characteristics promoted by the financial product are attained.

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 14.42     | 76.15     |               |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 2022 | 17.07     | 77.43     |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 94.03%                    | 98.35%                    |
| #2 Other                            | 5.97%                     | 1.65%                     |
| #1A Sustainable                     | 94.03%                    | 98.35%                    |
| #1B Other E/S characteristics       | 0.00%                     | 0.00%                     |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 29.86%                    | 31.73%                    |
| Social                              | 64.18%                    | 66.62%                    |



## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

## **How were the indicators for adverse impacts on sustainability factors taken into account?**

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

## **Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:**

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions. ,

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 51 meetings: for 98.04 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 9 of which we supported 100 %.

More specifically, 1 proposals were related to climate (100 % support).

In addition, and for any voted director-election items (262 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 4 resolutions were filed by shareholders and we supported 75 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

6 issuers in the financial product are actually part of the priority targets of Candriam Net Zero Engagement campaign.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 44 financial product's issuers targeted, 93.18% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. Such initiatives targeted 1 issuer(s) of the financial product. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 34 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 35 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI3

In addition to companies involved in the thermal coal, oil and gas activities (PAI 4), electricity-generating companies with a carbon intensity greater than 354 gCO<sub>2</sub>/kWh (PAI 3), are considered risky for inclusion in sustainable investments, even if they are not universally controversial. Given that emissions vary according to electricity generation sources, it is important to assess the carbon footprint per kilowatt-hour (kWh) to determine how closely companies are aligned with the 2 degrees Celsius trajectory.

This is why Candriam includes the carbon intensity of energy producers in our sustainability assessment. Where carbon intensity data is not available, Candriam's ESG analysts use other indicators to assess alignment with the Paris Agreement, such as progress in the energy transition in line with Paris Agreement targets and integration of a 1.5D limit scenario, taking into account investment plans and the credibility of carbon neutrality targets. These indicators are forward-looking and evolve over time to reflect the progress made by companies in their transition.

The carbon intensity (PAI 3) threshold for the product in 2023 was established at 354 gCO<sub>2</sub>/kWh. Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding this threshold, in addition to those previously excluded.

#### **PAI4**

Exposure to fossil fuels (PAI 4) undergoes stringent exclusions across all Candriam sustainable funds. Thermal coal, recognized for its detrimental impact and serious financial and sustainability implications, poses systemic and reputational risks that financial benefits cannot outweigh.

Companies deriving more than 5% of their sales from coal mining, coal-fired power generation, and coal-related operations such as exploration, processing, transport, and distribution are automatically excluded.

Additionally, companies exceeding a 5% threshold of revenue from conventional oil and gas activities, including exploration, extraction, refining, and transportation, are ineligible for investment. Similarly, entities with over 5% exposure to unconventional oil and gas activities are also excluded.

Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding the 5% threshold of exposure to thermal coal activities, supplementing the previously excluded entities.

Furthermore, no additional issuer(s) lost their eligibility due to surpassing the 5% threshold of exposure to conventional oil and gas activities, while no additional issuer(s) lost their eligibility for exceeding the 5% threshold of exposure to unconventional oil and gas activities.

#### **PAI10**

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 3" SRI exclusion policy, companies with severe to very severe violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

#### **PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value     | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|-----------|-----------------------------------|--|
| Scope 1 GHG Emissions   | 8,770.12  | 94.03%                            | 94.03%   |
| Scope 2 GHG Emissions   | 6,688.34  | 94.03%                            | 94.03%   |
| Total GHG Emissions   | 15,458.46 | 94.03%                            | 94.03%   |
| 2 - Carbon Footprint  | 14.42     | 94.03%                            | 94.03%   |
| 3 - GHG intensity of investee companies   | 41.54     | 94.03%                            | 94.03%   |
| 4 - Exposure to companies active in fossil fuel sector  | 0.38%     | 92.14%                            | 94.04%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00%     | 94.03%                            | 94.03%   |
| 13 - Board gender diversity   | 40.61%    | 92.96%                            | 94.06%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00%     | 94.03%                            | 94.03%   |



## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments          | Sector                                 | % of Assets | Country |
|------------------------------|--|-------------|---------|
| BIOMERIEUX SA                | Pharmaceuticals                        | 4.38%       | FRA     |
| HEXAGON - REG SHS -B-        | Machine and apparatus construction     | 4.19%       | SWE     |
| DASSAULT SYST.               | Internet and internet services         | 4.14%       | FRA     |
| NESTLE SA PREFERENTIAL SHARE | Foods and non alcoholic drinks         | 4.08%       | CHE     |
| KERRY GROUP -A-              | Foods and non alcoholic drinks         | 4.00%       | IRL     |
| HALMA PLC                    | Electronics and semiconductors         | 3.87%       | GBR     |
| SCHNEIDER ELECTRIC SE        | Electrical engineering                 | 3.37%       | FRA     |
| FINECOBANK                   | Banks and other financial institutions | 3.24%       | ITA     |
| SPIRAX-SARCO ENGIN           | Machine and apparatus construction     | 3.17%       | GBR     |
| TECAN GROUP NAM.AKT          | Pharmaceuticals                        | 3.09%       | CHE     |
| TOMRA SYSTEMS ASA            | Machine and apparatus construction     | 2.93%       | NOR     |
| CARL ZEISS MEDITEC AG        | Pharmaceuticals                        | 2.91%       | DEU     |
| SYMRISE AG                   | Chemicals                              | 2.64%       | DEU     |
| DSM FIRMENICH                | Banks and other financial institutions | 2.57%       | CHE     |
| ASML HOLDING NV              | Electronics and semiconductors         | 2.56%       | NLD     |


Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



● **In which economic sectors were the investments made?**

| Top sector                             | % of Assets |
|--|-------------|
| Pharmaceuticals                        | 22.70%      |
| Machine and apparatus construction     | 14.29%      |
| Banks and other financial institutions | 14.00%      |
| Foods and non alcoholic drinks         | 8.55%       |
| Internet and internet services         | 7.33%       |
| Electronics and semiconductors         | 7.19%       |
| Chemicals                              | 6.15%       |
| Electrical engineering                 | 4.86%       |
| Biotechnology                          | 2.83%       |
| Miscellaneous consumer goods           | 2.73%       |
| Building materials                     | 2.03%       |
| Retail trade and department stores     | 1.94%       |
| Insurance                              | 1.71%       |
| Precious metals and stones             | 1.33%       |
| Miscellaneous services                 | 1.08%       |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

### Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.



● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

 **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 29.86% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**


The Sub-fund had a share of investments with a social objective of 64.18%

 **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 5.97% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.

 **What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve a carbon footprint that is lower than the Benchmark.

Over the reference period, the financial product emitted 14.42 Tons CO2eq per million € invested, 81.06% lower than the benchmark.

Compared to the previous year, the financial product's carbon footprint has decreased by 15.53%.

The financial product has achieved its objective by favouring issuers with lower carbon footprint.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Environmental and/or social characteristics

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 95.34% of sustainable investments
  - with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- achieving a lower carbon footprint than the benchmark
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 20.67     | 76.15     |               |
| ESG Score - Corporate - Higher than bench                   | 59.31     | 53.67     |               |

### ● ... And compared to previous periods?

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 2022 | 27.07     | 77.43     |
| ESG Score - Corporate - Higher than bench                   | 2022 | 59.98     | 53.65     |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 95.55%                    | 95.05%                    |
| #2 Other                            | 4.45%                     | 4.42%                     |
| #1A Sustainable                     | 95.34%                    | 92.08%                    |
| #1B Other E/S characteristics       | 0.21%                     | 2.97%                     |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 30.76%                    | 30.58%                    |
| Social                              | 64.58%                    | 61.49%                    |

## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its exclusive ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

## **How were the indicators for adverse impacts on sustainability factors taken into account?**

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

## **Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:**

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions. ,

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 57 meetings: for 98.25 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 15 of which we supported 100 %.

More specifically, 1 proposals were related to climate (100 % support).

In addition, and for any voted director-election items (329 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 4 resolutions were filed by shareholders and we supported 75 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

8 issuers in the financial product are actually part of the priority targets of Candriam Net Zero Engagement campaign.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 56 financial product's issuers targeted, 96.43% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. Such initiatives targeted 4 issuer(s) of the financial product. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 37 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 41 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI3

In addition to companies involved in the thermal coal, oil and gas activities (PAI 4), electricity-generating companies with a carbon intensity greater than 354 gCO<sub>2</sub>/kWh (PAI 3), are considered risky for inclusion in sustainable investments, even if they are not universally controversial. Given that emissions vary according to electricity generation sources, it is important to assess the carbon footprint per kilowatt-hour (kWh) to determine how closely companies are aligned with the 2 degrees Celsius trajectory.

This is why Candriam includes the carbon intensity of energy producers in our sustainability assessment. Where carbon intensity data is not available, Candriam's ESG analysts use other indicators to assess alignment with the Paris Agreement, such as progress in the energy transition in line with Paris Agreement targets and integration of a 1.5D limit scenario, taking into account investment plans and the credibility of carbon neutrality targets. These indicators are forward-looking and evolve over time to reflect the progress made by companies in their transition.

The carbon intensity (PAI 3) threshold for the product in 2023 was established at 354 gCO<sub>2</sub>/kWh. Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding this threshold, in addition to those previously excluded.

#### **PAI4**

Exposure to fossil fuels (PAI 4) undergoes stringent exclusions across all Candriam sustainable funds. Thermal coal, recognized for its detrimental impact and serious financial and sustainability implications, poses systemic and reputational risks that financial benefits cannot outweigh.

Companies deriving more than 5% of their sales from coal mining, coal-fired power generation, and coal-related operations such as exploration, processing, transport, and distribution are automatically excluded.

Additionally, companies exceeding a 5% threshold of revenue from conventional oil and gas activities, including exploration, extraction, refining, and transportation, are ineligible for investment. Similarly, entities with over 5% exposure to unconventional oil and gas activities are also excluded.

Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding the 5% threshold of exposure to thermal coal activities, supplementing the previously excluded entities.

Furthermore, no additional issuer(s) lost their eligibility due to surpassing the 5% threshold of exposure to conventional oil and gas activities, while no additional issuer(s) lost their eligibility for exceeding the 5% threshold of exposure to unconventional oil and gas activities.

#### **PAI10**

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 3" SRI exclusion policy, companies with severe to very severe violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

#### **PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value     | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|-----------|-----------------------------------|--|
| Scope 1 GHG Emissions   | 7,076.81  | 95.56%                            | 95.56%   |
| Scope 2 GHG Emissions   | 5,076.29  | 95.56%                            | 95.56%   |
| Total GHG Emissions   | 12,153.10 | 95.56%                            | 95.56%   |
| 2 - Carbon Footprint  | 20.67     | 95.56%                            | 95.56%   |
| 3 - GHG intensity of investee companies   | 68.50     | 95.56%                            | 95.56%   |
| 4 - Exposure to companies active in fossil fuel sector  | 0.49%     | 93.88%                            | 95.56%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00%     | 95.56%                            | 95.56%   |
| 13 - Board gender diversity   | 40.17%    | 93.57%                            | 95.56%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00%     | 95.56%                            | 95.56%   |





## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments          | Sector                                 | % of Assets | Country |
|------------------------------|--|-------------|---------|
| RECKITT BENCKISER GROUP PLC  | Miscellaneous consumer goods           | 3.34%       | GBR     |
| BEIERSDORF AG                | Pharmaceuticals                        | 3.34%       | DEU     |
| KERRY GROUP -A-              | Foods and non alcoholic drinks         | 3.21%       | IRL     |
| UNILEVER                     | Foods and non alcoholic drinks         | 3.19%       | GBR     |
| NESTLE SA PREFERENTIAL SHARE | Foods and non alcoholic drinks         | 3.16%       | CHE     |
| BUREAU VERITAS SA            | Miscellaneous services                 | 3.11%       | FRA     |
| BIOMERIEUX SA                | Pharmaceuticals                        | 3.09%       | FRA     |
| KBC GROUPE SA                | Banks and other financial institutions | 2.88%       | BEL     |
| DASSAULT SYST.               | Internet and internet services         | 2.75%       | FRA     |
| SCHNEIDER ELECTRIC SE        | Electrical engineering                 | 2.71%       | FRA     |
| AIR LIQUIDE SA               | Chemicals                              | 2.65%       | FRA     |
| TECAN GROUP NAM.AKT          | Pharmaceuticals                        | 2.62%       | CHE     |
| SANOFI                       | Pharmaceuticals                        | 2.60%       | FRA     |
| SIEMENS HEALTHINEERS         | Pharmaceuticals                        | 2.48%       | DEU     |
| ROCHE HOLDING LTD            | Pharmaceuticals                        | 2.20%       | CHE     |


Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



● **In which economic sectors were the investments made?**

| Top sector                             | % of Assets |
|--|-------------|
| Pharmaceuticals                        | 24.13%      |
| Banks and other financial institutions | 15.66%      |
| Foods and non alcoholic drinks         | 9.57%       |
| Chemicals                              | 9.31%       |
| Insurance                              | 5.96%       |
| Internet and internet services         | 5.40%       |
| Miscellaneous services                 | 4.73%       |
| Real estate                            | 4.11%       |
| Miscellaneous consumer goods           | 3.34%       |
| Electrical engineering                 | 3.10%       |
| Machine and apparatus construction     | 2.86%       |
| Biotechnology                          | 2.56%       |
| Hotels and restaurants                 | 2.07%       |
| Electronics and semiconductors         | 1.87%       |
| Retail trade and department stores     | 1.70%       |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

### Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

● **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 30.76% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **What was the share of socially sustainable investments?**

The Sub-fund had a share of investments with a social objective of 64.58%

● **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 4.45% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.



**What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve a carbon footprint that is lower than the Benchmark.

Over the reference period, the financial product emitted 20.67 Tons CO2eq per million € invested, 72.86% lower than the benchmark.

Compared to the previous year, the financial product's carbon footprint has decreased by 23.65%.

The financial product has achieved its objective by favouring issuers with lower carbon footprint.

The financial product aims to achieve an ESG score, based on Candriam's proprietary ESG methodology, higher than its benchmark.

Over the reference period, the financial product displayed an ESG score of 59.31, 10.51% higher compared to its benchmark.

The financial product has achieved its objective by selectively favouring issuers that display a stronger ESG profile. The financial product invested in 1 issuer(s) in Specialty Chemicals with improving ESG profiles.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Environmental and/or social characteristics

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 72.87% of sustainable investments
  - with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 20%). The proportion of sustainable investments in the Fund

**Sustainability indicators** measure how the environmental or social characteristics promoted by the financial product are attained.

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 20.20     | 47.39     |               |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 2022 | 30.40     | 51.74     |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 93.79%                    | 92.88%                    |
| #2 Other                            | 6.21%                     | 7.12%                     |
| #1A Sustainable                     | 72.87%                    | 71.53%                    |
| #1B Other E/S characteristics       | 20.92%                    | 21.35%                    |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 24.24%                    | 23.77%                    |
| Social                              | 48.63%                    | 47.76%                    |



## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 20%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

## **How were the indicators for adverse impacts on sustainability factors taken into account?**

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

## **Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:**

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdrl/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions.

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 66 meetings: for 95.45 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 4 of which we supported 100 %.

In addition, and for any voted director-election items (640 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 154 resolutions were filed by shareholders and we supported 77.27 % of them.

More specifically 48 were Human Rights, Climate or Diversity & Inclusion related: we supported 93.75 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

4 issuers in the financial product are actually part of the priority targets of Candriam Net Zero Engagement campaign.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 67 financial product's issuers targeted, 97.01% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. Such initiatives targeted 11 issuer(s) of the financial product. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 55 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 57 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI10

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 1" company exclusion policy, companies that have committed the most serious violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

**PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|-------|-----------------------------------|--|
| 2 - Carbon Footprint  | 20.20 | 93.59%                            | 93.79%   |
| 3 - GHG intensity of investee companies   | 86.48 | 93.59%                            | 93.79%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00% | 93.79%                            | 93.79%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00% | 93.79%                            | 93.79%   |



## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments                 | Sector                                 | % of Assets | Country |
|-------------------------------------|--|-------------|---------|
| MICROSOFT CORP                      | Internet and internet services         | 6.30%       | USA     |
| APPLE INC                           | Office supplies and computing          | 5.97%       | USA     |
| ALPHABET INC -A-                    | Internet and internet services         | 3.75%       | USA     |
| UNITEDHEALTH GROUP INC              | Healthcare                             | 2.44%       | USA     |
| VISA INC -A-                        | Internet and internet services         | 2.05%       | USA     |
| NESTLE SA PREFERENTIAL SHARE        | Foods and non alcoholic drinks         | 1.95%       | CHE     |
| WASTE MANAGEMENT                    | Environmental services and recycling   | 1.82%       | USA     |
| CONSOLIDATED EDISON INC             | Utilities                              | 1.78%       | USA     |
| JOHNSON & JOHNSON                   | Pharmaceuticals                        | 1.78%       | USA     |
| LVMH MOET HENNESSY LOUIS VUITTON SE | Miscellaneous services                 | 1.77%       | FRA     |
| JPMORGAN CHASE CO                   | Banks and other financial institutions | 1.73%       | USA     |
| MASTERCARD INC -A-                  | Banks and other financial institutions | 1.69%       | USA     |
| ABBOTT LABORATORIES                 | Pharmaceuticals                        | 1.56%       | USA     |
| MERCK & CO INC                      | Pharmaceuticals                        | 1.54%       | USA     |
| BROADCOM INC - REGISTERED SHS       | Office supplies and computing          | 1.53%       | USA     |


Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



**#1 Aligned with E/S characteristics** includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

**#2 Other** includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● **In which economic sectors were the investments made?**

| <b>Top sector</b>                      | <b>% of Assets</b> |
|--|--------------------|
| Banks and other financial institutions | 17.04%             |
| Internet and internet services         | 13.49%             |
| Pharmaceuticals                        | 9.31%              |
| Office supplies and computing          | 8.05%              |
| Electronics and semiconductors         | 7.12%              |
| Foods and non alcoholic drinks         | 5.88%              |
| Machine and apparatus construction     | 4.73%              |
| Retail trade and department stores     | 3.57%              |
| Insurance                              | 3.38%              |
| Graphic art and publishing             | 3.23%              |
| Utilities                              | 3.21%              |
| Hotels and restaurants                 | 2.69%              |
| Healthcare                             | 2.44%              |
| Miscellaneous services                 | 2.10%              |
| Tobacco and alcoholic drinks           | 1.91%              |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

**Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>**

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.



● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

● **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 24.24% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **What was the share of socially sustainable investments?**

The Sub-fund had a share of investments with a social objective of 48.63%

● **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 6.21% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.



**What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve a carbon footprint that is lower than the Benchmark.

Over the reference period, the financial product emitted 20.2 Tons CO2eq per million € invested, 57.38% lower than the benchmark.

Compared to the previous year, the financial product's carbon footprint has decreased by 33.55%.

The financial product has achieved its objective by favouring issuers with lower carbon footprint. More precisely, the financial product invested in 2 issuer(s) in Multi-Utilities and Oil & Gas Equipment & Services with improving carbon footprint.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Environmental and/or social characteristics

### Did this financial product have a sustainable investment objective?

| ●● <input type="checkbox"/> YES  | ●○ <input checked="" type="checkbox"/> NO   |
|--|---|
| <input type="checkbox"/> It made <b>sustainable investments with an environmental objective</b> : ___%                   | <input checked="" type="checkbox"/> It <b>promoted Environmental/Social (E/S) characteristics</b> and while it did not have as its objective a sustainable investment, it had a proportion of 86.42% of sustainable investments |
| <input type="checkbox"/> in economic activities that qualify as environmentally sustainable under the EU Taxonomy        | <input type="checkbox"/> with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy   |
| <input type="checkbox"/> in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy | <input checked="" type="checkbox"/> with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy   |
| <input type="checkbox"/> It made <b>sustainable investments with a social objective</b> : ___%                           | <input checked="" type="checkbox"/> with a social objective   |
|  | <input type="checkbox"/> It promoted E/S characteristics, but <b>did not make any sustainable investments</b>   |

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### ● How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 33%). The proportion of sustainable investments in the Fund

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                   | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| ESG Score - Corporate - Higher than bench | 56.84     | 51.59     |               |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                   | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| ESG Score - Corporate - Higher than bench | 2022 | 55.08     | 51.03     |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 96.99%                    | 97.28%                    |
| #2 Other                            | 3.01%                     | 2.72%                     |
| #1A Sustainable                     | 86.42%                    | 86.89%                    |
| #1B Other E/S characteristics       | 10.57%                    | 10.40%                    |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 3.63%                     | 3.86%                     |
| Social                              | 82.79%                    | 83.03%                    |

## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 33%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

### ***How were the indicators for adverse impacts on sustainability factors taken into account?***

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

### ***Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:***

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [<https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>].

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions. ,

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 110 meetings: for 91.82 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 3 of which we supported 100 %.

In addition, and for any voted director-election items (701 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 67 resolutions were filed by shareholders and we supported 71.64 % of them.

More specifically 7 were Human Rights, Climate or Diversity & Inclusion related: we supported 85.71 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [<https://vds.issgovernance.com/vds/#/NDA0Nw==/>]

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [<https://www.netzeroassetmanagers.org/signatories/candriam/>]. Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

In addition, we continue to actively support CDP Climate [<https://www.cdp.net/en>], a large transparency survey feeding our investment processes : out of the 76 financial product's issuers targeted, 78.95% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>].

Given the geopolitical context and observed increase in inequalities, 65 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 39 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [<https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>].

### EXCLUSIONS

#### PAI10

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations

Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 1" company exclusion policy, companies that have committed the most serious violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

**PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|-------|-----------------------------------|--|
| 3 - GHG intensity of investee companies   | 20.76 | 97.13%                            | 97.80%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00% | 97.81%                            | 97.80%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00% | 97.81%                            | 97.80%   |





## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is:  
01/01/2023 - 31/12/2023.

| Largest investments                    | Sector                             | % of Assets | Country |
|--|------------------------------------|-------------|---------|
| UNITEDHEALTH GROUP INC                 | Healthcare                         | 7.00%       | USA     |
| ELI LILLY & CO                         | Biotechnology                      | 4.40%       | USA     |
| MERCK & CO INC                         | Pharmaceuticals                    | 3.83%       | USA     |
| JOHNSON & JOHNSON                      | Pharmaceuticals                    | 3.59%       | USA     |
| THERMO FISHER SCIENT SHS               | Electronics and semiconductors     | 3.49%       | USA     |
| MEDTRONIC HLD                          | Pharmaceuticals                    | 3.40%       | IRL     |
| ROCHE HOLDING LTD                      | Pharmaceuticals                    | 3.21%       | CHE     |
| DANAHER CORP                           | Machine and apparatus construction | 3.01%       | USA     |
| BECTON DICKINSON                       | Pharmaceuticals                    | 2.57%       | USA     |
| ABBVIE INC                             | Pharmaceuticals                    | 2.28%       | USA     |
| BOSTON SCIENTIF CORP                   | Pharmaceuticals                    | 2.22%       | USA     |
| ASTRAZENECA PLC                        | Pharmaceuticals                    | 2.20%       | GBR     |
| NOVARTIS AG PREFERENTIAL SHARE         | Pharmaceuticals                    | 2.09%       | CHE     |
| NOVO NORDISK - BEARER AND/OR - REG SHS | Pharmaceuticals                    | 2.00%       | DNK     |
| SANOFI                                 | Pharmaceuticals                    | 1.95%       | FRA     |


*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



**#1 Aligned with E/S characteristics** includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

**#2 Other** includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● **In which economic sectors were the investments made?**

| Top sector                             | % of Assets |
|--|-------------|
| Pharmaceuticals                        | 62.60%      |
| Healthcare                             | 12.75%      |
| Biotechnology                          | 10.46%      |
| Electronics and semiconductors         | 4.17%       |
| Banks and other financial institutions | 3.12%       |
| Machine and apparatus construction     | 3.01%       |
| Photographic and optics                | 1.44%       |
| Miscellaneous services                 | 0.91%       |
| Internet and internet services         | 0.79%       |
| Chemicals                              | 0.74%       |
| Non Classifiable Institutions          | 0.00%       |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

**Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>**

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

 **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 3.63% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**

The Sub-fund had a share of investments with a social objective of 82.79%

 **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 3.01% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.

 **What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve an ESG score, based on Candriam’s proprietary ESG methodology, higher than its benchmark.

Over the reference period, the financial product displayed an ESG score of 56.84, 10.18% higher compared to its benchmark.

In comparison to the previous year, the financial product overall ESG score is higher by 3.19%.

The financial product has achieved its objective by selectively favouring issuers that display a stronger ESG profile. The financial product invested in 3 issuer(s) in Health Care Technology and Pharmaceuticals with improving ESG profiles.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Environmental and/or social characteristics

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 79.59% of sustainable investments
  - with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 20%). The proportion of sustainable investments in the Fund

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 8.14      | 60.19     |               |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 2022 | 8.15      | 64.55     |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 93.83%                    | 91.81%                    |
| #2 Other                            | 6.17%                     | 8.19%                     |
| #1A Sustainable                     | 79.59%                    | 81.29%                    |
| #1B Other E/S characteristics       | 14.23%                    | 10.52%                    |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 21.76%                    | 21.68%                    |
| Social                              | 57.84%                    | 59.60%                    |



## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 20%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

## **How were the indicators for adverse impacts on sustainability factors taken into account?**

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

## **Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:**

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions.

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 51 meetings: for 90.2 % of them we cast at least once against management.

In addition, and for any voted director-election items (351 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 53 resolutions were filed by shareholders and we supported 64.15 % of them.

More specifically 16 were Human Rights, Climate or Diversity & Inclusion related: we supported 87.5 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

1 issuers in the financial product are actually part of the priority targets of Candriam Net Zero Engagement campaign.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 47 financial product's issuers targeted, 87.23% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. Such initiatives targeted 1 issuer(s) of the financial product. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 29 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 25 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI10

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations

Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 1" company exclusion policy, companies that have committed the most serious violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

**PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|-------|-----------------------------------|--|
| 2 - Carbon Footprint  | 8.14  | 94.61%                            | 94.61%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00% | 94.61%                            | 94.61%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00% | 94.61%                            | 94.61%   |



## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments                      | Sector                         | % of Assets | Country |
|--|--------------------------------|-------------|---------|
| ADVANCED MICRO DEVICES INC               | Electronics and semiconductors | 2.88%       | USA     |
| GENERAL ELECTRI                          | Electrical engineering         | 2.84%       | USA     |
| SIEMENS AG PREFERENTIAL SHARE            | Electrical engineering         | 2.84%       | DEU     |
| MICROSOFT CORP                           | Internet and internet services | 2.83%       | USA     |
| ADOBE INC                                | Internet and internet services | 2.82%       | USA     |
| NVIDIA CORP                              | Electronics and semiconductors | 2.82%       | USA     |
| QUALCOMM INC                             | Communication                  | 2.82%       | USA     |
| ALPHABET INC -A-                         | Internet and internet services | 2.81%       | USA     |
| APPLE INC                                | Office supplies and computing  | 2.81%       | USA     |
| TAIWAN SEMICONDUCTOR CO ADR (REPR 5 SHS) | Electronics and semiconductors | 2.81%       | USA     |
| IBM CORP                                 | Office supplies and computing  | 2.80%       | USA     |
| BROADCOM INC - REGISTERED SHS            | Office supplies and computing  | 2.80%       | USA     |
| WALT DISNEY CO                           | Graphic art and publishing     | 2.80%       | USA     |
| SONY CORP                                | Electronics and semiconductors | 2.78%       | JPN     |
| INTUITIVE SURGICAL                       | Pharmaceuticals                | 2.56%       | USA     |


*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



**#1 Aligned with E/S characteristics** includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

**#2 Other** includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● **In which economic sectors were the investments made?**

| <b>Top sector</b>                      | <b>% of Assets</b> |
|--|--------------------|
| Internet and internet services         | 43.12%             |
| Electronics and semiconductors         | 16.19%             |
| Office supplies and computing          | 9.64%              |
| Electrical engineering                 | 8.18%              |
| Banks and other financial institutions | 5.37%              |
| Communication                          | 2.82%              |
| Graphic art and publishing             | 2.80%              |
| Pharmaceuticals                        | 2.56%              |
| Real estate                            | 1.95%              |
| Machine and apparatus construction     | 1.67%              |
| Non Classifiable Institutions          | 1.64%              |
| Hotels and restaurants                 | 1.64%              |
| Miscellaneous services                 | 1.64%              |
| Healthcare                             | 0.78%              |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

**Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>**

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.



● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

 **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 21.76% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**


The Sub-fund had a share of investments with a social objective of 57.84%

 **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 6.17% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.

 **What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve a carbon footprint that is lower than the Benchmark.

Over the reference period, the financial product emitted 8.14 Tons CO<sub>2</sub>eq per million € invested, 86.47% lower than the benchmark.

Compared to the previous year, the financial product's carbon footprint has remained stable.

The financial product has achieved its objective by favouring issuers with lower carbon footprint.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund

## Sustainable investment objective

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

| Did this financial product have a sustainable investment objective?   |  |
|---|--|
| <input checked="" type="checkbox"/> <b>YES</b>  | <input type="checkbox"/> <b>NO</b>   |
| <input checked="" type="checkbox"/> It made <b>sustainable investments with an environmental objective: 0.00%</b>                   | <input type="checkbox"/> It <b>promoted Environmental/Social (E/S) characteristics</b> and while it did not have as its objective a sustainable investment, it had a proportion of ____% of sustainable investment |
| <input type="checkbox"/> in economic activities that qualify as environmentally sustainable under the EU Taxonomy                   | <input type="checkbox"/> with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy  |
| <input checked="" type="checkbox"/> in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy | <input type="checkbox"/> with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy   |
| <input checked="" type="checkbox"/> It made <b>sustainable investments with a social objective: 95.60%</b>                          | <input type="checkbox"/> with a social objective   |
|   | <input type="checkbox"/> It promoted E/S characteristics, but <b>did not make any sustainable investments</b>  |



### To what extent was the sustainable investment objective of this financial product met?

**Sustainability indicators** measure how the sustainable objectives of this financial product are attained.

The attainment of the sustainable objectives was measured through the following sustainability indicators:

- Research and development spending: better-than-benchmark research and development spending as a proportion of the company's market capitalisation.
- The level of education of management teams: better-than-benchmark percentage of senior executives holding a PhD.

Moreover, the following indicators were monitored:

- to assure that there are no investments in companies that are in violation with the OECD Guidelines for Multinational Enterprises or the UN Global Compact.
- to assure that there are no investments in companies that are on the Candriam's SRI Level 3 exclusion list as a result of the application of Candriam's Exclusion Policy.
- Number of holdings for which Candriam voted.
- to assure that eligible companies have an individual exposure to oncology-related activities and/or the fight against cancer of at least 10% in terms of income or capex or pipelines.

### How did the sustainability indicators perform?

The Sub-Fund has been managed in accordance with its sustainability indicators as defined below.

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 75%). The proportion of sustainable investments in the Fund was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

The Sub-Fund's reference benchmark has not been designated for the purpose of attaining the sustainable investment objective of the Sub-Fund.

The Sub-Fund's reference benchmark does not qualify as an EU Climate Transition Benchmark or an EU Paris-Aligned Benchmark under Title III, Chapter 3a, of Regulation (EU) 2016/1011.

| Sustainability KPI Name                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| PhD in Mgmt - Corporate - Higher than bench | 23.56%    | 3.81%     |               |
| R&D Expense - Corporate - Higher than bench | 2.86%     | 0.94%     |               |

### ● ... And Compared to Previous Periods?

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| PhD in Mgmt - Corporate - Higher than bench | 2022 | 23.73%    | 3.94%     |
| R&D Expense - Corporate - Higher than bench | 2022 | 3.11%     | 1.19%     |

The asset allocation of the financial product has evolved over the years.

| Investment Category | Proportion of Investments | Proportion of Investments |
|---------------------|---------------------------|---------------------------|
|                     | 2023                      | 2022                      |
| #1 Sustainable      | 95.60%                    | 93.55%                    |
| #2 Not sustainable  | 4.40%                     | 6.42%                     |
| Environmental       | 0.00%                     | 0.00%                     |
| Social              | 95.60%                    | 93.55%                    |
| Taxonomy-aligned    | 0.00%                     | 0.00%                     |
| Other               | 0.00%                     | 0.00%                     |

Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

## **How did the sustainable investments not cause significant harm to any sustainable investment objective?**

Candriam ensured that its sustainable investments did not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate and sovereign issuers. Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology set clear requirements and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, do not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

## **How were the indicators for adverse impacts on sustainability factors taken into account?**

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

## **Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:**

The Sub-fund's investments were subject to a norms-based controversy analysis that considered the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.



## **How did this financial product consider principal adverse impacts on sustainability factors?**

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### **ENGAGEMENT**

Our engagement and voting policies are available on Candriam website [<https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>].

### **VOTING**

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions.

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 67 meetings: for 97.01 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 2 of which we supported 100 %.

In addition, and for any voted director-election items (344 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 31 resolutions were filed by shareholders and we supported 58.06 % of them.

More specifically 3 were Human Rights, Climate or Diversity & Inclusion related: we supported 66.67 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [<https://vds.issgovernance.com/vds/#/NDA0Nw==/>]

#### **DIALOGUE** with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [<https://www.netzeroassetmanagers.org/signatories/candriam/>]. Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

In addition, we continue to actively support CDP Climate [<https://www.cdp.net/en/>], a large transparency survey feeding our investment processes : out of the 56 financial product's issuers targeted, 51.79% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [<https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications>].

Given the geopolitical context and observed increase in inequalities, 27 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 22 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [<https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities>].

#### **EXCLUSIONS**

##### **PAI3**

In addition to companies involved in the thermal coal, oil and gas activities (PAI 4), electricity-generating companies with a carbon intensity greater than 354 gCO<sub>2</sub>/kWh (PAI 3), are considered risky for inclusion in sustainable investments, even if they are not universally controversial. Given that emissions vary according to electricity generation sources, it is important to assess the carbon footprint per kilowatt-hour (kWh) to determine how closely companies are aligned with the 2 degrees Celsius trajectory.

This is why Candriam includes the carbon intensity of energy producers in our sustainability assessment. Where carbon intensity data is not available, Candriam's ESG analysts use other indicators to assess alignment with the Paris Agreement, such as progress in the energy transition in line with Paris Agreement targets and integration of a 1.5D limit scenario, taking into account investment plans and the credibility of carbon neutrality targets. These indicators are forward-looking and evolve over time to reflect the progress made by companies in their transition.

The carbon intensity (PAI 3) threshold for the product in 2023 was established at 354 gCO<sub>2</sub>/kWh. Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding this threshold, in addition to those previously excluded.

##### **PAI4**

Exposure to fossil fuels (PAI 4) undergoes stringent exclusions across all Candriam sustainable funds. Thermal coal, recognized for its detrimental impact and serious financial and sustainability implications, poses systemic and reputational risks that financial benefits cannot outweigh.

Companies deriving more than 5% of their sales from coal mining, coal-fired power generation, and coal-related operations such as exploration, processing, transport, and distribution are automatically excluded.

Additionally, companies exceeding a 5% threshold of revenue from conventional oil and gas activities, including exploration, extraction, refining, and transportation, are ineligible for investment. Similarly, entities with over 5% exposure to unconventional oil and gas activities are also excluded.

Over the reference period, no additional issuer(s) became ineligible for the financial product due to exceeding the 5% threshold of exposure to thermal coal activities, supplementing the previously excluded entities.

Furthermore, no additional issuer(s) lost their eligibility due to surpassing the 5% threshold of exposure to conventional oil and gas activities, while no additional issuer(s) lost their eligibility for exceeding the 5% threshold of exposure to unconventional oil and gas activities.

**PAI10**

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 3" SRI exclusion policy, companies with severe to very severe violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

**PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value    | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|----------|-----------------------------------|--|
| Scope 1 GHG Emissions   | 3,344.84 | 92.78%                            | 96.18%   |
| Scope 2 GHG Emissions   | 3,023.83 | 92.78%                            | 96.18%   |
| Total GHG Emissions   | 6,368.67 | 92.78%                            | 96.18%   |
| 2 - Carbon Footprint  | 3.88     | 92.78%                            | 96.18%   |
| 3 - GHG intensity of investee companies   | 25.65    | 92.78%                            | 96.18%   |
| 4 - Exposure to companies active in fossil fuel sector  | 0.00%    | 94.22%                            | 96.18%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00%    | 96.15%                            | 96.18%   |
| 13 - Board gender diversity   | 33.51%   | 92.71%                            | 96.18%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00%    | 96.15%                            | 96.18%   |





## What were the top investments of this financial product?

The list includes the investments constituting the **greatest proportion of investments** of the financial product during the reference period which is:

01/01/2023 - 31/12/2023.

| Largest investments            | Sector                             | % of Assets | Country |
|--------------------------------|------------------------------------|-------------|---------|
| MERCK & CO INC                 | Pharmaceuticals                    | 9.13%       | USA     |
| ASTRAZENECA PLC                | Pharmaceuticals                    | 7.83%       | GBR     |
| ROCHE HOLDING LTD              | Pharmaceuticals                    | 6.72%       | CHE     |
| REGENERON PHARMACEUTICALS INC  | Biotechnology                      | 5.88%       | USA     |
| SIEMENS HEALTHINEERS           | Pharmaceuticals                    | 4.75%       | DEU     |
| HOLOGIC INC                    | Pharmaceuticals                    | 4.55%       | USA     |
| THERMO FISHER SCIENT SHS       | Electronics and semiconductors     | 4.47%       | USA     |
| DANAHER CORP                   | Machine and apparatus construction | 3.84%       | USA     |
| DAIICHI SANKYO CO LTD          | Pharmaceuticals                    | 3.19%       | JPN     |
| MERCK KGAA                     | Pharmaceuticals                    | 3.16%       | DEU     |
| NOVARTIS AG PREFERENTIAL SHARE | Pharmaceuticals                    | 2.96%       | CHE     |
| SEAGEN INC                     | Biotechnology                      | 2.79%       | USA     |
| AMGEN INC                      | Pharmaceuticals                    | 2.63%       | USA     |
| GENMAB AS                      | Biotechnology                      | 2.39%       | DNK     |
| IQVIA HOLDINGS INC             | Pharmaceuticals                    | 2.37%       | USA     |


*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*



## What was the proportion of sustainability-related investments?

Asset allocation describes the share of investments in specific assets.

### ● What was the asset allocation?



● ***In which economic sectors were the investments made?***

| <b>Top sector</b>                      | <b>% of Assets</b> |
|--|--------------------|
| Pharmaceuticals                        | 56.21%             |
| Biotechnology                          | 26.23%             |
| Banks and other financial institutions | 4.59%              |
| Electronics and semiconductors         | 4.54%              |
| Machine and apparatus construction     | 3.85%              |
| Photographic and optics                | 2.12%              |
| Chemicals                              | 1.15%              |
| Miscellaneous services                 | 0.79%              |
| Healthcare                             | 0.51%              |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*



## To what extent were sustainable investments with an environmental objective aligned with the EU Taxonomy?

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are economic activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.


Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies
- **capital expenditure** (CapEx) showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure** (OpEx) reflecting green operational activities of investee companies.

### Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy? <sup>1</sup>

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup>Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under the EU Taxonomy.

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

Therefore, this percentage is considered as nul.

 **What was the share of sustainable investments with an environmental objective that were not aligned with the EU taxonomy?**

The Sub-Fund had a share of 0% in sustainable investments with an environmental objective not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**

The Sub-Fund had a share of investments with a social objective of 95.60%

 **What investments were included under “not sustainable”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Not sustainable" are present in the Sub-fund for 4.4% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions and/or being the result of the market exposure decision of the Sub-fund.
- Investments with issuers considered as sustainable investments at the moment of the investment and that are not fully aligned anymore with the Candriam sustainable investment criteria. These investments have been sold during the period.
- Non single name derivatives used for exposition and hedging purposes.

These investments do not affect the delivery of the sustainable investment objectives of the Sub-Fund as they represent a minor proportion of its assets.

 **What actions have been taken to attain the sustainable investment objective during the reference period?**

The financial product seeks to outperform the benchmark by the level of education of management teams, measured as the percentage of senior executives holding a doctorate.

Over the reference period, the financial product invested in 23.56% of its net assets to issuers where at least one senior executive held a doctorate, 518.37% higher compared to its benchmark.

The financial product has achieved its objective by allocating a higher proportion of investments in issuers where at least one senior executive held a doctorate as compare to its benchmark.

The financial product seeks to outperform the benchmark by the amount of research and development spending as a proportion of the company's market capitalisation.

Over the reference period, the financial product displayed a proportion of 2.86% of issuers spending in research & development, 204.26% higher compared to its benchmark.

The financial product has achieved its objective by selectively favouring issuers that display a higher proportion amount spent in research and development as compare to its benchmark.



## How did this financial product perform compared to the reference sustainable benchmark?

No specific index is designated as a reference sustainable benchmark to meet the sustainable investment objectives.

**Reference benchmarks** are indexes to measure whether the financial product attains the sustainable objective.

## Environmental and/or social characteristics

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not

### Did this financial product have a sustainable investment objective?

YES

- It made **sustainable investments with an environmental objective**: \_\_\_%
- in economic activities that qualify as environmentally sustainable under the EU Taxonomy
- in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
- It made **sustainable investments with a social objective**: \_\_\_%

NO

- It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of 88.58% of sustainable investments
  - with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
  - with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
  - with a social objective
- It promoted E/S characteristics, but **did not make any sustainable investments**



### To what extent were the environmental and/or social characteristics promoted by this financial product met?

The environmental and social characteristics promoted by the Sub-fund have been achieved by:

- avoiding exposure to companies that present structural risks that are both material and severe and are most seriously in breach of normative principles taking into account practices in environmental and social issues as well as compliance with standards such as the United Nations Global Compact and the 'OECD Guidelines for Business standards.
- avoiding exposure to companies that are significantly exposed to controversial activities such extraction, transportation or distribution of thermal coal, the manufacturing or retailing of Tobacco and production or sale of controversial weapons (anti-personnel mines, cluster bombs, chemical, biological, phosphorus weapons white and depleted uranium.
- integrating Candriam's ESG research methodology into the investment process and investing a proportion of its assets in Sustainable Investments.

### ● How did the sustainability indicators perform?

For the selection of sustainable investments, the portfolio manager has taken into account ESG assessments of issuers, produced by Candriam's ESG analyst team.

For companies, these assessments are based on the analysis of the company's interactions with its key stakeholders and the analysis of its business activities and their impact, positive or negative, on key sustainability challenges such as climate change and resource depletion. In addition, Candriam's ESG analysis includes exclusion filters based on compliance with international standards and involvement in controversial activities.

Candriam's ESG research and analysis for sustainable investments also assesses the compliance of investments with the "do no harm" principle to a sustainable investment objective and with good governance practices.

This integration of Candriam's ESG research methodology has enabled the Fund to meet the minimum proportion of sustainable investments defined in the prospectus (minimum 20%). The proportion of sustainable investments in the Fund

was therefore above this minimum threshold, as detailed in the section "What was the proportion of sustainability-related investments?"

| Sustainability KPI Name                                     | Portfolio | Benchmark | New indicator |
|---|-----------|-----------|---------------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 7.33      | 47.39     |               |

● **... And compared to previous periods?**

The sub-fund has also been managed in line with its sustainability indicators.

| Sustainability KPI Name                                     | Year | Portfolio | Benchmark |
|---|------|-----------|-----------|
| Carbon Footprint - Corporate - Scope 1&2 - Lower than bench | 2022 | 7.43      | 51.74     |

The asset allocation of the financial product has evolved over the years.

| Investment Category                 | Proportion of Investments | Proportion of Investments |
|-------------------------------------|---------------------------|---------------------------|
|                                     | 2023                      | 2022                      |
| #1 Aligned with E/S characteristics | 94.51%                    | 95.18%                    |
| #2 Other                            | 5.49%                     | 4.82%                     |
| #1A Sustainable                     | 88.58%                    | 88.33%                    |
| #1B Other E/S characteristics       | 5.93%                     | 6.85%                     |
| Taxonomy-aligned                    | 0.00%                     | 0.00%                     |
| Other environmental                 | 26.01%                    | 23.57%                    |
| Social                              | 62.57%                    | 64.76%                    |



## ● **What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objective?**

The sustainable investments which the Sub-fund intended to achieve for a portion of the portfolio were to contribute to the reduction of greenhouse gas emissions by means of exclusions and the use of climate indicators in the analysis of companies, and to have a positive impact on environment and social domains in the long-term.

The proportion of sustainable investments was higher than the minimum defined in the prospectus (minimum 20%). It allowed the Sub-fund to exceed the objectives initially set.

However, the Sub-fund is not able to publish a percentage of alignment with the Taxonomy since a small number of companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

## ● **How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?**

Candriam ensured that those investments have not cause significant harm to any environmental and/or social sustainable investment objective by means of its ESG research and analysis of corporate issuers.

Based on its proprietary ESG Ratings and Scorings, Candriam's ESG methodology sets criteria and minimum thresholds to identify those issuers that qualify as 'sustainable investment' and, in particular, have not cause significant harm to any environmental and/or social sustainable investment objective.

The 'Do not significant harm' principle, in particular, was assessed for corporates through:

- the consideration of "principal adverse impacts"
- the alignment with the OECD Guidelines for Multinational Enterprises and the UN Global Compact to ensure minimum environmental & social safeguards.

For more details, refer to the section below on the consideration of principal adverse impacts on sustainability factors.

## **How were the indicators for adverse impacts on sustainability factors taken into account?**

The consideration of adverse impacts is central to Candriam's sustainable investment approach. Principal adverse impacts were taken into account throughout the entire ESG research and analysis process and through a wide range of methods:

1. ESG rating of corporates: the ESG research and screening methodology considers and assesses the principal adverse impact on sustainability from two distinct, but interlinked, angles:

- the company's issuers' business activities and how they impact, either positively or negatively, key sustainable challenges such as climate change and resource depletion;
- company's interactions with key stakeholders.

2. Negative screening of companies, which includes a norms-based exclusion and an exclusion of companies involved in controversial activities.

3. Engagement activities with companies, through dialogue and voting activities, which contribute to avoiding or reducing the extent of the adverse impacts. The ESG analysis framework and its results feed our engagement process, and vice versa.

The integration of the principal adverse impacts on sustainability factors has been based on the materiality or likely materiality of each indicator for each specific industry / sector to which the company belongs. The materiality is dependent on several factors, such as: type of information, data quality and breadth, applicability, relevance, and geographical coverage.

## **Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:**

The sustainable investments of the Sub-fund have been compliant with the OECD Guidelines for Multinational Enterprises and the United Nations Guiding Principles on Business and Human Rights.

They are subject to a norms-based controversy analysis that considers the compliance with the international social, human, environmental and anti-corruption standards, as defined by the United Nations Global Compact and the OECD Guidelines for Multinational Enterprises. The International Labour Organisation and International Bill of Human Rights are part of the many international references integrated into our norms-based analysis and ESG model.

This analysis aimed to exclude companies that have significantly and repeatedly breached any of these principles.

*The EU Taxonomy sets out a "do no significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.



## How did this financial product consider principal adverse impacts on sustainability factors?

At Financial Product level, the principal adverse impacts (PAI) on sustainability factors were considered through one or several means: voting, dialogue, exclusions and/or monitoring (cfr. Candriam's PAI statement: <https://www.candriam.com/en/private/sfdr/>)

### ENGAGEMENT

Our engagement and voting policies are available on Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### VOTING

The Candriam's approach to Corporate Governance relies on internationally-recognized standards.

Candriam has exercised voting rights when available on positions of the portfolio. Shareholders' rights, equality of shareholders, board accountability, transparency and integrity of financial statements are core pillars of our voting policy. When exercising our votes we pay a particular attention to the respect of pay-for-performance principle and to the board's independence level, diversity (PAI13) and expertise level.

In the context of Candriam's voting policy, specific guidelines are applied for a range of environmental- (e.g. climate (PAI1 to PAI6), biodiversity (PAI7)), social- (e.g. diversity, gender pay gap (PAI12), human rights (PAI10 PAI11)) and governance- related management or shareholder resolutions.

Candriam has an active approach to voting, in line with the consideration of the principle adverse impacts. Resolutions and voting opportunities are analysed in detail. Candriam always considers the relevance, consistence and feasibility of measures sponsored by any ESG resolution before casting vote. Thus, Candriam may vote against certain resolutions if they do not correspond to the principles defined in its voting policy or to the requirements relating to principle adverse impacts.

This year, we voted at 46 meetings: for 93.48 % of them we cast at least once against management.

With respect to environmental or social related resolutions, management submitted 1 of which we supported 100 %.

More specifically, 1 proposals were related to climate (100 % support).

In addition, and for any voted director-election items (355 resolutions), we took into consideration Board Gender diversity aspects (PAI13).

In total 30 resolutions were filed by shareholders and we supported 70 % of them.

More specifically 7 were Human Rights, Climate or Diversity & Inclusion related: we supported 100 % of them.

For more detailed information about Candriam Voting policy evolution, votes and associated rationales, please refer to our voting dashboard [\[https://vds.issgovernance.com/vds/#/NDA0Nw==/\]](https://vds.issgovernance.com/vds/#/NDA0Nw==/)

### DIALOGUE with corporate issuers

This financial product is invested in corporate issuers. Below statistics refer to engagement activities we have performed with these corporate issuers.

Climate (PAI1 to PAI6) is obviously central in our exchanges with companies. Priorities of Climate-engagement on the corporate side are identified taking into account :

- issuers presenting a weak transition profile (proprietary risk transition model), and/or still highly carbon intensive (Scope 1-2) or with large Scope 3 emissions
- issuers from financial sectors still largely exposed to fossil fuel and with a key role in financing the transition
- relative exposure of managed portfolios to the above issuers.

Candriam has joined in November 2021 the Net Zero Asset Management Initiative [\[https://www.netzeroassetmanagers.org/signatories/candriam/\]](https://www.netzeroassetmanagers.org/signatories/candriam/). Through engagement, our objective is to encourage companies to publicly report on how they align with a 1.5D trajectory and to encourage such an alignment. We expect issuers in particular to explain how their strategy and capital expenditures plan serve their decarbonisation commitment. We usually combine individual and collaborative dialogue.

3 issuers in the financial product are actually part of the priority targets of Candriam Net Zero Engagement campaign.

In addition, we continue to actively support CDP Climate [\[https://www.cdp.net/en\]](https://www.cdp.net/en), a large transparency survey feeding our investment processes : out of the 42 financial product's issuers targeted, 95.24% have properly filled the last survey. Filled surveys give us access to updated and more accurate Scope 1-2-3 emissions' data.

Candriam also actively participate to several collaborative initiatives such as Climate Action 100+ or IIGCC & ShareAction Climate initiatives on Financials. These initiatives contribute not only to increase the level of transparency on Greenhouse gas emissions and related strategy, but also to gain fundamental leverage for supporting strategic changes. Outcomes of these engagements are detailed in our annual engagement & voting report, available on our public website (Publications | Candriam) [\[https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications\]](https://www.candriam.com/en/professional/insight-overview/publications/#sri-publications).

Given the geopolitical context and observed increase in inequalities, 34 issuer(s) with presence in the financial product have also been contacted in relation to the protection of fundamental human rights at direct or indirect workforce level (supply chain due diligence) (PAI10 PAI11).

Inclusion is not to be outdone, with 24 issuers, of the portfolio having been more specifically engaged on topics related to PAI 12 (Unadjusted gender pay gap) or PAI 13 (Board gender diversity).

While above mentioned PAI are prevalent when considering engagement performed for this financial product in 2023, other PAI such as biodiversity-related ones may also have been addressed in our dialogues with issuers. For more information, please refer to Candriam Engagement Annual review under Candriam website [\[https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities\]](https://www.candriam.com/en/professional/investment-solutions/sustainability-documents/#engagement-activities).

### EXCLUSIONS

#### PAI10

In accordance with PAI10 Candriam's normative analysis determines whether a company complies with the 10 principles of the United Nations Global Compact for each of the main categories: Human Rights (HR), Labor Rights (LR), Environment (ENV) and Anti-Corruption (AC). Our norms based analysis incorporates various international references, including the United Nations Declaration of Human Rights, ILO Fundamental Conventions, and OECD Guidelines for Multinational Enterprises, ensuring comprehensive coverage of human rights, labor standards, corruption, and discrimination.

In Candriam's "Level 1" company exclusion policy, companies that have committed the most serious violations of the UN Global Compact principles are excluded. This list focuses on a strict interpretation of violations of the UN Global Compact, as assessed by Candriam's ESG analysts.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, for significant and repeated breaches of international social, human, environmental and anti-corruption standards, as defined by the UN Global Compact and the OECD Guidelines for Multinational Enterprises.

**PAI14**

Candriam is firmly committed to excluding from all its investments companies directly involved in the development, production, testing, maintenance and sale of controversial weapons (anti-personnel landmines, cluster bombs, depleted uranium weapons and armor, chemical weapons, biological weapons and white phosphorus weapons). We consider these damaging activities to present systemic and reputational risks.

Over the reference period, no additional issuer(s) directly covered became ineligible for the financial product, in addition to those previously excluded, due to their involvement in these activities.

**MONITORING:** calculation and evaluation of the principal adverse impact indicators

Some of these indicators may have explicit targets and can be used to measure the attainment of the sustainable investment objective of the Financial Product. See below the results of the indicators of this Financial Product

| PAI indicators  | Value | Coverage (% rated / total assets) | Eligible assets (% eligible assets / total assets) |
|---|-------|-----------------------------------|--|
| 2 - Carbon Footprint  | 7.33  | 94.51%                            | 94.51%   |
| 3 - GHG intensity of investee companies   | 39.66 | 94.51%                            | 94.51%   |
| 10 - Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | 0.00% | 94.51%                            | 94.51%   |
| 14 - Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)                                 | 0.00% | 94.51%                            | 94.51%   |



## What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is: 01/01/2023 - 31/12/2023.

| Largest investments           | Sector                         | % of Assets | Country |
|-------------------------------|--------------------------------|-------------|---------|
| ALPHABET INC -A-              | Internet and internet services | 5.38%       | USA     |
| MICROSOFT CORP                | Internet and internet services | 4.39%       | USA     |
| ADVANCED MICRO DEVICES INC    | Electronics and semiconductors | 3.44%       | USA     |
| PALO ALTO NETWORKS            | Internet and internet services | 3.30%       | USA     |
| SIEMENS AG PREFERENTIAL SHARE | Electrical engineering         | 3.08%       | DEU     |
| EMERSON ELECTRIC CO           | Electrical engineering         | 3.05%       | USA     |
| SERVICENOW INC                | Internet and internet services | 2.89%       | USA     |
| PTC INC                       | Internet and internet services | 2.82%       | USA     |
| INTUITIVE SURGICAL            | Pharmaceuticals                | 2.75%       | USA     |
| SALESFORCE INC                | Internet and internet services | 2.75%       | USA     |
| NVIDIA CORP                   | Electronics and semiconductors | 2.74%       | USA     |
| SCHNEIDER ELECTRIC SE         | Electrical engineering         | 2.71%       | FRA     |
| ASML HOLDING NV               | Electronics and semiconductors | 2.70%       | NLD     |
| ROCKWELL AUTOMATION           | Electrical engineering         | 2.50%       | USA     |
| KEYENCE CORP                  | Electronics and semiconductors | 2.45%       | JPN     |


*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*



## What was the proportion of sustainability-related investments?

**Asset allocation** describes the share of investments in specific assets.

### ● What was the asset allocation?



**#1 Aligned with E/S characteristics** includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

**#2 Other** includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category **#1A Sustainable** covers environmentally and socially sustainable investments.
- The sub-category **#1B Other E/S characteristics** covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

● **In which economic sectors were the investments made?**

| Top sector                             | % of Assets |
|--|-------------|
| Internet and internet services         | 37.33%      |
| Electronics and semiconductors         | 31.25%      |
| Electrical engineering                 | 14.51%      |
| Banks and other financial institutions | 5.88%       |
| Machine and apparatus construction     | 4.25%       |
| Pharmaceuticals                        | 4.00%       |
| Road vehicles                          | 1.85%       |
| Communication                          | 0.87%       |
| Non Classifiable Institutions          | 0.06%       |

*Data based on the main investments held on average during the reference period. This data is not comparable with those presented in the "Investment portfolio" section of the annual report.*

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities** are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:

- **turnover** reflecting the share of revenue from green activities of investee companies.
- **capital expenditure (CapEx)** showing the green investments made by investee companies, e.g for a transition to a green economy.
- **operational expenditure (OpEx)** reflecting the green operational activities of investee companies.




## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

### Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?<sup>1</sup>

- Yes
- In fossil gas  In nuclear energy
- No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds\*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



\* For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures

<sup>1</sup> Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left-hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.



● **What was the share of investments made in transitional and enabling activities?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, nor on the transitional and enabling activities, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

● **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

| Year | % EU Taxonomy Aligned |
|------|-----------------------|
| 2023 | 0.00%                 |
| 2022 | 0.00%                 |

● **What is the breakdown of the proportion of the investments per each of the EU Taxonomy to which those investments contributed?**

The Sub-Fund is unable to publish a percentage of alignment with the Taxonomy, as very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy

Therefore, this percentage is considered as nul.

 are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

 **What was the share of sustainable investments with an environmental objective not aligned with the EU taxonomy?**

The Sub-Fund had a share of 26.01% in sustainable investments on the environmental plan not aligned with the EU taxonomy.

Indeed to date, only two of the six objectives have entered into force in 2023 and very few companies at global level provide the data necessary for a rigorous assessment of their alignment with the Taxonomy.

 **What was the share of socially sustainable investments?**


The Sub-fund had a share of investments with a social objective of 62.57%

 **What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?**

The investments included under "Other" are present in the Sub-fund for 5.49% of the total net assets.

These investments include one or more of the following assets:

- Cash: Cash at sight, cash deposit, reverse repo needed to manage the liquidity of the Sub-fund following subscriptions/redemptions or being the result of the decision of market exposure of the Sub-Fund;
- Investments with issuers with E/S characteristics at the moment of the investment and are not fully aligned anymore with the Candriam investment with E/S criteria. These investments have been sold during the period or considered as other investments;
- Other investments (including single name derivatives) purchased for diversification purposes, which do not meet environmental or social characteristics or which may not be subject to an ESG screening or for which ESG data was not available. These investments have respected the good governance;
- Non single name derivatives used for exposition and hedging purposes.

 **What actions have been taken to meet the environmental and/or social characteristics during the reference period?**

The financial product aims to achieve a carbon footprint that is lower than the Benchmark.

Over the reference period, the financial product emitted 7.33 Tons CO2eq per million € invested, 84.54% lower than the benchmark.

Compared to the previous year, the financial product's carbon footprint has decreased by 1.39%.

The financial product has achieved its objective by favouring issuers with lower carbon footprint.



## How did this financial product perform compared to the reference benchmark?

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

No index has been designated as a reference benchmark for the purpose of attaining the environmental or social characteristics promoted by the Sub-Fund